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You do it fo r  L ove .
You give of your heart, your love, and your life,
To a grandparent, parent, husband or wife.
You dress and you feed them, you clean up the mess. 
For months, maybe years, you give of your best.
At times you can laugh, more often there's tears,
As you watch them decline year after year.
So often you feel like there's nobody there,
No one to talk to, there's no one who cares.
Then late at night, you'll sit and just cry,
"It all seems so hopeless, so why do I try?"
And then comes a voice, so soft and so clear,
You look all around you, but no one is near.
Again comes the voice, as soft as can be,
"You know why you try, just look and you'll see." 
"You do it for love, you know that is true."
"This love that you have, will help see you through." 
"You're not alone, there's someone who'll share." 
"The burden you carry, I'll help you bear."
Then in the darkness, a warmth you can feel,
A soft gentle presence, you know it is real.
As you drop off to sleep, the angels above,
Echo the words...."You do it for love."
© 1997, Jerrold L. Ham.
For all the carers.
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ABSTRACT
Family based linkage studies have confirmed that part of chromosome lq23.3 
contains a susceptibility gene for schizophrenia. This region was investigated by 
tests of allelic and haplotypic association in order to fine map a specific gene in the 
lq23.3 region. Previously published studies claimed that the genes RGS4 and 
CAPON on lq23.3 were associated with schizophrenia. For this research thesis 
multiple markers were genotyped at the RGS4 and CAPON loci in a London based 
case control sample, no evidence for association was found. Therefore further fine 
mapping was carried out in the region between the RGS4 and CAPON genes. Allelic 
and haplotypic associations with schizophrenia were found with three microsatellite 
and four SNP markers within the serine threonine kinase (UHMK1) gene. A 
replication study using an Aberdeen based case control sample also found 
statistically significant evidence of allelic and haplotypic association between 
UHMK1 and schizophrenia. Re-sequencing of the UHMK1 gene was carried out in 
those individuals who had inherited alleles and haplotypes associated with 
schizophrenia. Three genetic variants were found. Genotyping of the whole case 
control sample showed that these changes were not associated with schizophrenia. 
The previously reported associations between schizophrenia and RGS4 as well as 
CAPON could possibly be explained by linkage disequilibrium between UHMK1 
and both CAPON and RGS4. Alternatively there could be two or even three 
susceptibility genes within the 700 Kb region. At present no potential aetiological 
base pair changes have been detected in any of the three genes. UHMK1 is known to 
be highly expressed in regions of the brain implicated in schizophrenia and was 
found to be significantly down regulated in mice treated with the antipsychotic drug 
Clozapine. Further confirmation of the involvement of this gene in schizophrenia is 
needed followed by further efforts to detect genetic variation in or next to the gene 
which has an effect on expression and function of UHMK1.
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AIMS OF THESIS
• To screen a region of chromosome 1 that had previously been implicated by 
genetic linkage studies in families. The method employed would use the case 
control approach to detect evolutionarily determined linkage disequilibrium 
to fine map a novel schizophrenia susceptibility gene.
• To confirm or fail to replicate association with two genes previously 
implicated as involved in schizophrenia susceptibility. These genes were 
Regulator of G-protein Signalling 4 (RGS4) and Nitric Oxide (neuronal) 
Synthase 1 Adaptor protein (NOS1AP previously known as CAPON) present 
in the lq23.3 susceptibility region.
• To re-sequence the exons, the splice site junctions, promoter as well as the 5’ 
and 3 ’ untranslated regions (UTRs) in cases selected for showing association 
with UHMKI in order to find any potential aetiological base pair changes.
• To genotype any potential aetiological base pair changes in a large case- 
control sample in order to cofirm or reject involvement in genetic 
susceptibility to schizophrenia.
• To replicate the association in UHMKI in an independent Aberdeen case- 
control sample.
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1.0 INTRODUCTION
Schizophrenia is a common disorder with a lifetime prevalence of approximately 1% 
of the world population (SCZD [MEM 181500]), although it can be up to 5% if 
schizophrenia spectrum disorders are included (Robert Cancro 2005). Schizophrenia 
puts a huge burden on healthcare through out the world, for example in the United 
States it accounts for approximately 2.5% of health care cost (Bromet et al. 1999).
Schizophrenia is a collection of psychotic mental disorders consisting of variable 
clusters of symptoms. The variability of these symptoms is also associated with 
considerable prognostic variation. There is no characteristic neuropathology, such as 
neurofibrillary tangles that are found in Alzheimer disease, but abnormal brain 
morphology has been reported. Schizophrenia is mainly characterised by a 
disruption of processes of thought, perception, behaviour and reasoning as well as 
social and occupational deterioration. People affected with schizophrenia have 
difficulty differentiating what is generated by their illness and distinguishing it from 
reality.
In about a third of cases the disorder is chronic, perhaps with short periods with 
relative improvement but evidence of continuous deterioration. In a further one third 
there is moderate recovery between episodes with treatment, whilst in a third are 
treatment responsive and can also spontaneously remit without treatment. The onset 
can be sudden and insidious, and because of the relative early age of onset, 
schizophrenia is responsible for very high levels of morbidity. The mean age of 
onset of the disease is about 23 for males and a little later in females with a mean 
age of onset being 27.
A study ranking the severity of disabling health conditions in 14 countries, ranked 
Schizophrenia third overall, just behind quadriplegia and dementia (T Bedirhan 
Ustun et al. 1999). The detrimental effects of schizophrenia are experienced very
13
much by the families and carers of schizophrenics in terms of the emotional and 
financial support required and also the social stigma that it brings.
1.1 H ISTO R IC A L BAC K G RO UN D
The term “Schizophrenia” is less than 100 years old; however the disease itself has 
thought to have accompanied mankind through out its history. The disease has been 
known about since the ancient times, written documents have been found that 
identify schizophrenia as far back as ancient Egypt and India, in the second 
millennium before Christ (Okasha 1999). The evidence included many of the clinical 
symptoms commonly used to describe schizophrenia today, such as depression, 
hearing voices and thought disturbances, which were described in detail in the Book 
of Hearts of the Eber papyrus and also the Indian Ayurveda (Eve C. Johnstone et al. 
1998), as well as Shakespeare and the Greeks.
In the past many cultures have attributed psychosis to possession by evil sprits. This 
idea is still common in parts of Africa and all over the world. Treatments varied 
from the basic exorcisms to the dangerous and lethal practice of drilling holes in the 
skull to release the spirits.
The first clinically characterised cases of schizophrenia were described separately in 
1809 by two physicians, John haslam (1764-1844) In England and Phillipe Pinel 
(1745-1826) in France. In 1851, Falvet first described schizophrenia as a “Folie 
Circulaire” or cyclical madness. Twenty years later Hecker coined the term 
“Hebephrenia” or a silly undisciplined mind. In 1868 Kahlbaum documented both 
catatonic and paranoid disorders. Emil Kraepelin (1856-1926) combined these 
disorders into a single disease, which he called dementia praecox. There were four 
subtypes -
1. Simple, marked by slow social decline and withdrawal.
2. Paranoid, defined by persecutory delusions and fear.
14
3. Hebephrenic, marked by rambling and incoherent speech and incongruous affect.
4. Catatonic, characterized by a severely limited movement and expression.
The subtypes of schizophrenia in most diagnostic systems remain much the same 
today. Kraepelin believed that dementia praecox was primarily a disease of the 
brain, and particularly a form of dementia. Kraepelin named the disorder 'dementia 
praecox' (early dementia) to distinguish it from other forms of dementia (such as 
Alzheimer's disease) which typically occur relatively late in life. He used this term 
to emphasise the deterioration in mental abilities and the early age of onset of the 
disease. The Swiss psychiatrist, Eugen Bleuler, coined the term, "schizophrenia" 
(Split-mind) in 1911 to describe the fragmented thinking of people with the disorder. 
He was also the first to describe the symptoms as "positive" or "negative." Bleuler 
identified specific primary symptoms of schizophrenia to develop his theory about 
the internal mental schisms of patients. These symptoms included associational 
disturbances, especially looseness, affective disturbances, autism and ambivalence, 
summarised as the four A’s: associations, affect, autism and ambivalence.
More recently attempts have been made to classify the disease by subdividing the 
symptoms into groups of “positive” and “negative” effects. Positive symptoms are 
described as an exaggeration of normal functions and the presents of something that 
should be absent, where negative symptoms were the loss of normal function 
possibly due to neuronal loss (Andreasen 1995). A list of positive and negative 
symptoms can be seen in Table 1:1. However this categorisation is partially 
unsuccessful because many cases of schizophrenia have an onset characterised by 
positive symptoms which later change to negative symptoms.
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Table 1:1 Examples of Positive and Negative Symptoms.
Positive symptoms Negative symptoms
Hallucinations Alogia (inability to speak)
Delusions Affective blunting
Disorganised Speech/ formal thought 
disorder
Anhedonia (inability to experience 
pleasure)
Disorganised/bizarre/Catatontic behaviour Avolition (lack of desire, motivation or 
persistence)
Bleuler changed the name to schizophrenia as it was obvious that Kraepelin’s name 
was misleading as the illness was not a dementia (it did not always lead to mental 
deterioration) and could sometimes occur late as well as early in life.
Since then, both Kraepelin’s and Bleuler’s categories of schizophrenia based on 
prominent symptoms have been further refined and continually updated by modem 
psychiatrists who have used operational criteria to improve the diagnosis of the 
schizophrenias in a reliable and valid diagnostic method. Nowdays the diagnosis of 
schizophrenia is as valid and reliable as most medical diagnoses and the operational 
criteria are both sensitive and specific.
1.1.1 DIAGNOSIS OF SCHIZOPHRENIA.
Modem diagnostic schemes were developed out of the earlier nosological theories of 
Kraepelin and Bleuler. The third edition of Diagnostic and Statistical Manual of 
mental disorders of the American Psychiatric Association’s (DSM-III), diagnostic 
protocol is based on defining which category the patient fell into, disorganised, 
catatonic, paranoid, residual and undifferentiated. The first three categories were 
originally proposed by Kraepelin. These classifications are still employed in the 
DSM-IV (APA 1994) and also the International Classification of Disease, ICD-10 
(WHO 1992). Both diagnostic schemes are comparative or operationally defined, 
taking a phenomenological and natural history approach to the symptoms and 
defining schizophrenia based on a clustering of clinical signs, symptoms and 
prognosis. Particular emphasis is placed on inappropriate affect and mood 
incongruent psychotic symptoms as a defining feature. DSM-IV and ICD-10 criteria
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have been found to be as reliable and valid as diagnostic instruments as those used in 
other branches of medicine. Below are (section 1.1.1.1) examples of the 
classifications of schizophrenia that the diagnostic protocols help to determine.
1.1.1.1 SUBTYPES OF SCHIZOPHRENIA
Disorganized Type (formally known as hebephrenic).
A form of schizophrenia characterised by severe disintegration of personality 
including disorganised speech and childish mannerisms and bizarre 
behaviour; they tend to have an earlier age of onset, usually becomes evident 
during puberty; the most common diagnostic category in mental institutions, 
it has an unremittng course with poor prgnosis.
Catatonic Type
This subtype features gross psychomotor disturbances, i.e., stupor, 
negativism, mutism, rigidity, waxy flexibility, excitement, or posturing. They 
demostrate echolalia (repetition of words or phrases in a nonsensical manner) 
and echopraxia (mimicking the behaviours of others). Frequent fluctuation 
between these extreme physical states is common. During catatonic stupor or 
excitement, patients need careful supervision to prevent them from hurting 
themselves or others medical care is needed because of malnutrition, 
exhaustion, hyperpyrexia or self-inflected injury.
Paranoid Type
The paranoid type of schizophrenia is characterised by preoccupation with 
one or more delusions or more delusions of persecution or grandeur.
Common are delusions that there is a conspiracy against the patient. Patients 
with paranoid schizophrenia are typically tense, suspicious, guarded, 
reserved and sometimes hostile or aggressive, but some can conduct 
themselves adequately in social situations, in addition they tend to have they 
symptoms at an older age than do patients with catatonic or disorganised
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schizophrenia. One subtype of paranoid schizophrenia has a good prognosis 
enabling the patient to return to work with minamal drug treatment.
Undifferentiated Type
This type was originally designed as a catch-all category used when patients 
do not clearly fit into any one type, or fit into more than one type, this 
subtype is very common.
Residual Type
This type is commonly used when there is a history of an acute episode of 
schizophrenia, but at the time of presentation the patient does not manifest 
any of the associated psychotic or positive symptoms. However there is 
continued evidence for schizophrenia manifested in either negative 
symptoms or low grade symptoms. These may include odd behaviour, some 
abnormalities of thought processes, lack of volition and lack of self care.
Once the individual has been fully accessed and diagnosis has been made, a 
treatment program would need to be put into place, to try and resolve the symptoms. 
Once the symptoms are safely under control the subject may be reintegrated back 
into society with the correct support structure; this will be briefly discussed next.
1.1.2 TREATMENT
Although antipsychotic treatments are the mainstay of the treatment for 
schizophrenia, research has found that psychosocial interventions such as 
behavioural therapy and cognitive therapy and psychotherapy; can augment the 
clinical improvement. Most patients with schizophrenia benefit more from the 
combined use of antipsychotic drugs and psychosocial treatment than from either 
treatment alone. This is sanctioned in the UK national institute of clinical excellance 
guidelines which recomends ten cognitive therapy sessions for every in patient 
admission.
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1.1.2.1 HOSPITALISATION
Hospitalisation is induced during relapses. In-patient treatment can help in the 
stabilisation of the patient with medications, hospitalisation can ensure the patients’ 
safety because of their potential suicidal or homicidal tendencies. Also provide basic 
needs such as food, clothing and shelter which some patients are unable to maintain 
for themselves. This should be carried out for their own protection. The role of the 
hospital and community team is to plan specific treatment strategies for the 
individual and to aid in helping the individual to rehabilitate and adjust, also to 
educate the patients and the family about schizophrenia.
The severity of the patients’ illness should determine the length of admission rather 
then the availability of outpatient treatment or community care. After care for the 
patient should be organised whilst at hospital including day-care centres and home 
visits by nurses, occupational therapists, social workers and counsellors. Patients can 
often remain out of hospital and the quality of their daily lives can steadily improve 
(Benjamin J. Sadock et al. 2003).
1.1.2.2 PHARMACOTHERAPY
Antipsychotic medications were introduced in the early 1950s and have 
revolutionised the treatment of schizophrenia. Some medications only ameliorate the 
symptoms and do not seem to alter the out come. Other antipsychotics such as 
clozapine and risperidone seem to hold back or reverse the disease better than others. 
The antipsychotic drugs include two major classes: dopamine receptor antagonists 
and serotonin-dopamine antagonists (SDAs).
1.1.2.2.1 DOPAMINE RECEPTOR ANTAGONISTS
Dopamine receptor antagonists such as chlorpromazine and haloperidol, are 
effective forms of treatment of schizophrenia, particularly for the positive symptoms 
(e.g. delusions see Table 1:1) however, these drugs have two major short comings.
19
Firstly not all respond to treatment enough to return to normality and many still 
deteriorate. Second the dopamine antagonists were associated with a number of 
adverse side effects, such as akathisia and parkinsonian like symptoms of rigidity 
and tremor. The potential serious side effects included tardive dyskinesia and 
neuroleptic malignant syndrome.
1.1.2.2.2 SEROTONIN-DOPAMINE ATYPICAL ANTIPSYCHOTICS
The atypical antipsychotics produce minimal or no extrapyramidal symptoms, 
interact with different subtypes of dopamine receptors than do the standard 
antipychotics and affect both the serotonin and glutamate receptors. They are more 
effective in treating negative symptoms of schizophrenia (e.g. withdrawal see Table 
1:1) and also getting rid of delusion. Atypical antipsychotics, include risperidone, 
clozapine, olanzapine, sertindole, quetiapine and ziprasidone. These drugs have 
replaced the “typical” dopamine receptor antagonists as the drugs of first choice for 
treatment of schizophrenia.
Finding the correct drug to use to treat an individual with schizophrenia, is not 
strictly straightforward and depends on a number of factors, such as the method of 
medication (tablet or injection), unwanted side effects, and the effectiveness of the 
drug (see Figure 1:1).
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At each point drug treatments are chosen on the basis of:
• Past response
• Side effects
• Patient preference
• Planned route of administration
Figure 1:1 Pharmacological treatment of schizophrenia.
GROUP 1: Conventional antipsychotic medications 
GROUP 2: Risperidone 
GROUP 3: Clozapine
GROUP 4: New antipsychotic medications—olanzapine, sertindole, quetiapine
Intolerable 
side effects
Adequate response; /  
no intolerable side effects
Inadequate response 
of positive symptoms
Continue
A dequate response; 
no intolerable side effects
Inadequate response 
of positive symptomsIntolerable 
side effects
Inadequate response 
of positive symptoms
Intolerable 
side effects
A dequate response; 
no intolerable side effects "
Continue
Continue Go to B
Go to AChoose a  different medication 
from group 2, 3, or 4
Go to A; consider ECT; 
consider recommendations for 
treatm ent-resistant patients
Choose a  medication from 
group 1, 2, or 4
Choose a  different 
medication from group 1 
(if a  medication from group 1 
was not chosen  first),
2, 3, or 4
C hoose a different medication from 
group 1, 2, or 4; if extrapyramidal 
side effects, tardive dyskinesia, or 
increased prolactin is a  problem, 
consider group 4
practice guideline for the treatment of patients with schizophrenia (Lehman et al. 
1997; Benjamin J. Sadock et al. 2003)
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1.2 A E T IO L O G Y
The causes of the schizophrenias are not fully understood but some factors including 
biological, psychological and sociological are known to be relevant in the aetiology. 
Genes have been consistently shown to be an important biological risk factor for the 
development of schizophrenia. Further, schizophrenia-like psychoses may develop 
as a result of demonstrable organic diseases (Johnstone et al. 1987). Head injuries 
may also result in a schizophrenia-like psychosis and some types of epilepsy are 
associated with schizophrenia.
Numerous attempts have been made to implicate different environmental risk factors 
as possible causes for the disease including winter-spring season of birth, perinatal 
or obstetrical complications, urban birth and rearing, and viral infection. However, 
none of these factors have showed consistent or large effects on disease’s risk (Done 
et al. 1991). The most consistent risk factor for schizophrenia is a genetic 
susceptibility.
1.2.1 BRAIN MORPHOLOGY OF SCHIZOPHRENIA
Schizophrenia is not only characterised by psychopathological features but also by 
physiological and anatomical changes. Brain changes, first convincingly 
demonstrated following the introduction of non-invasive imaging by Johnstone et al 
(1976) have been consistently found to include the finding of enlarged ventricular 
spaces and reduced cortical volumes particularly involving temporal lob structures 
(Shenton et al. 1992). A meta-analysis of regional brain volumes found differences 
between normal controls and schizophrenic patients. Patients had a smaller cerebral 
volume, a bilaterally reduced volume of medial temporal lobe structures and a 
greater ventricular volume (Wright et al. 2000).
More recently, positron emission tomography scans suggested an activation 
hypofrontality (Liddle et al. 1992). Thompson et al. (2001) have shown accelerated 
gray matter loss in very early-onset schizophrenia with MRI. Repeated MRI scans 
over 5 years found that the deficits progressed anteriorly into temporal lobes,
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engulfing sensorimotor and dorsolateral pre-frontal cortices and frontal eye fields in 
some schizophrenics. Kovelman and Scheihel (1984) also found abnormanlly 
arranged pyramidal cells in the hippocampus (Kovelman et al. 1984).
The histological findings in schizophrenia are less convincing but include aberrantly 
located or clustered neurons particularly in lamina II of the entorhinal cortex (Jakob 
et al. 1986) and in the neocortical white matter (Akbarian et al. 1996). These 
abnormalities perhaps are indicative of an early neurodevelopmental anomaly 
affecting neuronal migration, survival and connectivity. Although there have been 
several positive reports of the above findings they should not be accepted without 
question (Harrison et al. 2005). Other findings include the cell bodies of pyramidal 
neurons in the hippocampus and in the neocortex are smaller (Zaidel et al. 1997; 
Pierri et al. 2001).
In summary, the neuropathology of schizophrenia has been suggested to consists of 
alterations in various neural microcircuitry ranging from the dendritic tree to the cell 
body and axon to the synaptic terminal (Harrison et al. 2005). Some investigators 
have tried to bring together all the neuropathological findings by explaining 
schizophrenia as a disorder of the synapse (McGlashan et al. 2000; Frankie et al. 
2003).
The development of the MRI led to more definitive findings of brain abnormalities 
in schizophrenics. A review was carried out by Shenton et al (2001) on over 193 
MRI studies between 1988 and august 2000. This showed multiple brain regions 
displayed morphological abnormalities in schizophrenics. These include ventricular 
enlargement in 73% of studies, also a preferential involvement of the medial 
temporal lobe structures 74%, which include the amygdala, hippocampus, and the 
parahippocampal gyrus, and neocortical temporal lobe regions (superior temporal 
gyrus) which forms the limbic system, this is important because it controls emotions. 
There was additional evidence that the hippocampus contained disorganised neurons 
(Benjamin J. Sadock et al. 2003). When the gray and white matter of the superior
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temporal gyrus was combined 67% of studies reported abnormalities. There was also 
evidence for frontal lobe abnormalities in 59% of cases and parietal lobe 
abnormalities in 60%. In addition there was strong evidence for subcortical 
abnormalities but more equivocal evidence for cerebellar abnormalities in 31% of 
the studies reviewed (Shenton et al. 2001).
Figure 1:2 A comparison a normal brain (left) and a brain and that from a schizophrenic 
patient (right).
Figure 1:2 shows a “coronal 1.5mm slice of a normal control (left panel) and a 
schizophrenic patient (right panel). Note the increased Cerebrospinal fluid (CSF) 
(black) in the left Sylvian fissure in the patient image (right panel, viewers right), as 
well as the increased CSF in the left temporal horn which surrounds the amygdala 
(see white arrow) and tissue reduction in the left superior temporal gyrus. The lateral 
ventricles are also enlarged in the patient image as can be seen by the black CSF 
regions in the centre of the image. Contrast this with the slice at approximately the 
same neuroanatomical level for the normal control (left panel)” (Shenton et al.
2001).
The basal ganglia and cerebellum have also been of great theoretical interest for at 
least two reasons. First, many patients with schizophrenia display odd movements, 
even in the absence of medication induced movements such as tardive dyskinesia. 
The odd movements include an awkward gait, facial grimacing, and stereotypes.
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Since the basal ganglia and cerebellum are involved in the control of movement, 
dysfunction in these areas are implicated in the pathophysiology of schizophrenia.
Second, many neurological disorders can have psychosis as an associated symptom. 
Movement disorders involving the basal ganglia (like Huntington’s disease) are the 
ones most commonly associated with psychosis in affected patients. Furthermore the 
basal ganglia and cerebellum are reciprocally connected to the frontal lobes. There 
are inconclusive reports about abnormalities in the basal ganglia; many studies have 
shown an increase of D2 receptors in the caudate, the putamen and the nucleus 
accumbens. However, it is not known whether this is due to the disease or due to the 
effect of medication.
The timing of when these abnormalities occur is not known, but there is evidence 
that a subset of brain abnormalities may change over the course of the illness 
(Shenton et al. 2001). One explanation is that the abnormalities are 
neurodevelopmental in origin, but unfold later in development and it is theorised that 
excessive pruning of synapses occurs during development and is abnormal in 
schizophenia. Thus setting the stage for the development of the symptoms 
contributing to schizophrenia.
The most plausible synthesis of the genetic, neuropathological and epidemiological 
evidence outlined briefly above is that schizophrenia is a chronogeneic 
neurodevelopmental disorder (Weinberger 1995) in which genetically timed 
abnormalities are expressed during development.
1.3 G EN ER A L G ENETICS
The evidence for genetic transmission of schizophrenia is compelling. The 
proportion of variance due to genetic effects of the “heritability” of the disease has 
been calculated to be about 81% (Sullivan et al. 2003).
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1.3.1 FAMILY STUDIES
The seminal work of Gottesman (1991) calculated the lifetime morbid risk of 
schizophrenia corrected for age. Which show that the closer the relation is to the 
person with schizophrenia the more likely the individual is to develop schizophrenia.
Parents
Offspring of dual 
matings
Monozygotic twins
| Dizygotic twins
Siblings with 1 
'schizophrenic parent
Siblings
Half siblings
, nieces
Uncles, aunts
First cousins (third 
degree)
H S pouses of patients 
General population
 1------- 1-------h
10 15 20 25 30 35 40
Lifetime risk of developing schizophrenia: %
45 50
Figure 1:3 Lifetime risk of developing schizophrenia Gottesman (1991).
Family studies have provided an important validation of Kraepelin’s original 
formulation of dementia praecox and manic depressive psychosis as separate 
disorders. These studies have repeatedly shown that biological relatives of parents 
with schizophrenia have increased risk of schizophrenia and schizophrenia spectrum 
disorders, whereas biological relatives with parents with major affective disorders 
have an increased risk for the affective disorder. The separation is not complete but 
it is supportive of the two disorders as independent disease entities.
1.3.2 TWIN STUDIES
Early studies (conducted before world war II in germany) found concordance in 
monozygotic twins to be in excess of 65%; these investigations were criticised for 
having potential sources of bias. The figures for dizygotic twins range from about 
6% to 20%. Further studies performed more recently have reproduced the finding of 
greater concordance in monozygotic versus dizygotic twins. The Maudsley Twin 
Series of Gottesman and Shields have been reassessed using a variety of modem 
methods and produced an estimate of 67% concordance for monozygotic twins 
(Farmer et al. 1984; McGuffin et al. 1984).
Finally, five recent systematically ascertained studies using modem diagnostic 
criteria report monozygotic (MZ) concordances estimated at 41-65% compared with 
dizygotic (DZ) concordances of 0-28%, resulting in an estimated broad heritability 
of 85% (Cardno et al. 2000).
1.3.3 ADOPTION STUDIES
Classic studies looked at parents suffering from schizophrenia who had their 
offspring adopted. The rates of illness in the adoptees of these psychotic probands 
was compared to that in adoptees of non-psychiatric controls.
The increased rates of illness in the children of schizophrenic probands conclusively 
showed that transmission of the disease within families was under genetic control 
rather than the environment (Gottesman et al. 1967; Gottesman et al. 1976).
A study looking at the effect of being raised by a psychotic adoptive parent was 
undertaken by (Wender 1974). In this cohort study, adoptees with schizophrenic 
biological parents raised by normal adoptive parents were compared with a group of 
adoptees bom to normal parents and adopted by parents who subsequently became 
schizophrenic. The adoptees who had schizophrenic biological parents had high 
rates of spectrum disorders, whereas those who had normal biological parents had 
low rates.
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1.4 G EN ETIC  TRA N SM ISSIO N  M O DELS
Family, twin and adoption studies demonstrate a genetic contribution to the 
aetiology of schizophrenia. Once familial aggregation with a probable genetic 
aetiology has been established for a trait, one may consider using segregation 
analysis to evaluate whether major or minor genes contribute to the expression of the 
phenotype. Segregation analysis is one of the most established methods for this 
purpose. It aims to determine the transmission pattern of the trait within families 
and to test this pattern against predictions from specific genetic models. Maximum 
likelihood statistics are used to compare likelihoods for an observed pattern 
occurring by chance (null hypothesis) to a maximum likelihood under a particular 
hypothesis.
Segregation analysis for schizophrenia using the simple model of Mendelian 
inheritance with high penetrance has been shown to be incompatible with the 
observed familial recurrence rates (Winokur et al. 1982; McGue et al. 1989a;
McGue et al. 1989b) while the purely environmental models cannot adequately 
explain the results of adoption studies (Kety 1983).
More plausible models, which might fit the data, are the generalized single major 
locus model and the multifactorial polygenic model. The relative validity of the 
different models has been investigated in several studies. The findings of many of 
these have been reviewed extensively by Baron (1986a) and Baron (1986b).
1.4.1 SINGLE MAJOR LOCUS (SML) MODEL
This model is often based on the assumption that the inheritance of a disorder is a 
consequence of a single locus with two alleles (Elston et al. 1970). The concepts of 
reduced penetrance and phenocopies are introduced to account for the deviations 
from classical Mendelian inheritance. Several analyses demonstrated that the SML 
model was sufficient to correctly predict the data from twin and family studies 
(Slater 1971; Kidd 1973), while other analyses found it insufficient, (Baron et al. 
1982; Risch et al. 1984; McGue et al. 1985).
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1.4.2 POLYGENIC OR OLIGOGENIC MODELS
A polygenic (or oligogenic) model is one where two or more disease alleles at two 
or more distinct loci are needed before a disease is expressed. Such models can be 
used to explain the recurrence of many common diseases. However, methodology in 
the area is undeveloped. Further understanding of how two or more loci interact will 
depend on the accurate identification of each locus. The oligogenic model assumes 
that several genes may act additively, interactively or multiplicatively on the 
aetiology of the illness.
Risch (1990a) assessed the compatibility of multilocus models with the observed 
recurrence risks in schizophrenia and suggested that there should be multiplicative 
effects from at least three loci acting on the risk for this illness. However, Risch and 
others assume a single subtype of schizophrenia with an equal effect size from 
oligogenes in every individual. The evidence to date is incompatible with this 
assumption and therefore multiple models of transmission with heterogeneity in the 
oligogenes increasing susceptibility to schizophrenia are more likely.
1.4.3 MULTIFACTORIAL-POLYGENIC (MFP) MODEL
In this model, Falconer’s method of partitioning genetic liability has been widely 
adopted. In Falconer’s model, the trait is assumed to be the result of many genes 
that have additive effects and unspecified environmental factors the sum of which 
follows a normal distribution in the general population (Falconer 1965). The disease 
is manifested when the liability exceeds a certain threshold where all individuals 
above this point are affected and those below are normal. Relatives have a greater 
risk for a genetic disorder than that of the general population and their mean liability 
is higher. The closer the degree of relationship to the affected individual the greater 
the pre-existing liability the individual has. Since first degree relatives have 1/2 their 
genes in common with their affected relative, first degree relatives of affected will 
be 1/2 of the way between the mean for affected and the population mean. A new 
normal curve with the same variance is then plotted using the mean for first degree
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relatives. The threshold does not move, so the overlap of the threshold will give the 
probability of recurrence to first degree relatives of affected. As can be seen a 
greater proportion of the first degree relatives are affected compared with the general 
population, due to prior liability factors they have inherited.
Thres lold
First
Degree
Relatives
Normal
Population
Affected
Liability
This model has produced a good fit with the observed risk in several family studies 
of schizophrenia especially when environmental factors are taken into account 
(Gottesman et al. 1967; Kidd 1973; Rao et al. 1981; McGue et al. 1985) but it has 
also been rejected in several other studies (Matthysse et al. 1976; Baron et al. 1982; 
Tsuangetal. 1983).
1.4.4 MIXED MODEL
While early segregation analyses considered SML or polygenic models, more recent 
approaches have considered a mixed model in which the phenotype may be the 
result of a combination of these two (Lalouel et al. 1983).
1.4.5 OTHER MODELS
Other models include the two-locus theory in which the phenotype is the result of 
the interaction of two separate loci and a polygenic model with graduated gene
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effects to allow variable contributions to the liability from the different loci 
(Matthysse et al. 1979). Segregation analyses have produced controversial results 
among the different studies. This is mainly due to limitations of the genetic models 
examined as well as diagnostic uncertainties. Most of the models used did not take 
into account factors associated with schizophrenia such as genetic heterogeneity, 
assortative mating, reduced fertility, and social isolation. The limitations of the 
analytical methodologies are further compounded by reduced penetrance, 
phenocopies, diagnostic difficulties, sampling bias, ascertainment bias, mortality, 
variable age of onset and the lack of enough family data to estimate the large 
number of unknown parameters required to accurately model the complex trait. 
However, it is clear that schizophrenia is a complex disorder that does not show a 
clear pattern of Mendelian inheritance in all families. For example, both dominant 
and recessive transmission is plausible for different subtypes. Yet, further subtypes 
may be oligogenic. As for other common disorders, a mixture of different genetic 
and non-genetic subtypes is highly likely. Some of these subtypes may be 
influenced by the environment or by multiple genes. Classical segregation analysis 
does not have the power to identify a definitive mode of transmission for this 
disorder and will not do so in the future due to the drawbacks mentioned above.
In order to overcome the limitations of segregation analysis, geneticists turned to 
linkage and/or association (linkage disequilibrium) studies using several different 
types of genetic markers (see below for full description). Investigators believe these 
forms of study do have enough power to detect the susceptibility genes underlying a 
common disorder (Risch et al. 1996).
Finally, it may be that a disease -  particularly complex ones -  results from 
interactions between different genes. These interactions can be direct and additive or 
multiplicative or other interactions could be epistatic in which a major gene effect is 
modified by another locus, this may be one of the reasons for the difficulties in 
finding the genes involved in the disease. If the effect of one locus is altered or 
masked by effects at another locus, power to detect the first locus is likely to be 
reduced and elucidation of the joint effects at the two loci will be hindered by their 
interaction. If more than two loci are involved, the situation is likely to be further
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complicated by the possibility of complex multi-way interactions among some or all 
of the contributing loci (Cordell 2002).
1.5 M ETH O D S OF M APPING
1.5.1 GENETIC MARKERS
RFLPs (Restriction Fragment Length Polymorphisms) were first used in 1978 (Kan 
1978) and became the first genetic markers to be used in a successful study to find 
the cause of a disease (Huntington’s disease) (Gusella et al. 1983). They are based 
on single base pair change that create or obliterate a cleavage sites for specific 
restriction enzymes. The resulting variation between individuals can be detected by 
digestion of the DNA by the appropriate restriction enzyme. RFLPs are inherited as 
simple Mendelian codominant markers, which can be readily identified in families. 
A disadvantage of RFLPs is that because they are biallelic they are not very 
informative, having low heterozygosity (usually<0.40) in linkage studies.
The heterozygosity of the genotyping markers was greatly increased by the 
identification of VNTRs (Variable Number of Tandem Repeats) in 1987 (Nakamura 
et al. 1987) and also the minisatellite markers. This class of marker is made of a 
specific set of consensus sequences that vary between 14 and 100 base pairs in 
length for a VNTR and even more coplex repeates for minisatellites. They are 
remarkably polymorphic, with a high heterozygosity rates (usually > 0 .6) in the 
population. However, there are only a small number of VNTRs available and their 
distribution is rather limited in the genome, often tending to cluster toward human 
telomeres. Minisatellites tened to be too polymorphic with producing the same 
fragment sizes but having different sequences.
STRs (Short Tandem Repeats) or microsatellites were initially described by Weber 
and May (1989) and Litt and Luty (1989). STRs are distributed widely and evenly 
in the genome. They sometimes have high heterozygosities (usually > 0.7) and are 
relatively easy to score. The number of the repeated motifs varies, the most 
common consisting of two (dinucleotide), three (trinucleotide) or four 
(tetranucleotide) bases. The dinucleotide (CA)n-(GT)n is the most common repeat,
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with a highly polymorphic form of the repeat occurring approximately every 0.4 cM. 
Following the success of the dinucleotide repeat markers, other polymorphic 
markers namely microsatellites were isolated and characterized. They are usually tri- 
and tetra-nucleotide repeat markers.
Finally, in recent years, attention has been re-focused back on the use of single 
nucleotide polymorphisms (SNPs) as genetic markers. They are the most common 
type of human DNA variation and as the name suggests they represent a position at 
which two alternative bases occur at an appreciable frequency (>1%) in the human 
population (Wang et al. 1998). Previously SNPs were analysed with restriction 
enzymes to produce RFLPs. On average, they occur 1 per 300-1000 base pairs 
(Collins et al. 1997), of which restriction enzymes can not detect all of the SNPs. 
However now technology has advanced, it enables us to analyse and characterise the 
SNPs in a variety of different ways. Although individual SNPs are less informative 
than typical multi-allelic simple sequence length polymorphisms, they are more 
abundant and their genotyping can be automated with the use of DNA chip-based 
microarrays (Hacia et al. 1996), which allow the very rapid analysis of very large 
numbers of SNPs. Large collections of mapped SNPs have been developed to 
provide a powerful tool for human genetic studies. The International HapMap 
project is one of several such ventures (2003).
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1.5.2 POSITIONAL CLONING
Positional cloning -  involves identifying disease genes through their position in the 
genome rather than through their function (Collins 1992). The power of positional 
cloning lies in the fact that it is conducted in the absence of a priori knowledge as to 
the disease pathogenesis. It is seen by some as the “pure” geneticists approach. The 
methods adopted for positional cloning are linkage followed by association analyses.
1.5.3 LINKAGE ANALYSIS
Linkage analysis relies upon the ability to detect the co-segregation of marker alleles 
with those of the disease gene. For a marker to be “informative” for a particular 
meiosis, the individual concerned must be heterozygous at both the marker and 
disease locus. Therefore, the usefulness of a given genetic marker in linkage analysis 
or “informativeness” depends on the frequency with which it is heterozygous within 
a population. Microsatellites gave investigators polymorphic, regularly spaced 
markers across the whole genome. Linkage studies investigate the departure from 
independent assortment of a marker and the disorder by estimating the amount of 
recombination between the marker and the disease. This recombination results from 
cross-over between the homologous pair of chromosomes during meiosis. Offspring 
where cross-over has occurred are known as recombinants: offspring where non 
crossing-over has occurred are known as non-recombinants.
Linkage involves calculating how much the recombination fraction (the number of 
recombinants divided by the total number of offspring) is significantly different 
from 0.5, the value expected on the null hypothesis of no linkage.
If two loci are on different chromosomes or are very widely separated on the same 
chromosome, then independent assortment takes place and the recombination 
fraction would be 0.5 or V2. That is there would be a 50:50 chance of offspring being 
either recombinants or non-recombinants.
When two loci are close together (or linked), the assortment is no longer 
independent and recombination fractions of less than Vi would be seen.
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Morton (1955) showed that calculating the lod score represented the most efficient 
statistic for evaluating pedigrees for linkage.
A lod score (or log of the odds score) is the common log of the likelihood that the 
recombination fraction has a certain value, 0 ’ divided by the likelihood that 0 is 'A:
Lod (0’) = logio (likelihood (0 = 0’) / likelihood (0 = 0.5)}
Traditionally a lod of 3 or more is taken as "significant" evidence for linkage 
(although this is does equate with the meaning of statistical significance in other 
contexts).
Linkage analysis conventionally was undertaken using a two-point analysis, where 
the co-segregation of the disease and a single marker are studied. This method was 
extended to multi-point linkage analysis (Ott 1991) where multiple markers lying 
reasonably close together on the same chromosome are studied. This allows for 
greater precision in the positioning of the disease locus. It also allows the 
investigator to rule out a particular locus as being responsible for causing the 
disease.
1.5.4 PARAMETRIC
Standard lod score analysis is called parametric because it requires a precise genetic 
model, detailing the mode of inheritance, gene frequencies and penetrance of each 
genotype. For non-Mendelian conditions this method has be accused of causing 
problems but simulation of two locus transmission and uncertain penetrance have 
shown it to be a robust method (Vieland et al. 2003). The parametric method has a 
lot more power to detect linkage than the sib-pair non-parametric approach when all 
the parameters of the model are known and specified correctly. Power is decreased, 
often severely when the wrong assumptions about the genetic model are made. In 
most complex traits the true degree of each parameter is not known, this would make 
the results of the model unreliable.
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1.5.5 NON-PARAMETRIC
Model free or non-parametric methods of linkage analysis look for alleles or 
chromosomal segments that are shared by affected individuals (Risch 1990b; Risch 
1990c; Risch 1990d).
A common alternative approach is to examine allele-sharing between pairs of 
affected relatives; an example of this is the sib-pair method. Taking pairs of affected 
siblings, we would expect that by chance they would share two alleles of a DNA 
marker 25% of the time, one allele 50% and no alleles 25%. However if the marker 
is linked to the disease gene then alleles will be shared between affected sib pairs 
more often than expected. If parents are also genotyped then the inheritance of the 
marker alleles can be studied directly (identity-by-descent, IBD analysis), but even if 
the parents are unavailable one can use population allele frequencies to estimate 
whether increased allele-sharing is occurring (identity-by-state, IBS analysis). The 
strength of evidence in favour of linkage can be given by a chi-squared statistic or 
by a maximum likelihood score (MLS), the latter being similar to a lod score.
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Figure 1:4 Sib pair analysis
(courtesy Dave Curtis’s website: http://www.smd.qmul.ac.uk/statgen/dcurtis.htmn. 
The second sib pair shares one allele IBD, while all the others share both alleles, 
suggesting a recessive gene may be quite closely linked to the marker.
The lod score method, which requires specification of values for transmission model 
parameters, is termed parametric, whereas tests which do not involve model 
specification are termed non-parametric. The latter consist mainly of tests for 
increased allele-sharing between affected relatives. They are sometimes regarded as
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being more appropriate for studying complex diseases (although there is controversy 
about this), but they are poor at providing a precise location of the disease gene 
compared to the lod score method.
Linkage studies rely on studying sets of related affected subjects and are capable of 
detecting a disease gene over a relatively large range. Approximately 300-400 
markers are sufficient to carry out a screen of the whole genome. Thus linkage 
studies provide initial localisations for disease genes without any prior knowledge of 
the function or chromosomal location.
1.5.6 ALLELIC AND HAPLOTYPIC ASSOCIATION STUDIES
Case control and family based genetic association studies represent the final 
common pathway for all genetic studies regardless of the initial design and are 
necessary for the ultimate identification of the alleles that confer vulnerability to 
specific phenotypes.
Association studies play a critical role in the analysis of genetically complex traits in 
fine mapping a region already implicated by linkage studies.
Association studies look for an allelic association between a marker and a disease 
allele. Linkage disequilibrium is the reason for observing allelic association between 
two adjacent markers or between a marker allele and disease allele (Jorde 1995). 
Linkage disequilibrium between alleles mainly reflects the recombination history in 
the evolution of that haplotype. Therefore, recently acquired mutations, or those in 
founder or isolated populations with limited chromosome diversity, are likely to 
show linkage disequilibrium that might extend over long distances. However, as a 
result of a number of different factors including regional variability in recombination 
patterns, recent population admixture and local chromosomal composition linkage 
disequilibrium can vary significantly within and between populations.
Comparison is made of the frequency of marker phenotypes in a sample of patients 
and a sample of healthy controls. The statistical analysis is a 2x2 contingency table 
as shown below. See Table 1:2.
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Table 1:2 Marker-disease association in a population.
Marker n affected n unaffected
Present a b
Absent c d
In case-control studies, the odds ratio can be calculated. The odds of an event 
happening are the ratio of the probability that it happens to the probability that it 
does not. The odds ratio is the ratio of the two odds and can be calculated from 
ad/bc. The 95% confidence interval for the log odds ratio is obtained as 1.96 
standard errors either side of the estimate. The standard error of the log odds ratio is 
estimated by the square root of the sum of the reciprocals of the four frequencies as 
shown in the formula in Figure 1:5.
Figure 1:5 Calculation of the 95% confidence interval of an odds ratio
SE(log OR)= i i i ^— i-----------1— — i—
<^2 b c d j
With a 2x2 table it is also possible to calculate the x2 statistic using the formula 
shown in Figure 1:6 below where there is one degree of freedom.
Figure 1:6 Calculation of the yl statistic using a 2x2 table
(ad -  be)2 {a + b + c + d ) 
(ia + b \c  + d \ b  + d \ a  + c)
Association may be found because of:-
1) Direct causation - such that having an allele results in susceptibility to the disease. 
Possession alone may not necessarily lead to the development of the disease, but it 
increases the likelihood.
2) Population stratification -  the population contains several genetically distinct 
subsets, and both the disease and a particular allele happen to be more frequent in 
one subset. Lander & Schork (1994) gave an example of the association in the San 
Francisco Bay area between HLA-A1 and ability to eat with chopsticks. HLA-A1 is 
more frequent among Chinese than among Caucasians.
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3) Type I error -  association studies test a large number of markers, even without 
true effects 5% will be significant at the p=0.05 level.
4) Linkage disequilibrium truly exists between the marker and a disease locus.
5) Natural selection -  possession of the marker allele of the disease may lead to 
increased survival against adverse conditions. Therefore their children are more 
likely to inherit the disease and the allele associated with it will be more likely to be 
seen in a population of cases.
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1.6 TH E PRO BLEM  OF H ETERO G ENEITY
In the search for genes involved in the causes of complex diseases, investigators 
have suffered from the problem of heterogeneity at all stages.
In linkage studies, the problem of locus heterogeneity has been the greatest cause of 
difficulties in identifying regions of importance within families. There may be two 
or more loci at which mutations result in similar phenotypes. The mutations at the 
different loci may have different modes of transmission. Charcot-Marie-Tooth, 
tuberous sclerosis and retinitis pigmentosa all result from a number of distinct 
mutations of different chromosomes. Charcot-Marie-Tooth exists in an X-linked 
form and two autosomal dominant forms the loci of which are on different 
chromosomes. If homogeneity had been assumed and linkage analysis carried out on 
a collection of families containing a mixture of the two autosomal forms the results 
could have been misleading and linkage might have been overlooked.
It may be that in a minority of cases schizophrenia are due to a major locus but the 
majority are polygenic. Indeed Murray (1985) divided the disease into genetic and 
non-genetic forms; the non-genetic forms being those with no family history, 
however this does not equate to lack of genetic susceptibility as low penetrance 
alleles may be present in unaffected family members. Bleuler (1978) found that 60% 
of patients have no history of schizophrenia in first or second degree relatives but 
these stuies were not age corrected. Those without a family history maybe due to 
environmental factors and would therefore be classified as phenocopies. However 
twin and adoptin studies show that most schizophrenics have a genetic effect.
The adoption of non-parametric linkage analysis was devised to overcome 
difficulties of being able to define:-1) the model of inheritance or 2) the degree of 
penetrance. The results of parametric and non-parametric linkage analysis have 
resulted in several regions being identified where association studies have been used 
in an effort to narrow the area even further. The linkage studies strongly supported 
heterogeneity for schizophrenic genes and chromosomes were duplicated.
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Locus heterogeneity is now the problem facing SNP association studies. For the 
power of association studies decreases dramatically as soon as there is more than 
one susceptibility locus influencing schizophrenia.
The question is, are most susceptibility-alleles ancient common polymorphisms (the 
so-called Common-Disease/Common-Variant model) or are they a heterogeneous 
collection of rare recent mutations, like most Mendelian diseases?
Wright et al. (2003) explain that in a review of the genetics of breast cancer, it can 
be seen that the two familial breast cancer genes, BRCA1 and BRCA2, there are at 
least 1200 and 1400 different mutations of large effect, each of which are rare -  
except in the founder populations. By contrast, out of the five or six common SNPs 
within BRCA1 and BRCA2 coding regions only one has been shown to exert a 
marginal (1.3-fold) increase in breast cancer risk. Wright et al. (2003) conclude that 
the common SNPs in the coding region are less interesting “precisely because they 
have little or no functional effect either on disease or on reproductive fitness.”
Reich (2001) looks at population genetics and various examples of common diseases 
including Alzheimer’s disease (APOEe4 ) to conclude that the common 
disease/common variant model is a good predictor of disease alleles in complex 
disorders. However studies of hypercholesterolemia favoured multiple rare variants 
as being aetiological in three genes This view is also supported by the findings of 
Lohmueller et al. (2003).
1.7 L IN K A G E RESULTS IN SC H IZO PH REN IA
Thus far there have been two meta-analyses of linkage studies undertaken in 
schizophrenia (Badner et al. 2002) and (Lewis et al. 2003). The methods used by 
Lewis et al. are set out by Levinson et al., (2003).
There are two areas where both studies agree, chromosome 8p and 22q.
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Table 1:3 The meta-analyses of linkage studies in schizophrenia Lewis et al. (2003) and Badner 
and Gershon (2002).
Lewis et al. Badner & Gershon
iq
2q
3p
5q
6q
6p
8p 8p
lOp
n q
13q
14p
15q
16q
18q
20q
22q 22q
Lewis et al. (2003) most strongly favoured 2q, but also found that the number of loci 
meeting the aggregate criteria for significance was much greater than the number of 
loci expected by chance (p<0.001). Support was also obtained for regions on 
chromosomes lq, 3p, 1 lq, 6p, 5q, 22q, 8p, 20q and 14p. It is worth mentioning that 
the region most strongly supported by the evidence of Lewis et al. (2003) on 
chromosome 2q, is not one that had received strong support previously.
1.8 ASSOCIATION RESULTS IN SCHIZOPHRENIA
1.8.1 CHROMOSOME 5
There is evidence of a schizophrenia susceptibility gene on chromosome 5 (Schwab 
et al. 1997; Straub et al. 1997; Devlin et al. 2002). Pimm et al. (2005) had found 
significant evidence of linkage disequlibrium of the 5’ end of the gene Epsin 4 
(5q23.1-33.3) and also two single nucleotide polymorphisms (SNPs) within Epsin 4 
(a clathrin-associated protein enthoprotin). This association was further supported in 
a replication by Tang et al. (2006) in a sample of 308 Han Chinese family trios,
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however Liou et al. (2006) failed to find independent evidence of association to 
Epsin 4.
Petryshen et al (2005) and Ikeda et al (2005) have also found some evidence of 
association between GABAA receptor gene cluster on 5q31-35 being involved in 
schizophrenia although the results are weak and are suggestive. Epsin 4 is so far the 
most promising candidate gene on chromosome 5.
1.8.2 CHROMOSOME 6
Dysbindin (DTNBP1)
The protein Dysbindin is encoded by a gene on chromosome 6p linkage between 6p 
and schizophrenia was originally found by Straub et al. (2002) and the region was 
fine mapped to implicate DTNBP.
The finding has been replicated by the several groups including Williams et al. 
(2004); Kirov et al. (2004); and Numakawa et al. (2004). Raybould et al. (2005) 
found no evidence for Dysbindin being involved in bipolar disorder.
Finally, Breen et al. (2006) found a positive association with dysbindin and bipolar 
affective disorder.
1.8.3 CHROMOSOME 8
NRG1 - More than 11 individual studies have reported a positive association of 
Neuregulin (NRG1) with schizophrenia, the original one being Stefansson et al. 
(2002); two have reported negative findings. Law et al. (2006) have recently 
reported an interesting variation in mRNA in post-mortem hippocampi associated 
with a single SNP within a risk haplotype.
Green et al. (2005), showed association (p=0.003) with a core haplotype in the 
NRG1 locus with bipolar disorder.
PCM1 - Other genes on chromosome 8p have been implicated. One of these (PCM1) 
has been fine mapped on chromosome 8p. This was found in both UK and USA 
samples (Gurling et al. 2006) but further confirmations are needed.
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Frizzled, a transmembrane receptor essential in neurodevelopment was shown to be 
associated by Yang et al. (2003); the finding has not been replicated by Wei et al. 
(2004) and Hashimoto et al. (2005).
PPP3CC (protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform 
(calcineurin A gamma)) also on 8p22, was found to show allelic and haplotypic 
association with schizophrenia by Gerber et al (2003); a finding not replicated by 
Kinoshita et al. (2005).
1.8.4 CHROMOSOME 13
Chumakov et al. (2002) obtained a strong LD signal from haplotypes within a 5Mb 
candidate gene on 13q. The signal localised around two overlapping genes, G30 and 
G72. Analysis of G72 revealed an interaction with D-amino acid oxidase (DAO, 
DAAO also known as DAOA). Hattori et al. (2003) found both individual SNP 
markers and haplotypes to be associated with bipolar disorder. Chen et al. (2004) 
also found an association with bipolar disorder. A large case control study found 
evidence of association for select SNPs and a haplotype with both schizophrenia and 
bipolar disorder Schumacher et al. (2004).
1.8.5 CHROMOSOME 22
Velocardiofacial and DiGeorge syndromes are associated with learning disability 
and usually arise from small, relatively frequent deletions on the long arm of 
chromosome 22 (22ql 1 deletion syndromes).
The associated phenotype is highly variable with congenital heart defects occurring 
in approximately three-quarters of patients. Nearly 90% have a 3Mbp deletion 
encompassing 30 genes. The relative risk of schizophrenia in people with 22ql 1 
deletion syndromes is around 25-30.
Two genes in the region stand out through linkage and association studies as 
possible candidates for psychiatric outcomes. These are catechol-O- 
methyltransferase (COMT) and proline dehydrogenase (PRODH). Shifman et al 
(2002) found a highly significant association between schizophrenia and a COMT
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haplotype in a large case-control sample in Ashkenazi Jews (P=9.5xl0' ), and also a 
resulting lower expresson of the gene in the human brain . shifman now report errors 
in their genotyping and meta-analysis of COMT in schizophrenia (Munafo et al.
2005). Li et al (2004) analyzed the PRODH gene in patients with schizophrenia and 
their families from Sichuan Province in China, comprising 528 family trios and sib 
pairs. They found association of schizophrenia with 2 haplotypes consisting of the 
1945T-C and 1852G-A variants (global p = 0.006) and the 1852G-A and 1766A-G 
variants (global p = 0 .01 ).
1.8.6 CHROMOSOME 1
DISCI and DISC2.
The presence of a schizophrenia susceptibility locus on chromosome lq42.1 was 
first suggested by the observation of linkage between schizophrenia and other 
psychiatric disorders with a balanced translocation involving chromosomes 1 and 11 
[t( 1; 11)(q42.1;ql4.3)] (St Clair et al. 1990; Blackwood et al. 1998; Millar et al.
2000). Investigators in Edinburgh identified an individual with a reciprocal 
translocation between chromosomes 1 and 11 (+(1;11)). The segregation of this re­
arrangement was followed through an extended pedigree. Clinical studies found 
schizophrenia, major depression and bipolar disorder in translocation carriers but not 
in members of the family that were non-carriers (Blackwood et al. 2001).
Further analysis showed the chromosome 1 breakpoint directly disrupted two over­
lapping genes, termed disrupted in schizophrenia 1 and 2 (DISCI and DISC2). 
DISC2 coded on the opposite DNA strand to DISCI, DISC2 is transcribed but not 
translated and is possibly an RNA gene with some regulatory function (Millar et al.
2001).
Subsequently two linkage studies found significant evidence for linkage at lq23.3, 
which is centromeric to the locus implicated by the cytogenetic abnormality 
(Brzustowicz et al. 2000; Gurling et al. 2001). Another study combined allelic 
association, cytogenetic and family linkage data on chromosome 1 using 
heterochromatic C-band variants in the 1 q22.1 -23 region and found cosegregation of
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a lqH (C-band) variant and Duffy blood group alleles with schizophrenia in a single 
family (Kosower et al. 1995).
RGS4 maps to one of the two regions showing linkage of chromosome lq23.3, it 
was targeted for genetic analysis following a microarray based gene expression 
study in which decreased RGS4 expression was found in schizophrenic post-mortem 
brain (Chowdari et al. 2002). Several replications have been reported (Morris et al. 
2004) and (Williams et al. 2004). But a meta-analysis was inconclusive (Talkowski 
et al. 2006).
CAPON (also known NOS1AP) Brzustowicz et al. (2004) first reported an 
association of novel candidate gene CAPON (now known as NOS1 AP) on lq23.3. 
This gene was identified in 24 Canadian familial-schizophrenia pedigrees, and 
encodes a protein nitric oxide synthase 1 (neuronal) adaptor protein which is thought 
to be involved in neuronal signalling.
Other linkage studies from Finland found significant evidence for linkage to 
schizophrenia in a position that was telomeric to lq23.3 but proximal to lq42.1 
(Ekelund et al. 1997; Hovatta et al. 1999; Ekelund et al. 2000). However, the 
marker that was found to have the highest parametric lod in the earlier Finnish 
linkage study (Hovatta et al. 1999) was also the marker closest to the more 
centromeric linkage region at lq23.3. Two further analyses from Finland in 
independent family samples found a lod of 3.21 (Ekelund et al. 2000) and then 2.7 at 
the more distal position of lq42 near the DISCI locus (Ekelund et al. 2004). Three 
further linkage studies found less conclusive but supportive evidence for linkage to 
schizophrenia at lq23.3 with a lod of 1.7 at a position 20 cM proximal to DISCI 
(Cai et al. 2002). A Taiwanese linkage study reported weakly positive lods at both 
the RGS4 region at lq23.3 and at lq42.1 (Hwu et al. 2003). A linkage study based 
on a combined UK/USA sample supported linkage at lq23.3 with a lod of 1.80 with 
the marker D1S196, which is the same marker that showed a lod of 3.20 in the 
UK/Icelandic genome scan (Shaw et al. 1998; Gurling et al. 2001). At present the
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linkage studies lead one to suspect that there are two schizophrenia susceptibility 
loci in the lq region, sixty four megabases apart at lq23.3 and lq42.
Recently, Mah et al. (2006) have undertaken a genome-wide scan using over 25,000 
SNPs located within approximately 14,000 genes. They have found a marker on 
lq32 within a novel candidate gene (PLXNA2).
1.9 C H R O M O SO M E 1Q23.3 AS A SC H IZO PH REN IA
SU SC EPTIBILITY  LOCUS
The lq23.3 locus was chosen to be further investigated as it had been implicated in a 
meta-analysis linkage study with a rank of 7th through weighted analysis (Lewis et 
al. 2003). The region was also implicated in our own sample (Gurling et al. 2001). It 
was therefore clearly an interesting site upon which to focus further attention. Two 
promising genes RGS4 (Chowdari et al. 2002) and CAPON (Brzustowicz et al.
2004) have been implicated by association in the lq23.3 region in a small sample.
To confirm or reject these genes as candidates for schizophrenia susceptibility, a 
replication study in a British case control sample would be carried out alongside fine 
mapping a broader area to see if the surrounding regions are associated with 
schizophrenia or not.
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2.0 MATERIALS AND METHODS
2.1 SC R EEN IN G , ASSESSM ENT AND A SC ER TA IN M EN T OF  
SC H IZO PH R EN IC  CASES AND OF SU PER NO RM AL  
CO N TR O LS
DNA samples from 450 volunteers with schizophrenia (70% male, 30% female, 
mean age 44.8) and 450 controls (46% male, 54% female, mean age 36.5) had been 
collected and were used in our case control sample (figure correct from 2004 to
2006). All subjects were included only if both parents were of English, Irish, Welsh 
or Scottish descent and if three out of four grandparents were of the same descent. 
One grandparent was permitted to be of Caucasian European origin but not of 
Jewish or non-EU ancestry, based on the EU countries before the recent enlargement 
(2004). The ancestry information was recorded in an Ancestry Questionnaire and it 
was confirmed from the family histories recorded in medical records. The ancestry 
selection criteria is not meant to be discriminatory, but was carried out to ensure that 
the observed genetic differences are disease related and not ancestry related. UK 
National Health Service (NHS) multicentre and local research ethics committee 
approval was obtained and all subjects signed an approved consent form after 
reading an information sheet. All 450 schizophrenic research subjects had previously 
been diagnosed and assessed by NHS psychiatrists as part of routine clinical 
diagnosis and treatment. Subjects with short-term drug-induced psychoses, learning 
disabilities, head injuries schizoaffective bipolar disorder or schizo-mania and other 
symptomatic psychoses were excluded. Schizophrenic subjects were recruited for 
research interviewing on the basis of having an International Classification of 
Diseases version 10 (ICD10) diagnosis of schizophrenia recorded in the medical 
case notes. The Schizophrenia and Affective Disorders Schedule- Lifetime Schedule 
(SADS-L) interview (Spitzer et al. 1977) was completed by a research psychiatrist 
who interviewed all cases and controls. Cases were defined as having schizophrenia 
with the SADS-L interview according to the “probable” level of the Research
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Diagnostic Criteria (RDC). The “supernormal” control subjects were selected based 
for not having a personal history of any RDC defined mental disorder derived from 
the SADS-L interview and for not having a family history of schizophrenia, 
alcoholism or bipolar disorder at interview or recorded in case notes.
Volunteers’ blood was collected in 8ml EDTA or citrate plastic tubes and was stored 
at -80°C until DNA extraction. For patient confidentiality, all samples were 
anonymomised.
2.2 CH EM IC A LS AND REAGENTS USED TH R O U G H  OUT  
TH E EXPERIM EN TS
The following sections contain information on all of the regents used in the 
experiments for each particular technique.
2.2.1 MILLI-Q SYSTEM
The water used to make up all reagents (except PCR master mixes which used ultra 
pure water (Sigma, W4502) which is known to be DNase and RNase free) was pure 
water produced by the Milli-Q system, referred from now on as Milli-Q water.
The Milli-Q water system works by taking in mains tap water and filtering it. The 
first step of the filtration is through the reverse osmosis filter which removes the ions 
and main contaminants present in the water. This distilled (deionised) water is then 
passed to a main holding tank which houses an Ultra Violet (UV) light source. The 
UV light is there to destroy and prevent any micro-organisms from contaminating 
the water and also break down any organic compounds present by photo-oxidation. 
The water then moves to another resin filter to remove any remaining water 
contaminants present, the water finally moves to a small final filter to polish the 
water before the water is finally dispensed for use.
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The Main reagents used through out the experiment are listed below.
2.2.2 REAGENTS FOR DNA EXTRACTION:-
• 0.5M ethylene diamine tetraacetate acid (EDTA) (BDH, product number
100935v)
186.1 g was added to 800mL of Milli-Q water, and dissolved by adjusting to pH 8.0 
using sodium hydroxide pellets (Sigma S5881) the solution was then sterilised by 
autoclaving at 15 pounds per square inch (15 PSI) at 121°C for 15 minutes, using 
autoclave tape as an indicator that the process has taken place.
• 2M Tris-HCL
121.1 grams of Tris base (BDH, 103156X) was dissolved in 400ml of Milli-Q water, 
the pH was adjusted to pH 8.0 with concentrated hydrochloric acid (BDH 10125), 
and the final solution was brought up to 500ml before being sterilised by 
autoclaving.
• TE Buffer.
This solution is made up by combining lOmM of Tris-HCL with ImM of EDTA. 
Hence 5ml of 2M Tris-HCL and 2ml of 0.5M EDTA were mixed and the solution 
was brought up to 1000ml with Milli-Q water. The solution was then sterilised by 
autoclaving.
• Proteinase K Buffer
50mM of Tris-HCL, 50mM EDTA and lOOmM of NaCl (Sigma S7653) is required. 
Hence 25ml of 2M Tris-HCL, 100ml of 0.5M EDTA, and 25ml of 4M NaCl were 
mixed and the solution was brought up to 1000ml with Milli-Q water before 
sterilising by autoclaving.
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• 10X Lysis buffer
5.84g of NaCl was mixed with 37.22g of EDTA in 1000ml of Milli-Q water. 
Solution was then autoclaved. (EDTA is an important component as it removes 
magnesium ions that are essential for preserving the structure of cell envelope, and 
inhibits cellular enzymes that could degrade DNA.)
• 3M Sodium Acetate (pH 5.2)
246.09g of anhydrous sodium acetate (Sigma S2889) was dissolved in 800ml of 
Milli-Q water. The pH was adjusted to 5.2 with Glacial acetic acid (BDH, 
10001) the volume was brought up to 1000ml and then autoclaved.
• 10% Sodium dodecyl sulfate SDS
This was made by dissolving lOg of SDS (Sigma L4509) in 100ml of Milli-Q 
water.
• 20mg/ml Proteinase K enzyme solution (BDH 39509)
• Buffered Phenol (Sigma P4457) mixed with a few flakes of indicator dye 8- 
hydroxyquinoline (Sigma H6878) this dyes the phenol yellow and becomes 
brown once oxidised indicating that the phenol has been oxidised and 
therefore no longer useable.
• Chloroform (BDH, 100776B)
• Isoamyl alcohol (IAA) (Sigma, S5881) also known as 3-methyl-1-butanol
• PVPP (Polyvinylpolypyrrolidine [Sigma P-6755])
• Ethanol (BDH, 10107)
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• Virkon (VWR 148-0202), used to deactivate blood and cleanse work 
surfaces, (lOg dissolved in 1 litre of water). Once mixed with waste blood 
and left to stand for 5 minutes it was then safe to dispose of down the sink.
2.2.3 REAGENTS FOR DNA QUANTIFICATION
• Picogreen (molecular probes, Invitrogen P7581)
• Calf thymus DNA 50pg of dehydrated DNA (Sigma D3664)
2.2.4 REAGENTS FOR PCR AMPLIFICATION AND SEQUENCING 
REACTIONS
PCR amplification: reagents supplied by bioline in a BioTaq Red polymerase kit
(BIO-21041)
• 1 OX solution NH4 reaction Buffer
• 50mM magnesium chloride
• 25mM solution dNTPs
• Taq polymerase red lU/pl.
• 5M Betaine (Sigma B2629), 29.29g dissolved in 50ml of ultra pure water 
(for stock)
• Ultra Pure Water (Sigma, W4502)
• For Geneotyping (M l3 Forward LRD 800/700) also added (MWG, Ebersberg 
Germany).
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Template Clean-up
microCLEAN (Microzone 2MCL-50), removes mastermix reagents Enzymes and 
primer dimer to leave clean DNA template (for full method of use see section 2.8.4).
Sequencing reaction
Reagents used, SequiTherm EXCEL™ II (Microzone, SE9101LC)
Clean DNA Template.
3.5X SequiTherm Buffer.
SequiTherm Taq Polymerase.
Termination mix di-deoxyNTP.
M13F 700 and M13R 800 lOpmol/pl (MWG).
Ultra pure water.
2.2.5 REAGENTS FOR GEL ELECTROPHORESIS:-
• Low resolution electrophoresis: 1% agarose (Sigma, A9539) with lx TBE 
(National diagnostics EC-860)
• SequaGel XR (National Diagnostics EC-842) polyacrylamide gels for high 
resolution genotyping and sequencing were created as follows.
10% Ammonium Persulfate (APS) (Sigma, A9164) mixed with a set volume of the 
buffered acrylamide solution to allow polymerisation (800pL of 10% APS to every 
lOOmL of buffered Sequagel solution). The gel was then caste between the 2mm gap 
of two glass plates of 25cm length for genotyping or a 44cm length for sequencing. 
The gel was allowed to set for two hours
• TBE (Tris-Borate-EDTA) (National diagnostics EC-860) electrolyte buffer.
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• Fuchsin: (Sigma, S5881)
This loading buffer was used for sequencing and genotyping and was made with 
0.05g of Fuchsin and 50ml of Formamide (Sigma, F9037).
• Ethidium bromide (Sigma, E215) used in agarose gels to intercalate with 
double stranded DNA in order to visualise DNA bands under Ultraviolet 
light
• Hyperladder IV (Bioline, London, UK, BIO-33029) molecular weight for 
agarose gels sizes from 1 OObp to 1 OOObp increasing in 1 OObp increments
• MicroSTEP20a (Microzone, lN700/80020a) molecular weight for 
polyacrylamide gels, both IRD 700 and 800 molecular weights are used 
molecular weight markers were as follows:- 70, 90, 100, 120, 140, 160, 180, 
200, 220, 240, 260, 280, 300, 310, 330, 340, 350, 360, 380 and 400 base 
pairs.
2.3 D N A  EX TR A C TIO N  FROM  W H OLE BLO O D CELLS
Genomic DNA was extracted from whole blood samples using a standard cell lysis, 
proteinase K digestion, phenol/chloroform ethanol precipitation method. It is a two 
day method where in the first day the leukocytes are isolated and then lysed to 
release the genomic material, followed by overnight digestion of proteins with 
proteinase K. The second day involves the isolation and extraction of genomic DNA.
DNA was extracted from fresh blood if it was practical to do so. Otherwise the blood 
was stored at -80°C.
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Day 1.
If the blood was frozen, the required blood was removed from cold storage at -80°C, 
and was allowed to gently thaw out in a water bath at 30-35°C. This was done to 
prevent the cells from lysing from shock, and preventing the release of damaging 
enzymes such as DNAase from damaging the genomic DNA.
The fully thawed blood was then transferred to 50ml centrifuge tubes, which were 
then toped to 50ml with lysis buffer. The tube was inverted several times to ensure 
mixing. This allowed the lysis buffer to break up the whole red blood cells 
(erythrocytes) whilst leaving the DNA containing white blood cells (leukocytes) 
intact.
The lysate was then spun in a balanced centrifuge at 3000rpm (2000g) at 4°C for 15 
minutes to pellet and isolate the white blood cells. The supernatant was disposed of 
into Virkon disinfectant leaving the white blood cell pellet behind.
The pellet was re-suspended in 50ml of lysis buffer to remove any remaining red 
blood cells and again centrifuged at 3000rpm for 15 minutes. The supernatant was 
again disposed of in Virkon.
The cleaned white blood cell pellet was re-suspended in 500pl of 10% sodium 
dodecyl sulfate (SDS) which would break open the cells by disrupting the lipid 
membrane, hence releasing its contents including the genomic DNA into the 
solution. In addition 10ml proteinase K buffer was added to provide stable optimum 
conditions for the proteinase enzyme. To the lysate, 50pl of 20mg/ml proteinase K 
was mixed in. The presence of the enzyme would break down complex protein 
allowing for their efficient removal and also to deactivate any damaging enzymes 
such as DNAase which would harm the targeted DNA. This lysate was incubated in 
a water bath at 55°C (just below the optimum temperature of proteinase K at 65 °C) 
on a shaking platform overnight, to allow for the reaction to occur as far as possible.
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Day 2.
5ml of buffered phenol along with 5ml of chloroform (1:24 Isoamyl alcohol : 
chloroform) was mixed with the cell lysate. The phenol-chloroform mixture is used 
to dissolve the lipids and precipitate the proteins this would leave the nucleic acids 
in an aqueous layer, white coagulated protein would be left at the interphase after the 
mixture was centrifuged.
The mixture is centrifuged at room temperature for 15 min at 3000rpm which would 
allow the mixture to separate out into the organic solvent (phenol-chloroform) layer 
at the bottom of the centrifuge tube (containing lipids), the protein interphase, and 
on top the aqueous layer containing the nucleic acid. This aqueous layer is 
transferred into a fresh labelled 50ml centrifuge tube for DNA precipitation, and the 
organic solvents are disposed of safely according to UCLs’ health and safety 
disposal of hazardous solvents protocol.
As a note, it is notoriously difficult to extract the aqueous layer up to the interphase 
without disturbing the layer itself. So we used in addition to the phenol-chloroform 
mix, 1 gram of PVPP (Polyvinylpolypyrrolidine) mixed with 5ml of TE. Once 
centrifuged with the organic mix, it will hold down the protein interphase along with 
the organic solvents allowing one to remove the maximum amount of the aqueous 
layer without contamination.
From this aqueous layer DNA was precipitated by adding 1500pl of 3M Sodium 
Acetate then adding 30ml of absolute ethanol. The tube was then inverted gently 
until the DNA precipitates out of solution into a condensed white clump.
The DNA clump was removed with a sterile glass or plastic rod and then washed in 
70% ethanol to remove as much sodium acetate as possible (in order not to interfere 
with any Polmerase Chain Reactions (PCR)). The DNA clump is then transferred 
into a labelled 1.5ml micro screw tube in 500pl of TE. The DNA samples were
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stored away from light at room temperature for about a week. This was to allow the 
DNA to dissolve into solution before quantification.
2.4 DN A  Q U A N TIFIC A TIO N
All DNA samples were quantified with Picogreen (Molecular Probes), by 
fluorimetry. (FLA-3000 scanner (Fuji))
All the extracted DNA samples were quantified to allow for standardisation. This 
standardisation was done in order to have known amounts of DNA for use in 
genotyping and sequencing.
The DNA samples were quantified by transferring 2pl of each sample into a fresh 
labelled 2ml eppendorf tube containing 78pl of TE. This was thoroughly mixed by 
votexing, form which lOpl of each sample was transferred to a (known recorded 
location) flat bottomed well plate (96 well plate) containing 90pl of TE. Along side 
the samples to be quantified was a series of wells containing known concentrations 
of DNA derived from calf thymus. This was diluted to produce samples at 0, 1, 10, 
20, 50, 75 and lOOng/pl. This was done in order to produce standard curve from 
which the concentration of the samples could be derived from.
The DNA samples were mixed with lOOpl of Picogreen (150pl Picogreen dissolved 
in 30ml of TE) which is a fluorescent dye which specifically binds to double 
stranded DNA. Once the picogreen is mixed, the plate containing the sample is 
scanned by fluorimetry. The fluorescence is directly proportional to the quantity of 
DNA present. From the results, the DNA was then diluted to form two 1.5ml micro­
screw tubes with a concentration of 25ng/pl for direct use, the rest is labelled up as 
stock with its known concentration. All DNA is stored below 5°C in a dark place to 
maintain its quality.
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2.5 M IC R O SA TELLITE AND SINGLE NU CLEO TID E
PO LY M O R PH ISM  (SNP) SELECTION FO R  A SSO C IA TIO N  
STUDIES
Genetic markers such as polymorphic Microsatellites and Single nucleotide 
polymorphisms (SNPs) are used to detect association between alleles and the 
disease. Microsatellites are useful for detecting distant linkage disequilibrium; 
however they are not very common in the genome. Further fine mapping of a region 
was then carried out by SNPs which tend to be more common (approximately 1 SNP 
in 300 to 1000 bases). Selection of markers, genotyping and analysis of the data are 
described below.
2.5.1 MICROSATELLITE SCREENING AND SELECTION
Microsatellites are short tandem repeat polymorphisms (STRPs) which consist of a 
short repetitive sequence typically of one to four bases. The most common type is 
the (CA)n dinucteotide repeat, tetra nucleotide repeats are more rare. What is useful 
about microsatellites is that they are common and dispersed throughout the genome 
and found even within genes. The size (number of repeats) of these microsatellites 
has altered though evolutionary history increasing or decreasing their repeat size. 
These polymorphic microsatellites contain information which enables us to map and 
screen the genome, to carry out linkage and association studies which, enables one 
to fine map and identify a candidate gene. The theory is that during the same 
evolutionary time scale, the mutation event which produced a schizophrenia 
susceptibility/causative gene, also was the same time point that a nearby, linked 
microsatellite mutated. This would produce an associated allele linking the gene 
with that particular allele size, which would co-segregate with the 
susceptibility/causative gene. In addition other events could have occurred where the 
mutation occurred on the evolutionary background of a pre-existing polymorphism.
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Finding a polymorphic microsatellite marker is fairly hit and miss. The best way to 
find them is to use bioinformatic databases to find established microsatellites such as 
The Human Genome Database GDB, and University of California Santa Cruz 
(UCSC) Genome Browser. In order to find microsatellites in regions where there are 
not many established microsatellites, bioinformatic databases can be used in order to 
search for simple repeats to find non established microsatellites. Dinucleotide and 
tetranucleotide repeats are sort, and a minimum repeat copy size of approximately 
10 is used to select the putative microsatellite to increase ones chances for selecting 
a polymorphic microsatellite.
Once the desired sequences are selected, primers are designed to amplify the 
sequence. This was carried out using an internet program called Primer3 (developed 
by MIT Whitehead institute (Rozen et al. 2000)) this program uses algorithms to 
pick primer sequences with sequence specificity (avoiding repetitive sequence) 
forward and reverse primers with similar melting temperatures (Tm), and with a low 
probability of forming hairpin loops, which would inhibit amplification.
With the desired primers picked, Ml 3 tails were added to the 5 prime end of a single 
primer for genotyping, or a forward and reverse M l3 sequence to each primer for 
sequencing. M l3 tails are used to detect the PCR product through fluorescence, by 
also adding a second Ml 3 complementary primer with a particular wavelength dye 
to incorporate itself into the product.
The M l3 wave length used were M l3 forward 800 and M l3 forward 700 for 
genotyping to allow one to genotype more than one marker of similar size at the 
same time. For sequencing, M l3 forward 700 and M l3 Reverse 800 were used to 
capture the sequence of both strands.
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Table 2:1 Primer tail sequences for genotyping and sequencing.
P rim er Sequence of tail
Genotyping 
M13F 700/800
M13F CACGACGTTGTAAAACGAC
Sequencing 
M13F 700, 
M 13R 800.
M13F CACGACGTTGTAAAACGAC M13R GGATAACAATTTCACACAGG
With the Ml 3 tail sequences added to the 5 prime end of the primer. The entire 
primer sequence was checked to see if a secondary structure such as a hairpin loop 
would impede amplification. This was checked by using the NetPrimer (Premier 
Biosoft international) program. A score under 70 is undesirable, and hence the 
primer with the best score for the M l3 tail was chosen. Microsatellites where chosen 
to target specific loci as described below.
The primers were ordered from MWG biotech (Ebersberg, Germany) at a 
concentration of 100 picomoles/micolitre.
2.5.2 SNP SELECTION FOR ASSOCIATION STUDIES
The problem with microsatellites is that they are not very densely interspersed 
within the human genome. Therefore fine mapping requires other types of markers 
in the implicated region. In these instances one can turn to single nucleotide 
polymorphisms (SNPs) to further fine map the area. These are bi-allelic systems 
which are far more common than microsatellites and are approximately present in a 
ratio of one SNP per 300 bases to 1000 bases of sequence. This enable one to fine 
map a region with greater density and also enable one to select SNPs within a gene 
of interest. As a result this greatly enhances the resolution of the implicated region 
and hence helps to implicate a susceptibility gene.
The ability to genotype densely populated SNP regions, has led to a new era of 
whole genome association studies. Where the whole genome can be mapped using 
densely populated SNPs enabling one to refine and enhance the resolution of the
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association study. When this project was started whole genome association did not 
exist and typing multiple SNPs was very costly.
2.5.3 CHOOSING SNPS
For fine mapping a particular area one can chose SNPs form an online database such 
as HapMap (HapMap 2003). HapMap is an online consortium consisting of typed 
SNPs in subjects from different ethnic groups. The aim of this project was to 
identify and genotype as many common SNPs in the genome as possible. This 
would enable researchers involved in association studies to pick out the most 
appropriate SNPs in their specific chromosomal region and specific ethnic 
population. A number of programs enable the selection of “Tag SNPs”. These are 
SNPs that are likely to carry identical genetic information to that of nearby SNPs in 
complete linkage disequilibrium. This enables one to choose SNPs which represent 
other SNPs in the region without duplicating information thereby extracting as much 
information about the region as possible. The data generated by HapMap can be 
interpreted by using a piece of software known as HAPLOVIEW (Developed at the 
Whitehead Instiute) (Barrett et al. 2005). With this software, one is able to visualise 
the Linkage Disequilibrium (LD) makeup of a chosen region graphically, and judge 
which SNPs are useful to type, based on their haplotype structure, also by using the 
tagger function (set to its default setting) which helps to pick up the best tagged 
SNPs with different information. One is also able to use their D' and r2 values as 
seen graphically on HAPLOVIEW (D’ and r2 in section 3.2.1) in brief D ’ and r2 
values are both different measures of LD and are both measured in a scale between 
zero (for no LD) to one (for complete LD) if both the values are “one” then the SNP 
is said to be genetically identical and share the same information.
An alternative method of selecting SNPs is through sequencing of selected 
individuals in the sample which one thinks are significantly associated with a 
putative region or susceptibility gene (through statistical haplotypic analysis of 
previous implicated markers (section 3.2.4.3). One may come across undefined 
(non-database) polymorphisms within a targeted region, which in turn can then be
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genotyped in the entire case-control sample to see if this marker is also associated 
with the disease. This would help to add further evidence for the involvement of a 
putative susceptibility gene, help to identify the most likely individuals for targeted 
sequencing for causative mutations, or even may be implicated in directly 
influencing the expression of the gene, which may cause a non-synonymous 
mutation of an exon or disrupt intron splicing or binding of transcription factors.
Genotyping the SNPs in the selected sample can be carried out a number of ways 
and are further described in section 2.8.3. The methods used to type SNPs in brief 
are, Sending the higher frequency SNPs to Kbioscience Ltd (Hoddesdon, UK) to 
genotype on in our sample. This company have developed a cost effective optimised 
KASPar assay system to type SNPs. Another method used in this thesis is single 
base sequencing (mini sequencing), where the nucleotide which carries the SNP is 
solely used in chain termination sequencing (see Figure 2:4), this high throughput 
method was used to identify and genotype rare SNPs which Kbiosciences Ltd are 
less effective in formatting because they screen for SNPs and optermise initially in a 
small number of samples. Often we are aware of SNPs that do not observe because 
of their low frequency.
2.6 O PTIM ISA T IO N  OF PRIM ERS AND PCR
2.6.1 WHAT IS PCR?
PCR is a method to amplify a specific target DNA sequences present within a source 
of complex DNA. To permit specific amplification of the targeted sequence, 
information about the sequence is required to produce two specific primers that 
enclose the targeted sequence these primers are generally 15-25 nucleotides long for 
specific targeting and amplification, the design of primers is mentioned in section 
2.5.1.
Lyophilised primers are first rehydrated in TE to produce a concentration of 100 
pmoles/pl. Before each use they are votexed and briefly spun down. Newly designed 
primers need to be optimised to find the optimal master mix concentrations and PCR
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conditions to produce the best results and a successful amplification of the targeted 
region. Optimisation is carried out on a few DNA samples that have been excluded 
from the study and PCR products are visualised on agarose and polyacrylimide gels. 
The components of the mastermix and the PCR conditions used (both of which can 
be vaired) will be discussed next.
2.6.2 MASTERMIX FOR GENERAL OPTIMISATION AND 
AMPLIFICATION
For optimisation of primers, four common conditions were used to amplify the target 
region (Table 2:2). These conditions can be altered and manipulated to produce the 
optimal conditions to amplify the target region specifically in conjunction with 
choosing PCR conditions.
For amplifying and genotyping a microsatellite, the relevant M l3 Forward 700 or 
800 is added to the master mix, to produce a product at the relevant frequency. Once 
amplified Fuchsin loading buffer was added (equal volume). The amplified samples 
were then denatured at 95°C for 3 minuets and then loaded on the polyacrylamide 
gel and visualised by the LICOR DNA sequencers.
However for sequencing, M13F/R is not added at this stage. The first stage is to 
amplify the target for sequencing without integrating any of the IRD 700/800 dye. 
The template is then cleaned up and set up for the next PCR phase, the Sanger- 
Coulson chain termination sequencing method using the M13F/R primers for PCR 
amplification (Section 2.8.4.1).
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Figure 2:1 Intergation of the M13 sequence into the amplimer and subsequent amplification of the target 
sequence with the M13 primers containing the infra red dyes for visualisation by LICOR DNA
Genotyping Sequencing
Amplification of 
target with M13F 
sequence attached 
to one primer.
A third universal 
M13F primer 
attaches to the 
integrated M l3 
sequence to 
commence 
amplification.
The M13F primer 
integrates the IRD 
800/700 dye into 
the amplimer.
Figure 2.1 shows the difference between the genotyping step where M13F primer is 
solely used in a single step PCR reaction. The Sequencing first step is to integrate 
the M 13 forward and reverse sequence and amplify the target, before it is cleaned. 
The template is then amplified with the M13F/R primers in the sequencing reaction 
integrating the IRD dye and the dNTPs, the reactions are terminated upon 
integration of ddNTPs.
Amplification of target 
with M13F & R 
attached to the primers.
Amplimer is cleaned 
and used as template 
for sequencing 
reaction.
■ ■ ■ ■ I
■ ■ ■ ■
■ ■ ■ ■ l
■ ■ ■ ■ l
■ ■
■ ■
M13F 700 & M UR 800 
primers attach to 
integrated sequence and 
amplify inserting the 
corresponding dye during 
sequencing reaction.
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For PCR optimisation four Master Mix conditions were commonly used, the four 
Master Mix optimisation conditions used are shown in Table 2:2. The magnesium 
ion concentration is varied which influences the specificity of the PCR reaction and 
also acts as an co-enzyme to the Taq polymerase. In addition the presence or 
absence of 5M betaine is used. Betaine helps to reduce the melting point and is 
useful in regions of high GC content. Each of the four conditions is listed in Table 
2:2 along with variable PCR conditions in Table 2:3. The optimisation conditions 
that provided the best results were then used to amplify the entire sample. Where the 
samples are suboptimal, further “tweaking” of the PCR conditions were performed.
Table 2:2 Showing the volumes (pi) of reagents in a single 12pl reaction and the common 
conditions used for primer optimisation and amplification.
Condition A Condition B Condition C Condition D
2.0mM MgCl2 
+ Betaine
2.0mM MgCl2 
+ No Betaine
2.5mM MgCl2 
+ Betaine
2.5mM MgCl2 
+ No Betaine
10X Buffer 1.2 1.2 1.2 1.2
Betaine 5M 2.4 0 2.4 0
50mM MgCl2 0.48 0.48 0.6 0.6
25mM dNTP 0.1 0.1 0.1 0.1
F primer 
lOOpmol/pl
0.036 0.036 0.036 0.036
R primer 
lOOpmol/pl
0.036 0.036 0.036 0.036
M13 800 
100pmol/pl
M13 700 
100pmol/|il
0.036 0.036 0.036 0.036
Taq lU/pl 0.19 0.19 0.19 0.19
DNA 25ng/pl 2.0 2.0 2.0 2.0
Water 5.52 7.92 5.39 7.79
Total Volume 
(Pi)
12.0 12.0 12.0 12.0
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2.6.3 POLYMERASE CHAIN REACTION (PCR) CYCLING 
CONDITIONS
Once the primers are added to the master mix containing all the required reagents for 
DNA amplification (such as dNTPs, Taq, magnesium and buffer and also the 
genomic template) the PCR can begin.
First the DNA template is denatured for an extended period of time to separate the 
double stranded helix and allow for the template to become linear.
The PCR runs in a three step cycle of:-
1. Denaturation, which typically occurs at 93-95°C
2. Reannealing where the primers bind specifically to their complementary 
sequence, the annealing temperature usually depends on the melting 
temperature (Tm) of the expected duplex this tends to be approximately 5°C 
below the expected Tm.
3. DNA synthesis, extension of the complementary strand initiated by the 
annealed primer which occurs at 70-75°C.
This runs for approximately 25-35 cycles and is finished by a final extended hold at 
72°C to complete all synthesis and extensions of the targeted region. After about 25 
cycles approximately 226 copies of the targeted region would be made.
The PCR thermal cycler was an MWG-HT Primus 96.
Usually only three standard PCR programs are required to amplify a specific region 
successfully. They are Standard 55°C, Standard 60°C and Touch Down. These 
programs can be tweaked to adjust the annealing temperature and by adding or 
removing one or two cycles to obtain a clean specific amplification of the target 
region. The cycles are set out in Table 2:3. Also set out in Table 2:4 are the 
sequencing PCR conditions (sequitherm) with consist of a longer extension time to 
allow for full extension length variations before termination.
66
Table 2:3 PCR cycling conditions.
Standard 55°C
Lid Heated to 105°C 
Products are denatured at 
94°C for 5 minutes
35 cycles of:- 
94°C -  30 seconds 
55°C -  30 seconds 
72°C -  30 seconds
Hold at 72°C -  10 minutes 
Store at 4°C
Standard 60°C
Lid Heated to 105°C 
Products are denatured at 
94°C for 5 minutes
35 cycles of:- 
94°C -  30 seconds 
60°C -  30 seconds 
72°C -  30 seconds
Hold at 72°C -  10 minutes 
Store at 4°C
Touch Down
Lid Heated to 105°C 
Products are denatured at 
94°C for 5 minutes
3 cycles of:- 
94°C -  30 seconds 
63°C -  30 seconds 
72°C -  30 seconds
3 cycles of 
94°C -  30 seconds 
60°C -  30 seconds 
72°C -  30 seconds
3 cycles of 
94°C -  30 seconds 
57°C -  30 seconds 
72°C -  30 seconds
3 cycles of 
94°C -  30 seconds 
54°C -  30 seconds 
72°C -  30 seconds
3 cycles of 
94°C -  30 seconds 
51°C -  30 seconds 
72°C -  30 seconds
20 cycles of 
94°C -  30 seconds 
48°C -  30 seconds 
72°C -  30 seconds
Hold at 72°C -  10 minutes 
Store at 4°C
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The Sequencing PCR Protocol which consists of a longer extension time than 
standard PCR conditions to enable random chain termination is shown below in 
Table 2:4.
Table 2:4 Sequencing cycling conditions for Sanger-Coulson chain termination method. 
Sequatherm PCR cycle:
Lid Heated to 105°C
Products are denatured at 94°C for 5 minutes
30 cycles of:- 
92°C -  30 seconds 
60°C -  30 seconds 
70°C -  1 minute 
End
Store at 4°C.
2.7 G EL ELEC TRO PH O RESIS: AG ARO SE AND THE USE OF 
LIC O R  DN A  SEQ UENCERS W ITH  POLYACRYLAM IDE
Once amplification has occurred through PCR, the size of the amplimer can be seen 
by gel electrophoresis. The size of the amplimer can be deduced by running a 
molecular weight alongside it.
Gel electrophoresis is used to separate DNA fragments according to size. The gel 
always runs in a negative to positive direction with the DNA loaded near the 
negative cathode. This is because DNA carries a negative charge due to the 
phosphodiester backbone and will hence migrate to the positive anode. As the DNA 
migrates through the gel matrix the fragments separate out according to size with the 
small fragments migrating fast and hence further due to less impediment of its 
migration through the gels matrix. The more concentrated the gel matrix, and the 
further the product has to migrate, the finer the resolution of fragment separation 
becomes.
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2.7.1 AGAROSE GEL ELECTROPHORESIS
For low resolution of the amplimer, to judge the size of the overall band(s), one 
would use agarose gel electrophoresis. A 1% agarose gel is created by dissolving 
agarose powder in lx TBE (the electrolyte used). A molten solution is created by 
heating the solution in a microwave until the agarose powder is fully dissolved. 
Ethidium bromide is then added and mixed with the cooling molten agarose to make 
a final concentration of 0.5jil/ml. The molten agarose is poured into a sealed casting 
plate and a comb is inserted to cast wells within the agarose. The gel is then allowed 
to cool to set.
Once set, the comb is removed to form the wells and the gel is immersed in an 
electrolyte (lx  TBE). The samples are loaded into the wells with a molecular ladder 
running along side (such as hyperladder IV, Bioline). The molecular ladder will 
enable one to judge the size of the amplimer along with acting as a positive control. 
The voltage is held at a set value (the higher the voltage the faster the migration) for 
a length of time where one deems the product has migrated far enough through the 
gel to be properly resolved by eye. As the product migrates through the gel the 
ethidium bromide intercalates with the DNA, will allows the bands to fluoresce 
when the gel is viewed (safely) under Ultra Violet light.
2.7.2 POLYACRYLAMIDE GELS
Polyacrylamide gels are used to resolve DNA fragments to less than one base 
difference. The gels are prepared as in section 2.2.5, using amonium persulfate 
(APS) to polymerise the acrylamide (800pl of 10% APS to every 100ml of buffered 
Sequa gel solution). The gel apparatus consists of two glass plates separated by 
using two 2mm thick spacers. The gel is then poured into the gap. A single well is 
prepared at the top of the gel. Once the gel has set (in approximately 2 hours), the 
surplus polyacrylamide is cleaned from the plates, a sharktooth comb is inserted to 
form the wells that allow sample loading.
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The gel is loaded vertically into the LI-COR DNA sequencer, that contains a trough 
at the top of the gel that holds 500ml of electrolyte (lx  TBE) and stands in a second 
trough containing another 500ml of the electrolyte. This allows a current to be 
applied through the gel for electrophoresis to occur. A scanning laser at the bottom 
of the gel continually scans for both 700nm and 800nm wavelengths. The signal is 
then converted into a graphical image to view. The electrophoresis condition varies 
depending on the size of the gel and whether it is for genotyping or sequencing as 
seen in Table 2:5.
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The LICOR set up is usually as follows:-
Table 2:5 LICOR setup for genotyping gels and sequencing gels.
Settings Genotyping Sequencing
Plate size (cm) 25 40
Volts (V) 1200 2000
Current (Ma) 25 35
Power (W) 30 45
Temperature (°C) 45 45
Signal filter 3 3
Signal speed 4 4
The LICOR used through out this project was the “LICOR DNA Sequencer Long 
Reader 4200”.
The samples are first mixed with an equal volume of Fuchsin loading buffer and 
denatured at 95°C for approximately three minutes to allow the DNA strands to 
become single stranded. The gel is preheated to 45°C (to help prevent the formation 
of secondary structure and hence allow the linear DNA run in proportion to their 
length) before loading the gel.
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2.8 M ETH O D O LO G Y  OF GENO TYPING  AND SE Q U EN C IN G
Once the polymorphic markers are amplified for genotyping or the implicated region 
is amplified for sequencing, the next stage is to analyse the gel. The methodology for 
the process of genotyping, sequencing and the analysis of the data will be discussed 
in this section.
2.8.1 METHOD OF GENOTYPING
As discussed in section 2.5 and 2.6 polymorphic markers were chosen and amplified 
in our schizophrenic sample and matched control sample (each marker in a 96 well 
plate format), along with an M l3 forward primer (700 or 800 wavelengths) to allow 
more than one marker to be loaded on a gel simultaneously. The products were then 
pooled and mixed with an equal volume of loading buffer (Fuchsin). The sample 
was loaded (on to a vertical polyacryamide gel) using a 64 well loading comb, in 
addition eight molecular weight (MW) markers were run along the sample. The MW 
were evenly spaced to enable differentiation between the polymorphic marker alleles 
and also to show what the gel is doing to enable one to call the alleles correctly and 
give the correct size. The gel was analysed by the LICOR by using a dual laser 
scanning laser.
In addition to analysing the entire case control sample, a minimum of 17% of all the 
samples are repeated in separate microtitre plates as a cross check, to ensure the 
alleles were called correctly and the common allele size was kept constant between 
gels to prevent any gel shifts. This helped to improve genotyping accuracy and 
reliability.
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2.8.2 GENOTYPING WITH SAGA-GT
SAGA-GT is a software program (developed by LICOR) which is used to allow one 
to efficiently genotype gel images produced by the LICOR. It has the ability to load 
up the sample identifications, detect the lanes which they are in, and the location of 
each marker with the aid of the molecular weights. The program detects the 
uniformity of the gel with aid of the spaced molecular weights and produces a 
“desmile line” to allow correct calling of allele sizes. To some extent SAGA-GT is 
able to automatically call the genotypes, however each individual genotype was 
checked by eye and corrected if deemed necessary. As a result the software helps to 
reduce human error.
Both the entire sample of cases and controls were genotyped with the aid of SAGA- 
GT. The genotypes were then read by a second individual blind to their diagnosis. 
Any discrepancies between callers resulted in the individual in being re-amplified 
for the marker and re-genotyped, until the discrepancy was resolved.
The genotyping data was then extracted for each marker from SAGA-GT and 
entered into a database in Microsoft Access. This database contains a list of all 
individual identification codes and has a program to enable one to check for 
conflicts between repeat genotyped individuals. Conflicts were rechecked on SAGA- 
GT to determine the reason for the conflict and amended.
The genotype data was then ready for statistical analysis to check for allelic 
association to schizophrenia using an optimised Chi2 method “CLUMP”. CLUMP 
employs an empirical Monte Carlo test for significance and which does not require 
further correction for multiple alleles (Sham et al. 1995). Further statistical analyses 
are described in section 3.0.
73
, V W W '  V
' M Jf ^
^  * * » __
* y is j  9
* s 5f s'V * y •« w v «r y* V ^  y
/ 1 ~ / ~  -  „ / % * •  - -  ‘  v - - r -  -  "*» ■ J -  * * * «* « y» y * * * .  <* * * v
j ;  r  -  * v* *y * x * * * * *w* y
u w w w
Figure 2:2 Shows a tetranucleotide repeat marker that has been analysed using SAGA-GT 
software. Allele size calls for all the genotypes are shown using coloured “X” symbols.
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Figure 2:3 microsatellite polymorphisms visulised with infra red signal detectin on a Licor 
polyacrilamide gel. two genetic loci are shown multiplexed on a single gel.
2.8.3 GENOTYPING OF SNPs
SNPs were genotyped in several ways as shown before. Common established SNPs 
were sent off to Kbiosciences Ltd (Hoddesdon, UK) to be genotyped. They have 
developed and optimised a cost effective way of genotyping SNP using an adapted 
Fluoresence resonance energy transfer (FRET) reporter system, which they named
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KASPar. DNA had been sent to the company with 17% of the samples duplicated to 
test for reproducibility and accuracy of the genotypes, the results were sent back for 
analysis.
Occasionally, especially for markers that amplified poorly, we had to use a high 
throughput sequencing method. It is a method devised to type rare low frequency 
SNPs found through sequencing in our entire case control population that 
Kbiosciences were unable to produce an assay for. It was carried out by sequencing 
a single base in which the SNP would occur, alongside a known full sequence 
positive control. This allowed one to sequence 120 individuals on a single 
polyacryamide gel using both IRD 700 & 800 wavelengths.
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Reference sequence of Rare SNP insertion of “C” Sequencing using only the “C”
positive control, bases base.
G,A,T,C respectively
Figure 2:4 Showing single base sequencing for 60 individuals on a single infra red wavelength, 
example of high throughput dectection on a rare SNP in this case a “C”.
In all methods, 17% of the sample was duplicated to check for reproducibility and 
accuracy of the genotypes. The genotype data was collated in the required format 
and checked for Hardy-Weinberg equilibrium, and the chi square between cases and 
controls was assessed.
Further statistical analysis was carried out on the data for linkage disequilibrium 
between markers and and for haplotypic association with schizophrenia as described 
in section 3.2.4.
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2.8.3.1 KBIOSCIENCE
Kbioscience (KBiosciences, Hoddesdon, UK) were employed to undertake 
genotyping of SNPs in the case control sample. For each SNP fifty base pairs either 
side of the polymorphism were selected from dbSNP in The National Center for 
Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/). This 
information along with the SNP name was sent to KBiosciences for SNP assay 
development.
KBiosciences employ a modified version of the Amplifluor (Myakishev et al. 2001) 
genotyping method (Millipore, MA, US).
This method involves the allele specific amplification of SNP alleles using two 
tailed locus specific oligonucleotides and a standard locus specific reverse primer.
In addition two tailed oligonucleotides labelled with different fluorescent dyes are 
used in the reaction. In the early cycles of amplification the allele specific 
oligonucleotides compete with one another for template. The best fitting (matching) 
oligonucleotide binds the template with high affinity and thereby creates more of 
this allele’s template for subsequent amplification.
In the later cycles the appropriate tailed fluorescent oligonucleotide is incorporated. 
The end point fluorescence is then detected using a fluorescent plate reader. There 
are four different possible outcomes each with different fluorescent intensities: low 
intensity for both fluorescent dyes indicating that no amplification has occurred; 
high intensity for one fluorescent dye and low intensity for the other indicating a 
homozygote template for the appropriate SNP allele; the opposite scenario; and 
finally moderate intensities for both fluorescent dyes indicating a heterozygous 
template for the SNP. See Figure 2:5 and Figure 2:6.
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Figure 2:5 KASPar method for genotyping a two allele SNP using allele-specific primers 
coupled with two Universal Amplifluor primers (Bengra et al. 2002).
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Figure 2:6 An alternative diagrammatic representation of two-allele SNP detection using allele- 
specific primers coupled with two Universal Amplifluor primers (Bengra et al. 2002).
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2.8.3.2 EPOCH BIOSCIENCES IN HOUSE SNP GENOTYPING
This technology was used for this thesis to genotype rare non-data base SNPs (such 
as Figure 8:5 SNP A/C on page 153) in our entire case control sample these were 
SNPs that KBiosciences were not be able to produce a working assay for.
Epoch Biosciences (Epoch Biosciences merged into Nanogen, Inc., WA, US) were 
employed to develop an assay for the non database SNP (-15 A/C) in the case 
control sample. Fifty base pairs either side of the polymorphism were selected using 
the UCSC Genome Browser (http://genome.ucsc.edu/).
This sequence was sent to Epoch Biosciences along with genomic DNA from two 
known heterozygotes for the SNP and two known for the homozygotes common 
allele of the SNP. The probes contain a fluophore moiety at the 5 ’ end and a 
quencher at the 3’ end. Epoch Biosciences use a probe containing a minor groove 
binding (MGB) sequence attached to a quencher at the 5’ end and a fluorophore at 
the 3’ end. This method does not need the Taq DNA polymerase to cleave the probe. 
It simply emits fluorescence once hybridized to the sequence. Further, it is protected 
from 5’ digestion by Taq DNA polymerase during the the amplification stages.
Each MGB probe has a different fluorescent reporter dye. The DNA duplexes are 
denatured over a time course and the decrease in the fluorescent signal of each probe 
is measured. Comparison of the two-colour melting curves allows for differentiation 
of sequence variants of the SNP.
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Figure 1 -  denaturing phase -  the probe is unattached and no fluorescence is 
emitted.
Anrseama Pnose 36‘C
Fluorescence 18 «mne«
Figure 2 — the annealing phase -  the probe is attached in the minor groove and 
fluorescence is emitted
extension Ptow* 7&'C
Fluorescence 18 quenched
Figure 3 -  the extension phase -  the probe is unattached and no fluorescence is 
emitted.
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2.8.4 SEQUENCING
Primers for sequencing are optimised as described in section 2.6. DNA samples for 
sequencing were selected on the basis that cases of schizophrenia had inherited 
alleles and haplotypes that had previously shown association to schizophrenia. Once 
the primers were amplified, a proportion of the PCR products were analysed on an 
agarose gel. This was to check that the individuals which had been amplified, are the 
correct size, and to check for non specific amplification as shown by the presence of 
multiple bands, and intensity of primer dimer.
The amplimer for each individual was then cleaned from the master mix reagents 
and purified from any primer dimer by the use of microCLEAN (Microzone Ltd, 
West Sussex, UK). This reagent was mixed in equal quantities to the PCR reaction 
and left at room temperature for approximately 5 minutes. Then the eppendorf 
containing the mix was centrifuged at 14000g for 7 minutes to pellet the template. 
The supernatant was disposed of and the tubes briefly spun to pull down any 
remaining “dregs” which were then removed. The pellet was then re-suspended in 3- 
lOpl of ultra pure water. This targeted region was then used as a template for the 
“Sanger-Coulson” chain termination sequencing method.
2.8.4.1 SANGER-COULSON (CHAIN TERMINATION SEQUENCING 
METHOD)
Once the targeted region was amplified and cleaned, sequencing could take place on 
the DNA template. As the amplimer contains an integrated M13Forward/Reverse 
sequence, integrated by the primers used in the initial amplification. An M13F/R 
primer can be used for specific sequencing and simultaneous incorporation of the 
dye for visualisation on the LICOR.
The M13F/R primer during the PCR reaction binds to the specific template and 
allows extension and synthesis of the complementary strand by the sequatherm DNA
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polymerase. The advantage of using M13F IRD700 and M13R IRD800 is that both 
strands can be sequenced at the same time and used as a crosscheck for one another 
to assess whether novel bands (DNA variants) were artefacts or real polymorphisms.
In sequencing the usual dNTPs are used along with a small amount of 
dideoxynucleotide (like ddATP) which is incorporated just as efficiently into a 
growing polynucleotide strand but prevents further synthesis. This is because the 
dideoxynucleotide lacks a hydroxyl group at the 3 prime position of the sugar 
component and this prevents further incorporation into the polynucleotide. Therefore 
chain termination occurs wherever a dideoxynucleotide is incorporated. As a result 
the reaction can run with each individual ddNTP and will result with terminations at 
every base of the sequence showing exactly where each base belongs in a sequence.
Table 2:6 Table showing the master mix reagents and volumes required to sequence 16 
individuals.
Sequencing reagent for MasterMix Volume
3.5x Buffer 75pl
M13F 700 (lOpmol/pl) 1.33pl
M13R 800 (lOpmol/pl) 1.33pl
Sequitherm Polymerase l lpl
Water 27pl
3 pi of the cleaned DNA template is mixed with 6.8pl of the sequencing master mix. 
2pl of this is then mixed with 2pl of each ddNTP as shown in the figure below. The 
sequencing reaction is then PCR amplified by the Sequatherm program as stated in 
Section 2.6.3. Table 2:4. This is carried out on a 96 well plate and enables one to 
sequence 16 individuals at a time on a single polyacrylamide gel.
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Figure 2:7 Layout of the sequencing reaction, showing how the Master Mix and DNA are mixed with 
each ddNTP separately.
G
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the MasterMix 
(X) to each of 
the ddNTP s.
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DNA and 
MM
After PCR an equal volume of Fuchsin loading buffer is added to the product. The 
amplified product is aliquotted to a relevant plate format to enable loading with a 
multichannel pipette contiguously which will keep all the same nucleotides aligned.
The sequencing product is then loaded on a 44cm agarose gel, and analysed by the 
LICOR scanner on the preset sequencing parameters (Section 2.7.2 Table 2:5). The 
resultant sequencing image is read and checked against the database sequence to 
make sure the correct region is sequenced and also to check for any abnormalities. 
The sequence is examined for any polymorphisms and mutations both present in the 
database and not. These abnormalities are cross-checked with the reverse strand 
sequence to make sure they were not an artefact of the gel image. Any abnormalities 
were checked in random controls to see if they appear in the same frequency as the 
cases or more importantly not. In total 32 of the most significantly associated 
individuals were sequenced (these were chosen from haplotypes with the most 
significant markers section 3.2.4.3). The presence of these potential aetiological base 
pair changes were then investigated by sequencing with an equal number of random 
controls.
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Figure 2:8 An example of the result one would obtain by Sanger-Coulson chain termination 
sequencing method, with the image obtained from the LiCor DNA sequencer
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SNPs or any other abnormalities discovered in sequencing o f interest were further 
typed as described in section 2.8.3.
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Figure 2:9 Example of a four base insertion-deletion (INDEL), a mutation which is easily seen 
by eye.
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3.0 STATISTICAL ANALYSIS
A range of statistical analysis is used for these data to determine the reliability of our 
findings. It ranges from checking population stratification to calculating LD between 
markers and calculating the degree of genetic association between the markers and 
schizophrenia. Most of these analytical software were developed by Professor Dave 
Curtis et al (http://www.smd.qmul.ac.uk/statuen/dcurtis/software.htmO. Department 
of Adult Psychiatry Royal London Hospital.
3.1 C H ECK H ET
Case control association studies are prone to false positive findings due to 
population stratification. One way of preventing these false positive discoveries is to 
ensure that there is no overall heterogeneity in the samples. One method of testing 
for heterogeneity is a program called CHECKHET. This program helps to ensure 
that case control samples are drawn from a homogenous genetic background by 
detecting genetic outliers from the sample. This method is intended to be particularly 
sensitive in detecting a few subjects which are abnormal across a range of markers. 
CHECKHET does this by examining whether a subject tends to have normal 
genotypes across a range of markers using a log likelihood ratio test of heterogeneity 
as a measure of abnormality. The tests are summed over all markers and permutation 
tests are then used to identify subjects that have exceptionally large scores. These 
samples are then excluded from the analysis. The program depends on genotypes 
rather than allelic frequencies it does not make the assumption that all markers are in 
Hardy-Weinberg equilibrium (Curtis et al. 2002).
Data from fifteen genetic markers at chromosomal loci not thought to be involved in 
schizophrenia were genotyped in a subset of the sample (200 cases and 300 controls) 
and analyzed using CHECKHET. This test detected two schizophrenia cases with 
abnormal genotypes and these were excluded from further study before any of the 
study markers were genotyped (Curtis et al. 2002).
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3.2 H A P M A P
As described in section 2.5.3, HAPMAP was a project that aimed to identify all 
common SNPs in the human genome across four different populations. This project 
was designed to aid association studies by enabling one to fine map a region of 
interest by selecting tgging SNPs. The program Tagger was used to identify 
“tagging” SNPs. Tagger selects SNPs with varying genetic information, indicated by 
the different r2 LD vaules. This allows for the best statistical selection of single 
SNPs form ones in high LD. This method proves the most economical method to 
fully genotype a region with known SNPs.
3.2.1 WHAT IS LINKAGE DISEQUILIBRIUM (LD)?
Linkage disequilibrium is often termed "allelic association." When alleles at two 
distinctive loci occur in gametes more frequently than expected (rather from other 
causes such as population stratification or epistasis) given the known allele 
frequencies and recombination fraction between the two loci, the alleles are said to 
be in linkage disequilibrium. Evidence for linkage disequilibrium can be helpful in 
mapping disease genes since it suggests that the disease causing change and genetic 
marker may be very close to one another. LD is also commonly used to describe the 
relationship between genetic markers. LD reflects the genetic distance between 
markers, it also can be disrupted by the recombination rate and the presence of new 
mutations.
There are many measures of LD. The most common used through out this project
2are D’ and r values which will be discussed next.
3.2.1.1 LEWONTIN’S D’ MEASUREMENT OF LD
Lewontin’s D’ (Lewontin 1964a; Lewontin 1964b) is derived from D, which is a LD 
coefficient derived from haplotypic frequencies as displayed below. Using a biallelic
system such as a SNP the haplotypic frequencies can be simply estimated between 
two markers.
D measures the deviation of haplotype frequencies from the equilibrium state. LD 
occurs when D is significantly greater than zero. Considering two linked SNPs with 
alleles (A,a) and (B,b) resulting in four possible haplotypes: AB, Ab, aB, ab. “D” 
can be calculated as in the equation below
SNPI
A A
<N B fAB faB fB
£C/3 b fAb Fab fb
fA Fa
f = frequency
As a result the LD coefficient D could be worked out as follows
D = f(AB) -  f(A) x f(B)
The problem with the D coefficient is that is was dependent of the marginal allele 
frequencies in the contingency table. This disqualifies D as a measure of LD because 
the data is dependent and cannot be compared for different SNPs and different 
populations (Devlin et al. 1995). However D can be normaised to D’ allowing the 
measurement to be comparable across SNPs and populations.
D' is defined as the absolute ratio of D compared with its maximum value, Dmax, 
when D>0, or compared with its minimal value, Dmin, when D<0 (modal result 
taken), D' = 1 denotes complete LD, and historical recombination results in the 
decay of D' towards zero.
This means that D' is equal to 1 if alleles at adjacent marker loci are in LD with each 
as much as is possible given that they have different population allele frequencies.
D' values less than 1 imply that the maximum extent of LD between two marker 
alleles has not been observed. For example, D' = 0.87 represents a strong LD 
between SNP alleles; similarly D' = 0.12 represents weak LD between SNP alleles.
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D' has the same range of values regardless of the frequencies of the SNPs compared 
(Lewontin 1988). Its sign (positive or negative) depends on the arbitrary choice of 
the alleles paired at the two loci.
The normalised measure of D (D’) is worked out as follows:
^ p { \ - p ) q { \ - q )
Where p  and q the major and minor allele frequencies as described in the Hardy- 
Weinberg equation (section 3.2.2)
Where |Z>'| =1 denotes complete LD,
Where D ’ = 0 it shows no LD (linkage equilibrium).
And where |/)'| < 1 it shows various degree of LD between the markers (higher the 
number the stronger the LD).
The limitations of using D’ include its insensitivity to distinguish between different 
degrees of LD, a |Z)'| = 1 can reflect 2 to 3 haplotypes present. There is also upward
bias for small to moderate sample sizes, and it can take extreme values when at least 
one allele frequency is small (Devlin et al. 1995).
Another measure of LD is r2 this will be discussed in the next section.
3.2.1.2 r2 MEASUREMENT OF LD
r2 is another measurement of LD (Pritchard et al. 2001). It is thought to over come 
the problems of D’, as r2 is able to detect LD in small sample sizes and also is far 
more reliable for detecting LD for low allele frequencies compared to D \
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The equation for r2 is as follows:
i-2_ ( f ( A B ) - f ( A ) f ( B ) ) 2 ^  D 2
fA.fa.JB.fi fA.fa.JB.fi>
Where f means frequency of the alleles.
When r2 = 1 the markers are said to be in perfect LD. Observations of one marker 
provides complete information about the other marker, making them both redundant. 
Therefore they are genetically identical and one can be used as a “Tag SNP” for the 
other in association studies.
r2 = 1 only when no recombination has occurred between the markers and the allele 
frequencies are identical. It also corresponds to a situation where two haplotypes are 
present out of a possible four.
In general r2 is more useful for dividing closely located SNPs into blocks, if the 
purpose is to identify "tagging SNPs". However r2 represents statistical association 
at the population level as well as incorporating LD and has no direct relationship 
with recombination like D \ r2 depends on marker allele frequencies and can be 
difficult to interpret when comparing multiple markers in a region (Hedrick 1987). 
D’ is directly related to recombination fraction and its generalization to more than 
two loci is the only measure of LD not sensitive to allele frequencies.
Hence when judging LD both D’ values and r values are used to describe the LD 
relationship between markers and are used in selecting the most appropriate SNPs 
with the use of HAPMAP and HaploView.
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3.2.2 HARDY-WEINBERG EQUILIBRIUM.
With the data from genotyping of microsatalites and SNPs, the information is 
checked to make sure that they follow Hardy-Weinberg equilibrium before any 
further statistical analysis is considered. This is to check if the alleles have been 
genotyped correctly.
The equation for Hardy-Weinberg equilibrium is as follows:
p2 + 2pq + q2 = 1 
Where p  is the major allele and q is the minor allele.
The concept of Hardy-Weinberg equilibrium is used to understand the genetic 
characteristics of populations (Hardy 1908; Weinberg 1908). They independently 
stated that if p is the frequency of one allele (A) for a biallelic locus, then the HWE- 
expected frequency will be p2 for the AA genotype, 2pq for the Aa genotype and q2 
for the aa genotype. The three genotypic proportions should sum to 1, as should the 
allele frequencies.
The derivation of the Hardy-Weinberg equation is appreciated by use of a Punnett’s 
square shown in Figure 3:1 below.
Figure 3:1 Using a Punnett’s square to derive the Hardy-Weinberg equation.
Females
A (p) a (q)
Males A (p) AA (p2) Aa (pq)
a (q) Aa (pq) aa (q2)
The final three possible genotypic frequencies in the offspring become:
f  (AA) -  p2, f(Aa) = 2pq and f(aa) -  q2.
Testing for HWE is used for quality control of large-scale genotyping and is an 
important method to identify systematic genotyping errors in unrelated individuals
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(Gomes et al. 1999). Genotyping errors are known specifically to affect certain 
genetic measurements such as LD, upon which association studies depend.
Tests for deviation of Hardy-Weinberg equilibrium is carried out by a simple chi 
squared test using the observed genotyped frequencies for the data and the expected 
genotype frequencies from the equation. Once the data is found to be in Hardy- 
Weinberg equilibrium it can be used to test for association using the statistical 
analysis as will be described in the following sections. However if the data is not in 
Hardy-Weinberg equilibrium, the data will have to be re-checked to verify if the 
calls are correct and the data is in the correct format.
3.2.3 STATISTICAL TESTS FOR ASSOCIATION BETWEEN 
MARKER ALLELES AND DISEASE
To test for association between the polymorphic marker and disease, a simple Chi 
square test is employed to test if alleles are more frequent in cases compared to 
controls.
3.2.3.1 TESTING FOR ASSOCIATION WITH SNPs USING CHI SQUARE
The data from SNP genotyping is first checked for accuracy by comparing the data 
with duplicates (17% of the sample is duplicated). The data is then checked to 
ensure that it follows Hardy-Weinberg equilibrium. Once the data has satisfied these 
criteria, the genotypic information is checked for association. Allelic association is 
tested for by forming a table with the allele frequencies for both cases and controls 
then performing a chi square test with one degree of freedom. Genotypic association 
is also tested for with a similar table representing each genotype frequency and 
performing a chi square test with two degrees of freedom.
In association studies allelic association is the most reliable test of association and 
genotypic association is not generally trusted in the absence of allelic association, 
because in the absence of allelic association there is a high probability that the result
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is due to discrepant genotyping results rather than a genuine result. The reason 
behind this, is if one genotype predominates then you would expect the allele 
frequency to also show allelic association
3.2.3.2 CLUMP TEST FOR ASSOCIATION OF MICROSATELLITES.
Allelic tests of association for microsatellites were tested using a program called 
“CLUMP” (Sham et al. 1995). The data is first also tested for accuracy by cross 
checking the genotypes with duplicates which make up a minimum of 17% of the 
sample. The data is then tabulated for allele frequencies for the microsatellite in both 
cases and controls. The data is then fed in to CLUMP to perform a number chi 
square tests for association.
As stated by the creators, CLUMP is a program developed to assess the significance 
of the departure of the observed values from the expected values conditional on the 
marginal totals within a 2 x N contingency table. The significance is assessed using 
a Monte Carlo approach, by performing repeated simulations on randomly generated 
tables with the same marginal values using simulated data, and counting the number 
of times the chi square value is associated with the table under consideration by 
chance. This means that the significance levels assigned is unbiased (accuracy 
dependent on the number of simulations) and also means that no special 
considerations need to be made for small expected values (Sham et al. 1995).
CLUMP is used to calculate maximal chi square values by clumping together 
columns into a new two by two table in a way which is designed to maximise the chi 
square value. The method produces an “inflated” chi square value but does not cause 
any problems in interpretation because its significance is assessed using a Monte 
Carlo method which takes into account the increased chance of a false positive 
result.
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The output of CLUMP generates four chi square results and their significance is 
evaluated by testing how many times the value produces is exceeded by chance with 
the Monte Carlo simulation method. The four results produced are as follows.
1. Pearson’s £  statistic of the ‘raw’ 2-by-N contingency table originally 
supplied. The statistic is referred to as “X I” the Chi Square value is worked 
out for the original supplied table. However if there are small expected 
values (less than 5) in some cells then these values might not follow the 
expected distribution of a chi-squared statistic with N-l degrees of freedom. 
However the significance can be reliably accessed using the Monte Carlo 
simulations.
2. The ^  statistic of a table with rare alleles grouped together to prevent small 
expected cell counts. If any cell has a value less than 5, then its column is 
clumped together with the column of the next smallest value. This process is 
repeated until all columns have values of 5 or more. The resulting statistic is 
referred to as “T2” the significance is assessed by Monte Carlo simulations 
and the degrees of freedom is N-l (where N is the number of resulting 
columns after they were clumped).
3. A 2-by-2 table obtained by comparing one column of the original table 
against the total of all other columns. (The largest of the £  statistics of 2x2 
tables each of which compares one allele against the rest grouped together). 
This tests the hypothesis that there is one particular column with a number of 
cells deviating form the expected values. For each column in turn, all the 
other columns are clumped together to assess the chi square value. The 
columns, which produces the maximal chi square value is used and the 
results are outputed. This statistic is “T3”. Columns containing values less 
than 5 are not considered and the columns are clumped together with the next
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column with the lowest value. In this case the T2 table would be used. The 
significance of the result is assessed with Monte Carlo simulations.
4. A 2-by2 table obtained by clumping the columns of the original table to 
maximise the chi squared value. This method compares any combination of 
columns (alleles) against the rest to produce the maximum chi square value 
possible and produces the largest of all 2-by-2 contingency tables. Its 
significance is assessed using Monte Carlo simulations. This produces the T4 
statistic.
From the output the most significant statistic is chosen to show the degree of 
allelic association of the marker.
In order to run the CLUMP program, one needs to give the number of columns 
(alleles) the table has and the number of permutations to perform, and also provide a 
random number to start calculations in order to produce the pseudo-random tables 
for Monte Carlo simulations. The number of permutation should be significantly 
large to produce a satisfactorily accurate estimate of the true significance that is 
achieved, about 10 000 (9999 in the programme as it starts at 0) or more 
permutations are generally used.
3.2.4 STATISTICAL ANALYSIS OF GENOTYPIC INFORMATION  
USING “GENECOUNTING”
Ascertaining allelic association between a single marker and the disease is one 
method of extracting information from genomic data. However one can analyse a 
combination of neighbouring markers to extract more information to find out the 
relationship between markers (to judge the strength of LD between them) and to try 
increase the power of information generated for association to the disease by 
analysing different haplotypes between markers which are in LD with one another. 
Having a large number o f markers which form a positive haplotype is useful, as the
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information can be used to help select the most significantly associated individuals, 
who contain those haplotypes. These individuals can be chosen for sequencing 
candidate regions to increase ones chance of finding an abnormality in the genomic 
sequence.
The program which was used to ascertain the LD relationship between markers and 
haplotype significance was as sub-program of “GENECOUNTING” (Zhao et al. 
2000; Zhao et al. 2002; Curtis et al. 2006) and the functions will be discussed next.
3.2.4.1 LDPAIRS
LDP AIRS reports pair-wise linkage disequilibrium statistics between all pairs of 
markers. This program allows one to calculate LD between any set of selected 
markers, it will calculate a p value for the statistical significance of the test for 
linkage disequilibrium between the markers and from the estimated haplotype 
frequencies it will calculate a mesure of LD called Cramer’s v, which is equivalent 
to the square root of the r measure of LD (Bishop et al. 1975) (section 3.2.1.2). The 
program in addition will also work out the absolute value of the D’ statistic (section 
3.2.1.1) between the commonest alleles at each locus.
3.2.4.2 SCANGROUP
SCANGROUP compares haplotype frequencies in cases and controls of haplotypes 
built from subsets of markers, consisting either of groups of contiguous markers or 
of all possible combinations of a specified number of markers. This program is 
useful to detect if any of genotyped plates have been swapped over which would 
produced aberrant results.
3.2.4.3 RUNGC
RUNGC estimates haplotype frequencies between unrelated subjects and has the 
ability to deal with multiallelic markers and markers with missing genotypes.
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RUNGC compares haplotype frequencies in cases and controls, tests for significant 
differences using a likelihood ratio test and permutation test.
The program out-puts the frequencies of haplotypes and groups them side by side for 
comparison. This allows one to pick out hapotypes with the largest discrepancies (i.e 
over representation in cases) in order to pick out the most implicated haplotype or a 
range of implicated haplotypes. Also by adding a second output parameter (.hap) the 
RUNGC program is able to output grouped individuals containing their haplotypes 
enabling one to select individuals with the most significant hapotypes for specific 
sequencing of those “most at risk individuals”.
3.2.5 POWER CALCULATIONS.
Power calculations are carried out to find out the power of a sample and its ability to 
detect low frequency alleles in the population. It is known that the larger the sample 
the greater the power it has to detect rare allelic variants and a better chance the 
sample has to perform a replication association study of an implicated region in a 
smaller sample. Power calculations can be calculated by using online resources such 
as the “Genetic Power Calculator” (http://pngu.mgh.harvard.edu/~purcell/gpc/), 
(Purcell et al. 2003).
We have calculated that the sample used in this thesis (about 450 cases and 450 
controls) is large enough to detect a marker allele frequency difference of 5% in 
controls and 10% in cases with a power of 0.99 at p<0.05 and of 0.91 at p<0.001 
assuming the minor marker allele frequency is less than 10%. With a high frequency 
biallelic marker present in 45% of controls and 55% of cases the power of the 
sample is 0.90. If a high frequency marker is employed with only a five percent 
allele frequency difference between cases and controls, for example 45% versus 
50%, our sample had a power of only 0.41
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3.2.6 ODDS RATIO.
The odds ratio is a way of comparing whether the probability of a certain event is the 
same for two groups. An odds ratio of 1 implies that the event is equally likely in 
both groups. An odds ratio greater than one implies that the event is more likely in 
the first group. An odds ratio less than one implies that the event is less likely in the 
first group.
Shown below is the typical 2 by 2 table.
Allele 
 T  G
Control
Case
Where a & c = the number of T alleles observed in the controls and cases, and where 
b & d = the number of G alleles observed.
By definition the odds ratio (OR) is;
(a/(a + b))/(b/(a + b))OR=
(c !{c + d)) / (d !{c + d))
This can be reduced to:
OR = —
be
Confidence Limits can be worked out for the odd ratio by first working out the 
standard error (SE)
SE(lnOR)= f l  + I  + I  + L
V V a b c d
Confidence intervals for odd ratio is tested at the for a two sided 95% confidence 
interval where Zl is hence 1.96
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The confidence limits for odds ratio is calculated as follows
exp(ln(OR)± Z l x  SE).
4.0 ATTEMPTED REPLICATION OF REGULATOR OF 
G-PROTEIN SIGNALLING 4 (RGS4) IN BRITISH 
CASE CONTROL SAMPLE
4.1 G E N E R A L  IN TR O D U C TIO N
Regulator of G-protein Signalling 4 (RGS4) has been implicated as a schizophrenia 
susceptibility gene in several studies. Mimics et al (2001) first implicated the gene, 
by finding RGS4 mRNA expression had significantly decreased in schizophrenic 
brain samples using microarray technology. This was then followed by a significant 
association finding by Chowdari et al (2002). The finding was interesting as the gene 
is situated in genetic locus lq23.3, a linkage hotspot for schizophrenia susceptibility. 
The association has been replicated in part by a number of independent groups; 
however their results were not completely conclusive. We attempted to replicate the 
original finding by Chowdari et al (2002) in our own case control sample.
4.2 R E G U L A T O R  O F G -PR O TEIN SIG N A LLIN G  4 (RG S4) 
R E P L IC A T IO N  STUDY.
4.2.1 INTRODUCTION
Regulator of G-protein signalling (RGS) belongs to a diverse family of proteins 
modulating the G-protein signalling pathways. The RGS domain accelerates GTP 
hydrolysis, deactivates the molecule to the inactive GDP-bound form, and as a result 
quenches signal transduction through the involved G-protein coupled receptors 
(Sobell et al. 2005). The function of RGS4 is to regulate the activity of GTPase, 
which is coupled with several receptors involved in the signal transduction of 
dopamine, glutamate and several other neurotransmitters (Saugstad et al. 1998;
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Taymans et al. 2003; Taymans et al. 2004). These receptors are thought to play some 
sort of role in schizophrenia.
Regulator of the G-protein signalling 4 (RGS4) is an attractive candidate gene for 
schizophrenia and is close to the lq23.3 region implicated by linkage studies, 
((Brzustowicz et al. 2000; Blackwood et al. 2001; Gurling et al. 2001; Ekelund et al. 
2004)). RGS4 had initially been implicated through decreased gene expression in 
post mortem schizophrenia brain samples using microarrays (Mimics et al. 2001). 
Tests of allelic and haplotypic association with schizophrenia at the RGS4 locus 
were first carried out using three methods. These were case control, family and trios 
sample designs with samples from Pittsburgh, the NIMH (USA), and New Delhi. 
(Chowdari et al. 2002). Thirteen RGS4 SNPs were genotyped. Family-based 
association analyses using the transmission disequilibrium test (TDT) found 
transmission disequilibrium for individual SNPs as well as for haplotypes composed 
of four SNPs in the 5' flanking sequence and first intron of RGS4 (SNPs 1 
(rsl0917670), 4 (rs951436), 7 (rs951439) and 18 (rs2661319)). The alleles and 
haplotypes which were associated with schizophrenia differed between the 
Pittsburgh and NIMH samples. Comparison of the Pittsburgh cases with two 
independent groups of unrelated controls did not reveal significant associations, 
raising the possibility that the TDT results might reflect methodological problems or 
producing false positive results. Two subsequent studies involving cases and 
unrelated controls of Caucasian ethnicity did however reveal associations with these 
four SNPs. Williams et al (2004) studied the association between the four SNPs and 
schizophrenia in a large case (n = 709) control (n = 710) sample from Wales, UK. 
Modest but significant associations were found between alleles of SNPs 4 
(rs951436) and 18 (rs2661319) and schizophrenia. An Irish study (Morris et al.
2004) genotyped the same four SNPs in a sample of 249 cases and 231 controls from 
the Republic of Ireland and found significant but not very strong allelic association 
with two different SNP markers (SNP 1 (rsl0917670) and SNP 7 (rs951439)). More 
recently a family-based study (Chen et al. 2004) also found evidence for association 
of RGS4 with schizophrenia in the Irish Study of High Density Schizophrenia
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Families (ISHDSF). Single marker TDT for the four SNPs showed modest 
association for SNP 18 (rs2661319) and a trend for SNP 4 (rs951436). The goal of 
the present study for this thesis was to attempt to replicate the original reported 
associations between RGS4 markers and schizophrenia.
Figure 4:1 Showing the location of SNPs and the GT microsatellite in the region of RGS4 
(UCSC BLAT diagram).
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4.2.2 METHOD FOR TESTS OF ALLELIC ASSOIATION BETWEEN 
RGS4 AND SCHIZOPHRENIA
Markers chosen for genotyping were the SNP markers 4 (rs951436), 7 (rs941439) 
and 18 (rs2661319) (Chowdari et al. 2002). SNP 1 is in strong LD with SNP 7. D/ 
and r2 values close to 1 between both SNPs have been reported in the earlier studies 
of RGS4 and schizophrenia from Caucasian origin. According to Morris et al (2004) 
D7 was more than 0.98 and r2 was more than 0.96 in both cases and controls. This 
was confirmed in Wales (D7 was 0.987 in Cases and 0.981 in controls, and r2 was 
0.96 in cases and 0.963 in controls) (Williams et al. 2004). Therefore SNP 7 should 
carry the same information as SNP 1. In addition we genotyped a polymorphic 
microsatellite (GT)m which is approximately 7Kb distal from RGS4 for an 
additional test of association. The SNPs were genotyped using sequence data 
available from the University of Pittsburgh website
(http://www.pitt.edu/~nimga/research/RGS4). The microsatellite (GT)i4 marker was 
obtained from the University of California at Santa Cruz
(http://www.genome.ucsc.edu/) and was at database position 159783591-159783618 
base pairs on chromosome lq23.3. The marker was genotyped using the following 
primer sequences:
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Forward: CTGTAATCCCAACAACACGG.
Reverse: CACTCAGCATAGGCAGGACA.
PCR amplification of the microsatellite marker was carried out using an Ml 3 tailed 
primer and a second non-tailed primer. A third universal M l3 sequence primer 
labelled with IRD 700 or IRD 800 was used to hybridise against the M l3 tailed 
locus specific primer. The microsatellite marker was genotyped by Licor and 
SAGA-GT as previously described in section 2.8. Single nucleotide polymorphisms 
were determined by the Amplifluor SNP genotyping method as modified by 
KBiosciences (KBiosciences: http://www.Kbioscience.co.uk/). 17% of samples on 
each microtitre plate were reduplicated in order to detect error and confirm the 
reproducibility of genotypes section 2.8.3.1. The data were then analysed to confirm 
Hardy Weinberg equilibrium (HWE). Next the data were analysed for allelic 
association with schizophrenia using CLUMP and Chi2 tests section 3.2.3.2.
4.2.3 RESULTS FOR REPLICATION STUDY OF RGS4
None of the markers (SNPs 4 (rs951436), 7 (rs951439) and 18 (rs2661319)) which 
were previously found to be associated with schizophrenia (Chowdari et al. 2002) 
could be implicated in the present sample. The (GT)]4 microsatellite approximately 
7Kb distal from RGS4 also failed to show allelic association with schizophrenia 
(Table 4:1). Tests of haplotypic association using GENECOUNTING and 
permutation testing also did not produce any evidence for association at this locus 
with any of the SNPs and the microsatellite marker as shown in Table 4:1.
Taking the example of SNP 4, the most consistently associated SNP, our sample 
only had the power of 0.53 to detect the effect size observed by (Williams et al. 
2004).
A comparison between the alleles frequencies of the SNPs markers in our sample 
and the previous case control studies was shown in Table 4:2.
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After these results were analyzed and published (Rizig et al. 2006) a number of new 
papers on the results of association of RGS4 with schizophrenia had been published. 
The results of known published papers are shown in Table 4:3 including the more 
recent meta-analysis (Talkowski et al. 2006) of RGS4. The meta-analysis consisted 
of results from all studies using trios, family samples and case controls samples.
From the overview of all results (Table 4:3), it is seen that the association results for 
RGS4 over all is very weak. Single SNP association from the majority of reports are 
weak or non-significant and haplotypic associations where reported positive are in 
different haplotypic combinations and marker numbers, or were negative. Even the 
published meta-analysis of 2160 families and 3486 cases with 3755 controls 
(Talkowski et al. 2006) shows that no individual markers were significantly 
associated in the family samples and haplotypic association were found not to be 
significant. In the case control samples, all SNPs were found to be non-significant 
apart from SNP 4 which had shown modest association, however there was no 
significantly associated haplotype.
4.2.4 RGS4 DISCUSSION
The sample employed here had greater power than the original sample of Chowdari 
et al (2002) and also greater power than the case control sample employed in the 
Irish study (Morris et al. 2004) as noted in Section 3.2.5. The Irish study only found 
associations with p values of about 0.04 with each of the two SNPs labelled 1 and 7 
(rs941439). In the case control association study from Wales (Williams et al. 2004) 
two different SNP markers (4 (rs951436) and 18 (rs2661319)) showed association 
with p values of 0.017 and 0.038.
It is possible that the original study (Chowdari et al. 2002) may have exaggerated the 
effect of association by confounding it with linkage which is known to be present in 
the region where association is claimed. The methods implemented in 
GENEHUNTER and TRANSMIT for detecting allelic association do not always
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eliminate the possibility of linkage being confounded with association especially 
when the commonest allele is found to be associated with the disease as in the case 
of the Pittsburgh and NIMH samples and where multiple cases within a sibship 
rather than just one case in a family are used to test for association. The authors do 
not specify whether they have used the option of using the most stringent test of 
association in family data where only one case per family is used in the TRANSMIT 
analyses. Such a procedure would have the effect of possibly removing some of the 
confounding of linkage with association. In any case the single marker evidence for 
transmission disequilibrium in the original Pittsburgh sample (p=0.05) was modest 
with SNP 4. In the analysis of the NIMH sample the authors also do not state what 
options for the global test of association were used for the TRANSMIT analyses. 
Different SNP markers were found to be associated, but the p values were stronger 
at 0.01, 0.003 and 0.005 for markers l(rs 10917670), 4 (rs951436) and 18 
(rs2661319) respectively.
However the Irish and Welsh studies do not suffer from the problems that tests of 
association using family data can suffer from, but the significance o f the associations 
between RGS4 SNPs and schizophrenia were not found to be strong. The 
discrepancy between our results and those of the Pittsburgh, Welsh and Irish studies 
could be due to locus heterogeneity with different proportions of disease alleles 
being present in different geographical regions.
However replication of the results through a more powerful meta-analysis has also 
failed to find clear positive independent marker or haplotypic association with 
family samples and no haplotypic association with case control samples (Talkowski 
et al. 2006). The meta-analysis collectively found modest association of over 
transmission of both common haplotypes consisting of SNPs 1-4-7-18 (haplotypes 
A-T-A-A & G-G-G-G). Talkowski et al (2006) had attributed the phenomenon to 
biological, statistical, molecular and population factors. This could happen as a 
result of recurrent mutations or transfer of liability alleles between haplotypes by 
recombination which accounts for the common haplotypes, also by allelic
106
heterogeneity or contribution of multiple loci to susceptibility or by a single rare 
mutation on a background of two common haplotypes.
It was also claimed by Talkowski et al (2006) that lack of consistent results could be 
attributed to lack of quality control over samples and genotyping errors could mimic 
biased transmission of common alleles/haplotypes. Over all the weight of the data 
which is inconsistent, the lack of good positive association with a large meta­
analysis data and the failure to replicate the positive results in our own case/control 
sample greatly weakens RGS4 as a putative candidate susceptibility gene for 
schizophrenia.
A more recent study by Ishiguro et al (2006), in a large Japanese population (1918 
cases, 1909 controls) also failed to find association with the four SNPs previously 
implicated by Chowdari at al 2002 (Table 4:3) Guo et al (2006) had also found no 
association with the four SNPs and also in two additional SNPs (rs2842030 and 
rs2344671) in a Han Chinese population (Table 4:3). In addition to the replication 
study, Guo et al had also carried out their own meta-analysis study which consisted 
of 3062 cases and 3564 controls, in which they had found no evidence of association 
with RGS4 to the disease.
Both meta-analysis and new data, shows that RGS4 is still not a strong or likely 
susceitibility gene for schizophrenia. Its expression may be altered due to drug 
effects or interaction with genes directly involved with the disease, but it does not 
seem to be a likely susceptibility gene for schizophrenia.
4.2.5 RGS4 CONCLUSION
Consideration should be given to the possibility that the observed allelic association 
could implicate other genes which are close enough to show linkage disequilibrium 
with the RGS4 marker alleles. Our findings, in addition to the two meta-analyses 
carried out (Guo et al. 2006; Talkowski et al. 2006) diminish support for the notion
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that RGS4 gene polymorphisms influence susceptibility to schizophrenia. They also 
suggest that more research is needed to prove that the RGS4 gene is implicated in 
the genetic susceptibility to schizophrenia.
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Table 4:1 Tests of Allelic and Haplotypic Association with Schizophrenia at the RGS4 Gene 
Locus.
M arker 
SNP 4 
(rs951436)
M arker 
location in 
base pairs 
on C l
159765000
bases
from
previous
m arker
Allelic bases 
o r fragment 
sizes and 
observed 
allele
frequencies
below
G T
Chi2
0.06
pab
0.80*
Con 445 413
Scz 
SNP 7 
(rs951439) 159765349 349
426
G
386
A 0.021 0.88*
Con 512 346
Scz 
SNP 18 
(rs2661319) 159771435 6086
491
G
327
A 0.077 0.78*
Con 470 394
Scz 447 385
(GT)14 159783591 12156 274 276 278 280 282 284 286 2.126 0.60T3
Con 262 1 215 107 84 175 12
Scz 217 1 177 94 71 131 17
Breakdown of 
the estimated 
three SNPs 
m arkers- 
haplotypes 
with frequency 
>0.01 T-A-A T-A-G T-G-A G-G-G
Con 0.377 0.024 0.079 0.519
Scz 0.382 0.015 0.077 0.52
Global haplotypic
association combining all Empirical p
SNPs value 0.43b
Global haplotypic 
association combining all
SNPs with m icrosatellite Empirical p
m arkers G T m value 0.79b
a p value for 2x2 chi squared (1 df)
T Most significant p value from CLUMP
b global haplotypic association permutation test p value based on 9,999 permutations
Table 4:2 Allele frequencies of SNPs 4, 7 and 18 in the UCL case control sample in relation to the previous case control studies of RGS4 and 
schizophrenia.
Rizig et al 
(Caucasian)
Williams et al 
(Caucasian)
M orris et al 
(Caucasian)
Corderio et al 
(Brazilian)
Guo et al 
(Han Chinese)
Ishiguro et al 
(Japanese)
M arker Polymorphism Con
(n=450)
Scz
(n=450)
Con
(n=710)
Scz
(n=709)
Con
(n=231)
Scz
(n=196)
Con
(n=576)
Scz
(n=271)
Con
(n=288)
Scz
(n=288)
Con
(n=1909)
Scz
(n=1918)
SNP 4 
(rs951436) T/G 0.481 0.475 0.468 0.514 0.524 0.464 0.592 0.586 0.45 0.51 0.486 0.51
SNP 7 
(rs951439) G/A 0.597 0.6 0.606 0.587 0.539 0.609 0.567 0.574 0.51 0.51 0.508 0.51
SNP 18 
(rs2661319) A/G 0.456 0.463 0.395 0.407 0.496 0.446 0.576 0.556 0.47 0.48 0.453 0.485
Table 4:3 Results of RGS4 previously reported genetic association studies.
A uthor Year Sample type Sample size Statistics P-value
Chowdari, K.V 2002 Pittsburgh Cases = 59, TDT (transmit)
et al Case- control controls = 89
SN P 1 0 .055
SN P 4 0 .05
SN P 7 >0 05
SN P 18 > 0 .05
H ap lo typeA TD T (global) 0 .035
NIMH family sample 25 families TDT (transm it)
SN P 1 0.01
SN P 4  0.003
SN P 7 > 0 .05
SN P 18 0 .005
H ap lo ty p eA TD T (global) 0 .016
Indian trios 269 case parent TDT (transm it)
trio  + 72 sib pair 
families
SN P 1 > 0 .05
SN P 4 > 0 .05
SN P 7 > 0 .05
SN P 18 > 0 .05
H ap lo typeA TDT (global) 0 .078
M orris, D.W et 2004 Irish Case-Control 249 cases 231 Chi squared Values are
al controls excluding cases with
schizoaffective
disorders
SN P 1 0 .042
SN P 4 0 .082
SN P 7 0.041
SN P 18 0 .149
H ap lo typeA G -G -G -G  FASTEHPLUS 0 .044
W illiams, N.M 2004 UK born Caucasins 709 cases 710 Chi squared
et al controls
SN P 1 0.51
SN P 4  0 .017
SN P 7 0.32
SN P 18 0 .038
H ap lo typeA 1-4 EHPLUS 0 .016
1-4-7-18  0 .266
Chen X et al 2004 Irish families (ISHDF) 247 pedigrees FBAT
SN P 1 0.35
SN P 4  0.11
SN P 7 0.43
SN P 18 0 .04
H ap lo typeA 1-4-18  SIM W ALK2 (global) 0 .04
1 -4-7 -18  0 .20
Z hang et al 2005 Han Chinese 322 families PDTPHASE
SN P 1 0 .88
SN P 4 0 .72
SN P 7 0 .24
SN P 18 0 .27
H ap lo typeA 1-4 -7 -18  0 .72
Scottish Case -control 580 cases COCAPHASE
620 Controls
SN P 1 0 .04
SN P 4  0 .082
SN P 7 0.011
SN P 18 0 .033
H ap lo typeA 4-7  0.01
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1- 4 - 7-18  0.10
S o b e lle /a / 2005 W estern/N orthern 568 cases Chi square
European Caucasians 689 controls
SN P 1 0.11
SN P 4 0 .39
SN P 7 0.11
SN P 18 0.52
H ap lo typeA Modified EM >0.05
Rizig et al 2006 British Caucasians 450 Cases 450 Chi Square
Controls
SN P 4 0 .80
SN P 7 0.88
SN P 18 0 .078
H ap lo ty p eA GENECOUNTING 0.43
SN P 4 
SN P 7 
SN P 18 
H aplotype*
Liu et al 2006 Taiwaneese 218 nuclear 
Families
TRANSM IT
0 .237
0 .356
0 .397
0 .277
Ish ig u ro e la / 2006 Japanese 1918 Cases
1909 Controls
SN P 1 0 .92
SN P 4 0.91
SN P 7 0.27
SN P 18 0.43
H ap lo typeA n/s
Guo et al 2006 Han Chinese 288 Cases SHEsis
288 Controls
SN P 1 0.64
SN P 4 0.11
SN P 7 0 .35
SN P 18 0 .80
rs2 8 4 2 0 3 0  0.35
Rs2344671 0.35
H ap lo ty p eA SHEsis Global haplotype 0.97
Meta-analysis 3062 Cases n/s
3564 Controls
Talkowski et al 2006 2160 Families Combined results
global results
M eta-analysis
SN P 1 n/s
SN P 4  n /s
SN P 7 n/s
SN P 18 n/s
H ap lo ty p eA n/s
3486 Cases 3755 
C ontrols
SN P 1 n/s
SN P 4 0.01
SN P 7 n/s
SN P 18 n/s
H ap lo typeA n/s
A the most significant haplotype. 
n/s not significant
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5.0 ATTEMPTED REPLICATION STUDY OF 
ASSOCIATION BETWEEN THE CAPON (NOS1AP) 
NITRIC OXIDE SYNTHASE 1 (NEURONAL) 
ADAPTOR PROTEIN AND SCHIZOPHRENIA
5.1 GENERAL INTRODUCTION
Another gene in the lq23.3 region had been associated with schizophrenia by fine 
mapping. The gene originally known as CAPON was implicated by Brzustowicz et 
al (2004) who had also implicated the region by linkage analysis using one of the 
original markers that was used for the association study D1S1679 (Brzustowicz et al. 
2000). The same region was implicated in two linkage studies that found significant 
evidence for linkage with lod scores of 6.35 and 3.20 (Brzustowicz et al. 2000; 
Gurling et al. 2001). A third study also found evidence supportive of linkage to 
schizophrenia at lq23.3 (Shaw et al. 1998).
The region of strongest linkage was further examined in 24 Canadian familial 
schizophrenia pedigrees. 14 microsatellites and 15 SNPs were genotyped between 
D1S1653 and D1S1677 of which 2 microsatellites and 6 SNPs had shown 
significant evidence of association. All of the markers exhibiting significant 
association with schizophrenia fell within the genomic extent of the gene for 
carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase (CAPON) 
(Brzustowicz et al. 2004) now known as Nitric Oxide Synthase 1 (neuronal) Adaptor 
Protein (NOS1AP).
CAPON’s location and identification through association analysis first, rather than 
through expression analysis and its neuronal expression and function made the gene 
an attractive candidate for schizophrenia susceptibility.
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CAPON (NOS1AP) is involved in signal transduction in the N-methyl-D-aspartate 
(NMDA) receptor mediated glutamate neurotansmision system, abnormalities of 
which have long been proposed to be involved in schizophrenia. It functions by 
competitively binding with neuronal nitric oxide synthase (nNOS) which prevents 
nNOS from forming a complex with the NMDA receptor hence preventing calcium 
reflux and signal transduction. Over expression of CAPON is thought to lead to 
impaired NMDA receptor mediated neurotransmission, this highlights the potential 
importance of this pathway in the aetiology of schizophrenia.
5.2 REPLICATION OF ORIGINAL CAPON STUDY
We attempted to replicate the original association implicated by Brzustowicz et al, 
(Brzustowicz et al. 2004) in our UK case control sample using their associated 
markers. The experimental set up and results are shown in the following sections.
5.3 INTRODUCTION
The Canadian family sample which showed linkage to schizophrenia at lq23.3 
(Brzustowicz et al. 2004) was used to test for allelic association with schizophrenia 
using the methods implemented in PSEUDOMARKER (Goring et al. 2000; 
Brzustowicz et al. 2004). This approach claims to be able to detect allelic association 
in a family sample by correcting for the confounding effects of linkage (Goring et al.
2000). The authors stated that their sample size was equivalent to a collection of 
forty five independent trios. Evidence for significant allelic association with 
schizophrenia (p=0.015) was found using two microsatellite and six SNP markers at 
the CAPON locus. A Chinese case control study showed significant association 
between a single SNP at CAPON and schizophrenia but failed to find association 
with any of the six SNP markers which had been implicated in the Canadian sample 
(Zheng et al. 2005). A Spanish study found evidence for positive extended 
transmission disequilibrium (ETDT) with schizophrenia using the marker D1S1679 
(p=0.004) at lq23.3 which is 23 kilobases distal to the 3 prime end of the CAPON
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gene. ETDT analysis is not able to separate the effects of linkage from allelic 
association (Sham et al. 1995; Rosa et al. 2002). The marker D1S1679 was not 
associated with schizophrenia (p=0.9) in the Canadian study. Positive allelic 
association between markers at the RGS4 gene on lq23 and schizophrenia has been 
reported. The RGS4 gene is 700 kilobases distal to CAPON (Chowdari et al. 2002; 
Chen et al. 2004; Morris et al. 2004; Williams et al. 2004). Although, both CAPON, 
D1S1679 and RGS4 are in the same region it is unlikely that the positive results 
reported at the CAPON locus are due to linkage disequilibrium with RGS4 which is 
700 Kb away and vice versa, but linkage disequilibrium between alleles at D1S1679 
and CAPON is possible as is LD between RGS4 and a susceptibility locus in the 
middle of the 700kb region between CAPON and RGS4.
Figure 5:0 Showing the location of SNPs and the microsatellites in the region of 
CAPON/NOSA1P (UCSC May 2004 assembly, BLAT diagram).
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5.4 GENERAL METHODS AND MATERIALS
The positive Canadian study markers were genotyped in a British ancestrally 
matched sample of DNA from 450 cases of schizophrenia 450 controls. SNPs and 
microsatellite markers were genotyped using primer sequences available from the 
NCBI databases (http://www.ncbi.nlm.nih.gov/). Genotyping was checked by a 
second independent person blind to diagnosis. Any discrepant genotypes were 
repeated. SNPs were determined by a modified Amplifluor method (KBiosciences, 
Hoddesdon, UK). 17% of genotypings were reduplicated in a separate microtitre 
plate to detect error (section 2.8.3.1). Markers with lack of Hardy Weinberg 
Equilibrium were rejected and genotyping repeated. The data were analysed for 
allelic association with schizophrenia using CLUMP (Sham et al. 1995). Haplotypic
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association with schizophrenia were tested using GENECOUNTING and an 
empirical permutation test of significance (Zhao et al. 2000; Zhao et al. 2002). LD 
relationship between markers were also analysed using the same software. The full 
method is described in the method section 2.0.
5.5 RESULTS AND DISCUSSION
Reduplication of SNPs showed an accuracy rate of 99.4%. None of the markers 
implicated in the Canadian study were found to show allelic, genotypic or haplotypic 
association with schizophrenia (Table 5:1). Six SNPs in introns 1, 2 and 3 of 
CAPON were found to be in strong LD with D1S2675 (all at p<0.00007) (LDPAIRS 
p value from Cramer’s V) (Table 5:2). It should be noted here that the more familiar 
D prime and r2 statistics cannot be used for measure of LD with multiallelic 
microsatellite markers. Cramer’s V (Bishop et al. 1975) is calculated and is output 
along with the associated p-value in order to show LD with multiallelic markers 
(Curtis et al. 2006).
The marker D1S1679 which is 23 kilobases from the 3 prime end of the CAPON 
gene was not in LD with any of the SNP markers in introns 1, 2 and 3, therefore 
there is a high level of recombination between CAPON and D1S1679 (Table 5:2). 
Introns 4, 5, 6 and 7 and exons 4 to 8 of CAPON are contained within a distance of 
only 67 kilobases and allelic association over this part of the gene should be 
detectable with D1S1679. Both the Canadian and the UK samples were negative for 
this marker.
The Chinese case control study which also claims to have implicated CAPON in 
schizophrenia (Zheng et al. 2005) only found association with a single SNP marker 
(rs348624). Other markers in linkage disequilibrium with rs348624 such as 
rs905721 should also have shown some evidence for association but did not. In 
addition rs348624 was not significant in the original study conducted by 
Brzustowicz et al (2004). The Chinese study did not genotype the marker D1S2675
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that showed association (p=Q.036) in the Canadian sample but which was negative in 
the UK study. One explanation for the different outcomes may be that different 
proportions of CAPON susceptibility alleles were present each sample. Alternatively 
it may be that CAPON does not influence susceptibility to schizophrenia and it is a 
false positive result. The study by Zheng et al (2005) might also be false positive 
because of the lack of support for association from adjacent markers. Finally, our 
own results may represent a false negative finding.
We used two microsatellite markers flanking the five prime end of CAPON gene 
and in the second intron and this suggests that additional markers would also fail to 
show association. There were equal proportions of successful schizophrenia and 
control genotypes obtained for the SNP and microsatellite markers except for marker 
D1S2675 for which there was a 19% excess of controls over cases. Further 
genotypes were not obtained because the sample already had more power to exclude 
association between schizophrenia and CAPON than the original study. The lack of 
evidence of association between schizophrenia and CAPON is further supported by 
our finding that D1S2675 shows strong linkage disequilibrium with all the SNPs 
found to be associated with schizophrenia within CAPON and that the microsatellite 
marker D1S1679 also shows strong linkage disequilibrium with the SNP markers 
that are in the 3 prime region of CAPON up to 210.35 kilobases distal from 
D1S1679. Brzustowicz et al (2004) had sequenced all the exons of the CAPON 
gene, but had found no aetiological mutations, however an aetiological mutation 
may still be present elsewhere. There could be a mutation affecting gene-splicing, 
the 5’ UTR and the 3’ UTR affecting the promoter region, transcription factor 
binding, RNA stability and enhancer elements. There is a possibility that association 
with CAPON is more revelent in the Chinese population than the European 
population therefore association with the SNP marker, rs348624, should be 
replicated in a Chinese rather than a European sample. Our findings however, 
diminish support for the notion that the CAPON gene influences susceptibility to 
schizophrenia in European samples.
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5.6 FURTHER PUBLICATIONS ON CAPON
Recent research by Xu et al (2005) from Brzustowicz’s group, examined the 
expression of CAPON, to test if gene expression is altered in schizophrenic patients 
and bipolar patients compared to controls (Xu et al. 2005). Two alternative 
transcripts were found in a fetal brain cDNA library by using exon 10 as a probe. 
Exon 10 was used as a probe on the brains as it contains an nNOS-binding PDZ 
domain which should therefore hybridise to neuronal transcripts containing the 
domain. One transcript was the original full length transcript, the second was a 
shortened transcript containing just exons 9 and 10.
Expression of the transcripts were assessed in the dorsolateral prefrontal cortex 
(which is thought to be a pathological hotspot) that has been identified in studies of 
schizophrenia (Xu et al. 2005) in 35 schizophrenic, 35 bipolar and 35 “control” 
brains. They have found that there was increased expression of the short form of the 
transcript in both the schizophrenics and bipolar brains when compared to the 
controls. In addition they had also found the individuals associated with the 3 most 
associated SNPs (rsl415263, rs4145621 and rs2661818) implicated to the disease 
also led to increased expression of the short form of the transcript. As the short form 
lacked the phosphotyrosine binding domain which is needed to bind to the amino 
terminal targets Dextrasl and Synapsin, the role of the protein would be limited to 
the competitive inhibition of the binding of other ligands to the PDZ domain of 
nNOS and PSD93 or PSD95.
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Figure 5:1 The figure shows the Eastwood et al (2005) interpretation on how expression levels 
of CAPON can lead to impaired NMDA receptor meditated glutamate neurotransmission, 
potentially causing schizohrenia. Nitric oxide synthase (NOS)-CAPON complexes result in 
reduced NMDA-NOS complexes leading to decreased NMDA receptor gated calcium influx and 
inactive NOS.
However, this study had a small sample size, lacked statistical significance and was 
not replicated of the results in another brain series. In addition with lack of evidence 
of other brain regions and histo-chemical studies such as in-situ hybridisation to 
show altered expression as confirmatory evidence, the evidence seems weak. Also 
the resulting protein from the truncated transcript would also need to be assessed if it 
was functional, as this could cause structural alterations to the protein, leaving the 
protein inert.
In addition, Miranda et al (2006) had reported a putative association with CAPON. 
The association was not a replication using the same positive SNPs as implicated by 
Bruzustowicz et al (2004), but only with the use of a single microsatellite (D1S1679, 
p=0.019) in 110 Columbian family trios. The original study including our own 
(Brzustowicz et al. 2004; Puri et al. 2006) did not find association with D1S1679. It
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is possible that Miranda et al’s results may have confounded linkage with 
association, or detected LD with CAPON or another gene within the region. Miranda 
et al (2006) should have included the positive SNPs found by Brzustowicz et al’s 
group for a conclusive result to show if they were detecting association with the 
gene or not, hence the results of the work by Miranda et al (2006) are non- 
conclusive and premature in implicating or supporting evidence in the association of 
CAPON with schizophrenia.
The failure to fully replicate the original association with the same markers, of the 
published studies (including our own), currently weakens support that CAPON is a 
susceptibility gene of schizophrenia in the UCL sample given the informativity of 
the markers used. Allelic heterogeneity in our sample may be responsible for not 
detecting association with CAPON in our sample and there is a possibility that rare 
mutations within in CAPON were detected by the Canadian family sample that 
could have failed to be detected in the UCL case control sample. There is a 
speculative possibility by fully fine mapping CAPON with Tagged SNPs in a larger 
case control sample; one may be able to detect association with CAPON. However 
we have failed to detect association with the markers in which the original study 
had.
Taking the example of rs 1415263, the most associated SNP in the Brzustowicz et al 
(2004) study, our sample had the power of approximately 0.8 to detect association.
Our failure to replicate the CAPON and RGS4 associations could be due to genetic 
heterogeneity or might arise from the previous positive studies actually picking up 
evidence for allelic association due to a susceptibility locus placed in between 
CAPON and RGS4. In our data there was no detectable LD between any of the 
markers within CAPON and any of the markers within RGS4 (see Table 6:4). It 
should be noted that the study by Brzustowicz et al which found association between 
schizophrenia and CAPON gene marker alleles (Brzustowicz et al. 2004) had a 
sample size equivalent to only forty five cases and forty five controls and had a
1 2 0
power of 11% to detect a 10% frequency difference, at p=0.05, for a marker allele 
frequency of 0.43 in controls and 0.53 in cases. By contrast our sample had a power 
of 83% to detect such a frequency difference. Thus there is a risk that the original 
CAPON result has arisen by chance or is due to the confounding of linkage with 
association because of the strong evidence of linkage to the CAPON region in this 
family sample. The study by Chowdari et al (2002) implicating RGS4 has been 
subjected to a meta-analysis in a very large sample (Talkowski et al. 2006). Despite 
the size of the sample, significant associations with individual SNPs and haplotypes 
were not observed in the combined meta-analysis. The global analysis revealed 
significant transmission distortion (p = 0.0009) for two very common haplotypes. 
Separate analyses of 3486 cases and 3755 control samples (eight samples) detected 
only a significant association with RGS4 SNP 4 (rs951436) (p = 0.01).
In the original study when the US patients were contrasted to two population-based 
control samples no significant differences were observed. Thus the evidence for 
involvement of RGS4 in schizophrenia derives more from transmission distortion in 
families than it does from allele frequency differences in case control samples.
With the lack of evidence for association with Regulator of G-Protein Signalling 4 
(RGS4), (section 4.0) and also Nitric Oxide Synthase 1 (neuronal) Adaptor Protein 
(NOS1AP/CAPON) with the British case control sample, this leaves the possibility 
that the linkage signal in the lq23-22 region may be due to another gene in the 
region. Hence the region should be further fine mapped to detect this signal with a 
better resolution using an even larger case control sample.
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Table 5:1 Tests of Allelic and Haplotypic Association with Schizophrenia at the CAPON Gene Locus.
M a rk e r _ 
location  in from
M a rk e r previous % geno typed  Allelic bases o r fra g m e n t s izes and  observed a lle le  freq u e n c ies below C h i2 P’b03S6 pairs
rsl572495
Con
Scz
158830959
97.60%
86.70%
C
797
715
T
81
65
0.409 0.5223’
rsl538018 158862139 31180 G C 0.414 0.5199’
C on 93.10% 631 207
Scz 86.70% 598 182
rs945713 158867328 5189 C T 0.023 0.8782’
Con 95.60% 321 539
Scz 86.70% 294 486
rs 1415263 158897701 30373 C T 1.238 0.2659’
Con 97.80% 549 331
Scz 85.80% 502 270
D1S2675 158941619 43918 168 174 176 182 184 186 188 190 192 194 196 4.533 0.1703T3
Con 75.60% 16 2 1 6 94 343 88 107 18 4 1
Scz 56.40% 17 3 1 3 70 278 61 58 10 4 3
rs 4145621 158950346 8727 C T 0.762 0.3828’
Con 93.80% 360 484
Scz 78.00% 284 418
rs2661818 158996472 46126 G C 0.245 0.6208’
Con 94.40% 394 456
Scz 87.10% 346 438
D1S1679 159093422 96950 164 168 172 176 180 184 188 192 196 200 8.908 0.115T4
Con 97.80% 7 159 102 113 144 170 132 41 11 1
Scz 96.00% 12 119 92 139 133 165 154 41 9 0
8 M ark er H aplotypes E m pirical p value 0.441b
a significance p from 2x2 chi squared 1 df or most significant p value from CLUMP Monte Carlo T l, T2, T3 or T4 as shown, 
haplotype permutation test empirical p, based on 99,999 permutations
Table 5:2 showing structure of Linkage disequilibrium between markers within CAPON with D’, r2 and p-value measurements.
Distance between markers 
Marker Position (bp) Absolute value of D'__________
rs1572495 160365925
Rs1572495 rs1538018 rs945713 rs1415263 D1S2675 rs4145621 rs2661818 D1S1679
0.156 0.662 0.209 0.016 0.028 0.411 0.081
rs1538018 160397105 31180 0.00757 0.134 0.007 0.225 0.017 0.101 0.054
rs945713 160402294 5189 0.07129 0.00941 0.667 0.392 0.608 0.538 0.09
rs1415263 160432667 30373 0.00740 0.00004 0.42250 0.784 0.869 0.677 0.003
D1S2675 160476585 43918 r2 value 0.05570 0.09734 0.22753 0.44756 0.679 0.392 0.228
rs4145621 160485312 8727 0.00010 0.00012 0.31923 0.62568 0.42903 0.769 0.019
rs2661818 160531438 46126 0.02045 0.00260 0.21437 0.32490 0.19184 0.50980 0.024
D1S1679 160628388 96950 0.02103 0.01538 0.01904 0.01613 0.01638 0.02103 0.01850
p values
rs1572495 rs1538018 
rs1572495 0.01194
rs945713
<0.00001
rs1415263
0.01235
D1S2675
0.00007
rs4145621
0.75171
rs2661818
0.00002
D1S1679
0.0926
rs1538018 0.00552 0.80679 <0.00001 0.70815 0.12939 0.18255
rs945713 <0.00001 <0.00001 <0.00001 <0.00001 0.07619
rs1415263 <0.00001 <0.00001 <0.00001 0.11205
D1S2675 <0.00001 <0.00001 0.57474
rs4145621 <0.00001 0.08822
rs2661818 0.1334
D1S1679
6.0 FINE MAPPING OF THE UHMK1 GENE
ENCODING A SERINE/THREONINE PROTEIN 
KINASE, AS A NOVEL SCHIZOPHRENIA 
SUSCEPTIBILITY GENE
Linkage studies by us and others have confirmed that chromosome lq23.3 is a 
susceptibility locus for schizophrenia (Brzustowicz et al. 2000; Gurling et al. 2001). 
Based on this information several research groups published evidence that markers 
within both the RGS4 and CAPON genes, which are 700Kb apart, independently 
showed allelic association with schizophrenia (Chowdari et al. 2002; Brzustowicz et 
al. 2004). Tests of allelic association with both of these genes in our case control 
sample were negative (Puri et al. 2006; Rizig et al. 2006) section 4.0-5.0. Therefore 
we carried out further fine mapping in the lq23.3 locus in the 700Kb region between 
the RGS4 and CAPON genes.
Microsatellites were first designed across the region and genotyped in the case 
control sample, three of which detected positive allelic association, implicating three 
genes SH2D1B, UHMK1 and HSD17B7. The region between SH2D1B and 
UHMK1 was more positively associated and hence further fine mapped with SNPs 
to ascertain which was the most likely gene to be associated with schizophrenia. In 
the following sections a description of the fine mapping of the region along with the 
results will be presented, leading to an initial implication of a susceptibility gene. 
This is followed by sequencing results, further evidence of association using tagging 
SNPs and in addition, an attempt to replicate our findings in an independent case 
control sample from the university of Aberdeen donated by Professor St Clair.
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6.1 INTRODUCTION
Association studies of schizophrenia at lq23.3 have implicated both CAPON 
(Brzustowicz et al. 2004; Zheng et al. 2005)and RGS4 (Chowdari et al. 2002; Chen 
et al. 2004; Morris et al. 2004; Williams et al. 2004). In the British case-control 
sample employed in this study we failed to replicate either of these associations 
(Puri et al. 2006; Rizig et al. 2006). The distance between CAPON and RGS4 is 
approximately 700Kb. In order to investigate whether the positive results at CAPON 
and RGS4 might actually be due to linkage disequilibrium (LD) with a closely 
linked gene, we carried out fine mapping in the region with a further set of markers 
as reported below
6.2 METHOD
SNPs rsl64126, rsl64123, rs3121196, rs351453, rsl64128, rsl0494370, rs7513662, 
rs423227, rs6427680 were chosen from the International HapMap Project and 
previously unformatted microsatellite repeats were identified from the UCSC 
Genome Browser (May 2004 assembly). These new repeats were formatted by us for 
genotyping. The primers were designed with Primer3 (Rozen et al. 2000). The 
microsatellite markers are now listed in the GDB database with the D segment 
numbers D1Z12, D1Z13, D1Z14, D1Z15, D1Z16, D1Z17, D1Z18 and D1Z19. The 
positions and primer sequences of these markers are shown in Table 6:1. PCR 
amplification of the microsatellite markers was carried out using an Ml 3 tailed 
primer and a second non-tailed primer. A third universal M l3 sequence primer 
labelled with IRD 700 or IRD 800 was used to hybridise against the M l3 tailed 
locus specific primer. Microsatellite marker fragment sizes were separated and 
visualised with either of two infrared dyes IRD700 and LRD800 on dual argon laser 
LiCor 4200L sequencers. Genotyping was carried out with the SAGA-GT 
genotyping software (LiCor) and checked by eye. Allele calling by SAGA-GT was 
checked by a second independent rater blind to diagnosis. Any genotypes discrepant 
between the two raters were PCR-amplified and run again. SNPs were determined 
by the Amplifluor SNP genotyping method as modified by KBiosciences. 17% of
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samples on each microtitre plate were reduplicated in order to detect error and 
confirm the reproducibility of genotypes. The data were then analysed to confirm 
Hardy Weinberg equilibrium (HWE). Markers with lack of HWE in the control 
group were rejected and genotyping was repeated. Before association analysis the 
genotype data for each 96 well microtitre plate were analysed for linkage 
disequilibrium with closely linked markers to ensure that LD relationships were 
similar for each plate.
Next this data were analysed for allelic association with schizophrenia using 
CLUMP (section 3.2.3.2), which employs an empirical Monte Carlo test of 
significance and which does not require correction for multiple alleles (Sham et al. 
1995).
The genotypes were then analysed for haplotypic association with schizophrenia 
using GENECOUNTING, which computes maximum likelihood estimates of 
haplotype frequencies from phase unknown case control data, and the significance of 
any overall haplotype association with schizophrenia was computed with a 
permutation test (Zhao et al. 2000; Zhao et al. 2002; Curtis et al. 2006). 
GENECOUNTING was also used to calculate pair-wise linkage disequilibrium 
between all markers.
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6.3 R E S U L T S
Twenty nine markers in the lq23.3 region were genotyped as shown in Figure 6:1. 
These included markers at the CAPON and RGS4 loci which had previously failed 
to show any evidence for association with schizophrenia (Puri et al. 2006; Rizig et 
al. 2006) in section 4.0 and 5.0. The first markers to be genotyped were 
microsatellites within the 700 Kb region between CAPON and RGS4. As shown in 
Table 6:2, three of these produced evidence for association with schizophrenia: 
D1Z12, D1Z13 and D1Z18. D1Z12 (significant at p=0.011) is a (CA)2o dinucleotide 
repeat 35.3Kb distal of CAPON and situated directly within the genomic extent of 
the gene SH2D1B [MIM608510]. SH2D1B, also known as EAT2, regulates signal 
transduction through receptors expressed on the surface of antigen-presenting cells 
(Morra et al. 2001). D1Z13 (significant at p=0.014) is situated between two genes, 
47.6Kb distal of SH2D1B and 64.3Kb proximal to UHMK1 [MIM608849].
UHMK1 (U2AF homology motif (UHM) kinase 1) is a serine/threonine-protein 
kinase also known as KIS or Kist (Kinase interacting with stathmin). This gene is 
highly expressed in the brain and other parts of the central nervous system and less 
so in other tissues (Maucuer et al. 1995; Maucuer et al. 1997; Maucuer et al. 2000; 
Boehm et al. 2002; Bieche et al. 2003). A third microsatellite marker D1Z18 was 
also found to be associated with schizophrenia (p=0.049). D1Z18 is located 90.2 Kb 
proximal to the five prime end of RGS4 and is 166.3 Kb distal to the gene encoding 
the enzyme 17-beta-hydroxysteroid dehydrogenase (HSD17B7 [MIM606756]). 
D1Z18 is also proximal to two overlapping predicted genes MGC48998 and 
BC040018, both with unknown function. A BLAST search for conserved domains in 
the NCBI Conserved Domain Search database did not reveal known functional 
domains. We found no evidence for association between RGS4 and schizophrenia in 
our sample (Rizig et al. 2006) (section 4.0).
SNP markers were genotyped in the SH2D1B and UHMK1 genes because these 
genes are in close proximity to the microsatellite markers D1Z12 and D1Z13. The 
results from these SNPs are shown in Table 6:2 (single marker table) and Table 6:3
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(haplotypic association table). No evidence for association with schizophrenia was 
found from SNPs within SH2D1B (rsl64126, rsl64123, rs3121196, rs351453, 
rsl64128). Furthermore, there was no evidence for haplotypic association with 
schizophrenia when these SNPs were combined with the marker D1Z12 (empirical 
permutation p = 0.123) or when these SNPs were combined with both D1Z12 and 
D1Z13 (empirical permutation p = 0.233). Tests of haplotypic association by 
combining D1Z12 and D1Z13 into a two locus haplotype were not formally 
significant (empirical permutation p=0.065).
By contrast, SNPs genotyped within UHMK1 demonstrated significant association 
(rs 10494370, p = 0.004, odd ratio 1.64 (95% Cl 1.16 - 2.32) and rs7513662, p = 
0.043, odds ratio 0.81 (95% Cl 0.66 - 0.99)) and two additional SNPs showed trends 
towards association (rs423227 p = 0.079 and rs6427680 p = 0.069). Evidence for 
haplotypic association at UHMK1 was found when data from these four SNPs were 
analysed as a single haplotype using GENECOUNTING (empirical permutation p = 
0.0086), the most significant individual haplotype (consisting of rsl 0494370- 
rs7513662-rs423227-rs6427680) over expressed in cases was haplotype 1 (GATT) 
present in 6.5% of controls and 10.2% of cases and haplotype 2 (AACT) present in 
10.8% controls and 14.1% in cases.
We found positive allelic association after the eighth marker was genotyped. Tests 
of experiment wide significance for marker rsl 0494370 remained significant 
following bonferroni correction (alpha=0.006) for multiple tests. Tests of haplotypic 
association were also significant for UHMK1 (p=0.009) using empirical permutation 
tests, which make it unnecessary to further correct for both multiple alleles and 
multiple markers
There was no evidence for haplotypic association when D1Z13 was included with 
the SNP data (empirical p = 0.337). D1Z13 did not show evidence for LD with SNP 
markers at UHMK1. However, D1Z13 showed good evidence for LD with markers 
within SH2D1B (see Table 6:4). Tests of haplotypic association in all neighbouring 
regions including at the CAPON and RGS4 loci were negative as shown in Table
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6:3. Thus the evidence from these results points to UHMK1 as the most likely 
susceptibility gene for schizophrenia.
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6.4 DISCUSSION
The positive results at CAPON and RGS4 could be that both are due to allelic 
association with aetiological base pair changes in or near the UHMK1 locus that has 
been implicated by us. This idea gains support from the fact that we detected significant 
linkage disequilibrium between markers at UHMK1 with markers at both RGS4 and
'y
CAPON with significant P values but unfortunately not with D ’ or r (p= 0.02 and 
0.00084 respectively Appendix Section 13.0 ). There is thus at least a possibility that 
the family-based methods used previously were unable to distinguish the effects of 
these three loci, implicating too broad a region.
The UHMK1 gene is a novel kinase with an RNA recognition site which has been 
shown to be highly expressed in the brain (Bieche et al. 2003). Five SNPs within the 
neighbouring gene SH2D1B (also known as EAT2, which regulates signal transduction 
through receptors expressed on the surface of antigen-presenting cells (Morra et al.
2001)) showed no allelic association with schizophrenia. The gene HSD17B7, which is 
proximal to the schizophrenia-associated marker D1Z18, is near to RGS4 on the distal 
side of UHMK1. HSD17B7 encodes the enzyme 17-beta-hydroxysteroid dehydrogenase 
(oxidizes or reduces estrogens and androgens in mammals and regulates the biologic 
potency of these steroids) (Krazeisen et al. 1999). SH2D1B, UHMK1 and HSD17B7 
are all plausible candidates for influencing susceptibility to schizophrenia. However, 
our haplotype analyses for SNPs in the SH2D1B do not implicate this gene (Table 6:3). 
The allelic and haplotypic analyses of SNPs within UHMK1 suggest that this gene itself 
is likely to be increasing susceptibility to schizophrenia (Table 6:3).
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The schizophrenic subjects we studied were routine clinical cases from United Kingdom 
NHS services in London and Southern England. They were not selected for having a 
positive family history of schizophrenia, although many of them did. The finding of 
association between schizophrenia and markers on chromosome lq23.3 suggests that 
genetic effects detected by linkage studies of large multiply affected pedigrees may also 
be operative in a significant proportion of patients not necessarily having a family 
history of schizophrenia. The sample in which we have found positive association with 
UHMK1 has also shown allelic association with markers at the EPSIN 4 gene on 
chromosome 5q (Pimm et al. 2005). This locus had also been implicated by prior 
linkage studies (Schwab et al. 1997; Straub et al. 1997; Gurling et al. 2001; Devlin et al.
2002) and further supports the conclusion that genetic effects found in families by 
linkage analysis may also operate in unrelated cases of schizophrenia drawn from 
general hospital patients.
131
Table 6:1 M icrosatellite and SNP m arker positions (UCSC M arch 2006 assembly) on lq23.3 used for fine m apping of schizophrenia.
Marker
name
Polymorphism Position of 
polymorphism (bp)
Left primer Right primer
rsl 64126 C/T 159097317
rsl 64123 C/T 159099312
rs3121196 A/G 159104376
D1Z12 (CA)2o 159105192 GCCAAGACATGGAATCAACC ATGCCACGTATGAGTGAGACC
rs351453 A/G 159107574
rsl 64128 G/T 159117169
D1Z13 (CA)21 159161203 TCCAAGAAGCCCAATGAAAC ACTCCTGGGCTCAAACAATC
D1Z14 (TTTA)10 159164066 TCCATTCCTTCTCACCCATC GCT GAGGCAGG AG AAT C ACT
rsl 0494370 A/G 159200571
rs7513662 A/G 159211803
rs423227 C/T 159217015
rs6427680 C/T 159221876
D1Z15 (TG)22 159332631 CCTCTGAACCATTCCCATGT GCAAACAGGAAAGGGAGGAT
D1Z16 (GT)13 159469256 GCTTCTGATGCACATTCGAG TGAAGAGGGACTCAGAGGGATA
D1Z17 (TC)12 159525259 TGAGCGATAGAGT CAGGATTCA AGCACAGAGCCAAACACCTT
D1Z18 (CA)23 159680585 CCCAGCCTT CCCT ATT GT CT GTTTTCCAACCCCTGTCAGA
D1Z19 (CA)i9 159705995 TTGCTGTCTTGCCCTACAGA CCTCATCATGGGCAGAGAAT
Table 6:2 Tests of allelic association w ith schizophrenia a t the lq23.3 region.
M arker 
rsl 6 4 126
M arker 
location  
(bp on C 1) 
159097317
bp from  
prio r 
m arker
C T
A llelic  bases o r fragm ent sizes w ith  observed  allele frequencies below C h i2
0.30
a
P
0.58
Con 561 321
Scz 516 312
rsl 64123 159099312 1995 C T 0.00 0.98
Con 180 698
Scz 175 677
r s 3 121196 159104376 5064 A G 0.67 0.41
C on 631 217
Scz 619 233
D 1Z 12 159105192 816 230 232 234 236 238 2 40 242 244 246 248 250 252 9.82
I
0.01
C on 288 0 1 1 2 106 237 21 37 141 39 5
Scz 217 1 1 1 1 95 211 16 61 128 43 1
r s 3 5 1453 159107574 2382 A G 0.67 0.41
C on 652 222
Scz 612 228
r s l  64128 159117169 9595 G T 0.27 0.60
C on 394 462
Scz 348 430
D 1Z 13 159161203 44034 212 214 216 218 220 222 224 226 228 230 232 2 34  236  238 240 242  26.2 O.Ol72
C on 35 3 1 39 186 2 21 20 84 118 67 138 32 21 11 0
Scz 37 5 2 19 172 10 27 24 59 117 48 127 40  19 18 4
D 1Z 14 159164066 2863 200 204 208 212 216 220 221 224 1.15 T30.89
Con 18 164 9 123 170 319 1 32
Scz 15 136 7 115 145 245 1 24
rs l  0494370 159200571 36505 A G 8.04 b0.004
Con 810 58
Scz 748 88
Table 6:2 Continued.
r s 7 5 13662 159211803 11232 A G 4.12 0 .043°
C on 537 317
Scz 561 269
rs423227 159217015 5212 C T 3.08 0.08
Con 95 757
Scz 119 733
rs6427680 159221876 4861 C T 3.30 0.07
Con 436 436
Scz 385 459
D 1Z 15 159332631 110755 312 314 316 318 320 322 324 326 328 2.74 0 .4913
Con 2 44 36 444 45 9 207 22 1
Scz 0 30 20 367 32 3 ■ 150 16 2
D 1Z 16 159469256 136625 276 278 280 282 284 286
Con 2 1 42 612 93 2 1.824
13
0.38
Scz 1 1 53 618 110 3
D 1Z 17 159525259 56003 212 214 216 218 1.23 T40.69
Con 0 418 415 5
Scz 1 336 342 3
D 1Z 18 159680585 155326 235 241 249 251 253 255 257 259 261 263 265 267 269  273 21.7 0 .049TI
C on 35 0 22 31 61 93 148 104 181 66 41 14 0 0
Scz 27 2 17 28 41 120 136 131 187 50 30 9 1 1
D 1Z 19 159705995 25410 372 374 376 378 3 8 0 - 382 384 386 388 3.29 0 .67T4
C on 0 26 138 42 370 150 86 35 15
Scz 1 23 106 40 276 108 8 ! 30 11
a significance p from 2x2 chi squared 1 df or most significant p value from CLUMP Monte Carlo T l, T2, T3 or T4 as shown. bOdds ratio 1.64 
upper limit 2.32, lower limit 1.16 cOdds ratio 0.81 upper limit 0.99. lower limit 0.66
Positions from UCSC March 2006 assembly
Table 6:3 Haplotypic association with schizophrenia at the lq23.3 region with markers within
CAPON, SH2D1B, UHMK1 (KIST) and RGS4.
Location Haplotype Empirical p Value3
Markers within CAPONb r s l 572495- r s l 538018 - rs945713- rs 1415263- D 1S 2675- rs4145621 - 
rs2 6 6 1 818- D 1S 1679
p = 0.441
Markers within SH2D1B rs 164126- rs 164123- r s 3 121196- 
D 1Z 12- rs351453 - rs l6 4 1 2 8 p = 0.123
Markers within SH2D1B 
with D1Z13
r s l 64126 - rs l6 4 1 2 3 -  r s3 1 2 1 196- 
D 1Z 12- rs351453 - r s l6 4 1 2 8 -  D 1Z 13 p = 0.233
Marker D1Z12 with 
D1Z13
D 1Z 12- D 1Z 13 P = 0.065
Markers within UHMK1 r s l 049 4 3 7 0 - r s 7 5 13662- rs423227 - 
rs6 4 2 7 6 8 0 p = 0.0086
Markers within UHMK1 
with D1Z13
D 1Z 13 -rs 10494370- r s 7 5 13662- 
rs4 2 3 2 2 7 -rs6 4 2 7 6 8 0 p = 0.337
Markers within UHMK1 rs423227 - rs6427680 p = 0.081
Markers within RGS4b rs951436 - rs9 41439 -rs2661319 p = 0.431
a haplotype permutation test empirical p, based on 99,999 permutations 
b (Puri et al. 2006; Rizig et al. 2006)
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Table 6:4 LD between all m arkers including RGS4 and CAPON (based on combined sample).
Marker
Distance
from
previous
marker
(bp)
rsl 572495 1
rs1538018 31180 2
rs945713 5189 3
rs1415263 30373 4
D1S2675 43918 5
rs4145621 8727 6
rs2661818 46126 7
D1S1679 96950 8
rs164126 3895 9
rs164123 1995 10
rs3121196 5064 . 11
D1Z12 816 12
rs351453 2382 13
rs164128 9595 14
D1Z13 44034 15
D1Z14 2863 16
rsl 0494370 36505 17
rs7513662 11232 18
rs423227 5212 19
rs6427680 4861 20
D1Z15 110755 21
D1Z16 136625 22
D1Z17 56003 23
D1Z18 155326 24
D1Z19 25410 25
rs951436 59005 26
rs941439 349 27
rs2661319 12156 28
GT 6086 29
D' above the diagonal and r2 below the diagonal
D' < H |  r
D’ < 0.8 
D‘ < 0.6
B r< 0.8
r < 0.6
CAPON SH2D1B RGS4
20 21 22 23 24 25 26 27 28 29
Figure 6:1 M arkers and gene positions in the lq23.3 region between CAPON and RGS4.
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7.0 CONFIRMATION OF THE GENETIC ASSOCIATION 
BETWEEN THE U2AF HOMOLOGY MOTIF (UHM) 
KINASE 1 (UHMK1) GENE AND SCHIZOPHRENIA ON 
CHROMOSOME 1Q23.3
7.1 INTRODUCTION
Our original genetic association studies did not find evidence for both the CAPON and 
RGS4 loci in the UCL case control sample (Puri et al. 2006; Rizig et al. 2006) section 4.0- 
5.0. Our original study of UHMK1 (Puri et al. 2007) section 6.0, found positive allelic 
association with two neighbouring microsatellites (D1Z12 and D1Z13) and two SNPs 
within UHMK1 (rsl0494370 and rs7513662), in addition two SNPs showed a trend 
towards association (rs423227 and rs6427680). A third microsatellite (D1Z18) located 
between the steroid dehydrogenase gene HSD17B7 and RGS4 was also associated.
The weakly associated microsatellite marker D1Z18 is close to the hydroxysteroid (17- 
beta) dehydrogenase 7 gene (HSD17B7). We have now genotyped tagging SNPs derived 
from HapMap to test whether HSD17B7 may be involved in the susceptibility to 
schizophrenia and have also genotyped HapMap SNPs in the UHMK1 gene selected to 
cover the 5’ and 3’ untranslated regions (UTRs). We have also carried out linkage 
disequilibrium (LD) analyses of the whole 700Kb region including markers in CAPON, 
UHMK1, RGS4 and HSD17B7.
Markers localised within UHMK1 and known to show association in the UCL sample have 
also been genotyped in a replication case control sample from Aberdeen.
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7.2 BRIEF METHODS AND MATERIALS
The methods and DNA samples employed were described previously in sections 2.0-3.0. 
The UCL case control sample consisted of DNA from 450 volunteers with schizophrenia 
and 450 controls. Selection and screening were carried out as stated in section 2.1. For the 
replication study using the Aberdeen sample, DNA from 858 cases of schizophrenia and 
591 controls was available. The cases were diagnosed using a combination of case note 
inspection and in the majority of cases (n=717) SCID interview. All met the DSM 111R 
diagnosis of schizophrenia by OPCRIT. The controls were drawn from the same Scottish 
population. They were recruited as volunteers via general practices and screened for 
absence of psychiatric illness. They were sex matched.
Tagging SNPs where ascertained from the international HapMap Project (in the CEU 
population) with the use of the Haploview (3.32) Tagger function (Barrett et al. 2005; de 
Bakker et al. 2005), on its default setting (aggressive tagging use of 2 and 3 marker 
haplotypes, with r threshold of 0.8 and a LOD threshold for multi marker tests of 3.0). All 
SNP markers were genotyped by the KASPar method which is a modification of the 
Amplifluor method (KBiosciences, Hoddesdon, UK). 17% of samples on each microtitre 
plate were reduplicated in order to detect error and confirm the reproducibility of 
genotypes. The data was then analysed to confirm Hardy Weinberg equilibrium (HWE). 
Markers with lack of HWE in the control group were rejected and repeated. The genotype 
data was analysed separately by 96-well DNA plate using SCANGROUP to test for plate 
by plate differences in haplotype frequencies (Curtis et al. 2006). Some genotyping errors 
can show up as rare haplotypes occurring on just a single plate whereas true haplotypic 
associations with will be manifest as certain haplotypes being preponderant among cases or 
controls spread across a number of plates.
Genotypic and allelic associations of individual markers were tested for using chi square 
tests. Tests for haplotypic association were carried out using GENECOUNTING, which 
computes maximum likelihood estimates of haplotype frequencies from phase-unknown 
data, and the empirical significance was obtained using permutation tests (Zhao et al. 2000; 
Zhao et al. 2002; Curtis et al. 2006). GENECOUNTING was also used to calculate pair­
wise linkage disequilibrium between all markers, and their relationship was visualised on 
LocusView 2.0 (Broad Institute) (Petryshen et al. 2003).
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7.3 R E S U L T S
The SNPs at HSD17B7 (Figure 7:1) did not demonstrate allelic or haplotypic association 
with schizophrenia (Table 7:1). Results from typing additional markers around UHMK1, 
covering the 5’ and 3’ UTRs along with results from the five SNPs previously found to be 
associated with schizophrenia (section 6.0) (Puri et al. 2007) are shown in Table 7:2. Two 
of the new SNPs, rs6604863 and rsl 0753578, were found to be associated with 
schizophrenia (p=0.02 and p=0.017 respectively). A third marker, rs6704428, showed a 
trend towards allelic association (p=0.089). A seven marker haplotype including the 
original SNPs described in Puri et al (2007) and the new SNPs described here produced an 
empirical significance of p=0.0033 (Table 7:3). These findings from the UCL sample 
provide additional evidence for UHMK1 as a schizophrenia susceptibility gene.
The following markers were genotyped in the Aberdeen sample: r s l0494370, rs7513662, 
rs423227, rs6427680, rs6604863, rsl 0753578 and rs6704428. Two of these SNPs yielded 
evidence for association, rs7513662 (p=0.0087) and rsl0753578 (p=0.022) (Table 7:2). 
Allele A of rs7513662 was associated with schizophrenia in both the UCL and Aberdeen 
samples. However the distribution of allele frequencies for rsl 0753578 is in the opposite 
direction to that found in the UCL sample. This may indicate that the aetiological 
nucleotide change is present on different haplotype background in the two samples or that 
the disease haplotype frequencies are different in the north and south of the UK. The four 
SNPs originally implicated in the UCL sample produced evidence for haplotypic 
association in the Aberdeen sample (empirical permutation p=0.0135) and the presence of 
two associated SNPs in the Aberdeen sample confirms UHMK1 as a gene increasing 
susceptibility to schizophrenia. Of relevance is also the fact that haplotypic association with 
the original four marker haplotype (rsl0494370, rs7513662, rs423227 and rs6427680) (Puri 
et al. 2007) has been confirmed and replicated (permutation p=0.0135), in addition a 
haplotype analysis of all seven markers in the Aberdeen sample was replicated producing 
an empirical p value of 0.0004. Amongst the other haplotypes tested with less than seven 
markers, the most significant in the Aberdeen sample comprised markers rs7513662 and 
r s l0753578 (permutation p=0.0002; see Table 3).
Data from the UCL and Aberdeen samples were combined and analysed together. Evidence 
for association was stronger in the combined sample for three SNPs, rs7513662, rs6427680 
and rs6694863 (p=0.0007, 0.0252 and 0.015 respectively). Haplotype association for the
140
original four markers was also significant (empirical p=0.011). However the strongest 
evidence for association came from haplotype analysis of all seven markers (empirical 
p^O.00005) (Table 7:3).
Global haplotypic analyses of the UCL and Aberdeen samples data showed that the same 
marker loci were associated in both samples. However inspection of the specific subgroups 
of alleles at these loci showed some differences between the sample. In the UCL sample, 
the four locus SNP haplotypes consisting of rsl 0494370-rs7513662-rs423227-rs6427680 
(haplotypes UHMK1F and UHMK1G) were elevated in cases relative to controls 
(UHMK1F 16.2% cases vs. 13% controls; UHMK1G 10.2% cases vs. 6.5% controls). In 
the Aberdeen sample, haplotypes UHMK1D and UHMK1E were elevated in cases relative 
to controls (32.7% cases and 29.1% controls; 13.8% cases and 11.4% controls 
respectively). However, in the analysis of the combined samples all four haplotypes were 
elevated in cases relative to controls (see table 3). For the 7 SNP haplotype analysis 
(rsl0494370-rs7513662-rs423227-rs6427680-rs6694863-rsl0753578-rs6704428) the 
elevated haplotypes in the UCL sample were UHMK1B (12.2% cases 11.7% controls,) and 
UHMK1C (12.8% cases and 10.9% controls). In the Aberdeen sample elevated haplotypes 
were UHMK1A (30.2% cases and 24.8% controls) and UHMK1B (13.8% cases and 11.4% 
controls). Haplotype UHMK1B is elevated in both individual samples. However, in the 
combined analysis all three haplotypes (UHMK1 A, UHMK1B and UHMK1C) are more 
common in cases (Puri et al. Submitted).
7.4 DISCUSSION
The failure to detect association between markers in HSD17B7 with schizophrenia suggests 
that this gene is unlikely to be involved in schizophrenia susceptibility in the British 
population. The weakly positive result from D1Z18 could be attributed to detecting long 
distance LD with aetiological base pair changes in UHMK1 or another gene in the region. 
Superficially we have managed to replicate association between UHMK1 markers and 
schizophrenia in second case control sample. However careful attention to the detail of 
which marker alleles and haplotypes were associated with schizophrenia in the original 
UCL and then in the Aberdeen sample show some differences which need explaining. The 
differences could be explained by the fact that the disease haplotype frequencies are
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different in the north and south of the UK. Indeed when allele frequencies of the seven 
SNPs typed at the UHMK1 locus in the UCL and Aberdeen samples were compared, the 
differences were greater between the two control samples as opposed to the schizophrenia 
samples.
As noted above two previous studies have implicated the microsatellite D1S1679 by 
showing association or linkage with schizophrenia. D1S1679 is 105.9Kb from the 5’ end of 
UHMK1 and displays significant LD with markers rs7532188, D1Z14, rsl64160, 
rsl64167, rsl64168 and rsl64171 with p values < lx l0 '5 (13.0 Appendix Figure 13:1) in the 
likely promoter region of UHMK1. The evidence for association between schizophrenia 
and D1S1679 might therefore be due to LD with aetiological base pair changes in UHMK1.
UHMK1 (U2AF homology motif kinase 1) is a serine/threonine-protein kinase with an 
RNA recognition site and it has been shown to be highly expressed in the brain (Bieche et 
al. 2003). Both the gene and its protein are highly conserved between mouse, rat and 
human. UHMK1 is also known to be highly expressed in most parts of the mouse brain, 
particularly in the amygdala and hippocampus, according to the Allen Brain Atlas. The 
protein has the ability to phosphorylate classical in vitro substrates such as myelin basic 
protein and synapsin 1 (Maucuer et al. 1997), as well as stathmin, a complex signal relay 
protein. Stathmin is phosphorylated in response to many signals such as hormone growth 
and differentiation factors, neurotransmitters or upon activation of T lymphocytes. It has 
also been proposed as a key regulator of microtubule dynamics (Maucuer et al. 1997). 
UHMK1 was formerly named as KIS (kinase interacting with stathmin) and had originally 
been discovered by a yeast two hybrid screen using stathmin as bait (Maucuer et al. 1995). 
The stathmin gene locus has been knocked out in the mouse, and it was found that mice 
homozygous for stathmin gene deletion lacked instinctive fear and had other behavioural 
abnormalities. The stathmin knockout also had weak memories for past aversive 
experiences such as those in fear conditioning tests (Shumyatsky et al. 2005). The gene is 
highly enriched in the lateral nucleus of the amygdala. Because of the close association of 
UHMK1 protein with stathmin protein a knockout of UHMK1 may also produce similar 
behavioural abnormalities. A study comparing anterior cingulate cortex gray matter 
proteomes between schizophrenia and controls found that stathmin was increased by 1.8 
fold change in a schizophrenia cohort (Clark et al. 2006). It has also been found that the
expression of UHMK1 is significantly down-regulated in mice treated with the 
antipsychotic drugs clozapine and haloperidol Rizig et al (2009)
7.5 CONCLUSION
Association between UHMK1 and schizophrenia has been successfully confirmed in a case 
control sample from Aberdeen. There was increased statistical significance when the 
sample was combined with the UCL sample. Further independent replications of 
association are now needed in as many populations as possible. Resequencing, expression 
analysis and several types of conditional and knockout transgenic mice are now needed to 
further explore the normal and abnormal biological functions of the UHMK1 gene.
143
Table 7:1 Tests of association between HAPMAP SNPs in HSD17B7 and schizophrenia in the UCL 
sample.
M arker
M arker loca tion  (U C S C  
M arch  2006  assem b ly ) b p  from  prio r m arker
A llelic  bases  o r  fragm en t 
sizes w ith  observed  a lle le  
frequenc ies be lo w
C h i2 pa
rsl892125 161031373 A C
UCL Controls 142 764 2.11 0.14
UCL Schizophrenia 118 772
rsl 780019 161033100 1727 G A
UCL Controls 193 679 1.22 0.27
UCL Schizophrenia 173 693
rs2684881 161033792 692 A T
UCL Controls 22 912 0.66 0.42
UCL Schizophrenia 16 868
rsl 1589262 161037271 3479 G A 0.41 0.52
UCL Controls 336 594
UCL Schizophrenia 333 553
rsl 0917598 161040138 2867 C G 0.81 0.37
UCL Controls 304 610
UCL Schizophrenia 309 567
rsl 039874 161043150 3012 C T 0.51 0.47
UCL Controls 47 893
UCL Schizophrenia 40 890
rsl 2402864 161048148 4998 A G
UCL Controls 277 593 1.29 0.26
UCL Schizophrenia 302 576
rs2805053 161048411 263 G A
UCL Controls 458 452 0.06 0.81
UCL Schizophrenia 450 434
8 SN P h ap lo type
G lobal 
em pirical 
p  value
0 .87
a two tailed significance p from 2x2 chi squared 1 df
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Table 7:2 Tests for association of SNPs within UHMK1 in the UCL, Aberdeen and combined samples .
Marker
Marker
location
(UCSC M arch  
2006 
assem b ly )
bp from 
prior marker
Bases with observed allele 
frequencies Chi2
pa
rs 10494370* 160735537 G A
UCL Controls 58 (0.07) 810 (0.93) 8.04 0.004
UCL Schizophrenia 88 (0.11) 748 (0.89)
Aberdeen Controls 110 (0.10) 1030 (0.90) 0.85 0.36
Aberdeen Schizophrenia 141 (0.09) 1493 (0.91)
Combined Controls 168 (0.08) 1840 (0.92) 1.12 0.29
Combined Schizophrenia 229 (0.09) 2241 (0.91)
Mantel Haenszel meta analysis calculated odds ratio 1.11 (Cl 0.87-1.43)
rs7513662* 160746769 11232 G A
UCL Controls 317 (0.37) 537 (0.63) 4.12 0.043
UCL Schizophrenia 269 (0.31) 561 (0.69)
Aberdeen Controls 419 (0.37) 727 (0.63) 6.88 0.0087
Aberdeen Schizophrenia 518 (0.32) 1112 (0.68)
Combined Controls 736 (0.37) 1264 (0.63) 11.34 0.00075
Combined Schizophrenia 787 (0.32) 1673 (0.68)
Mantel Haenszel meta analysis calculated odds ratio 1.23 (Cl 1.06-1.44)
rs423227* 160751981 5212 C T
UCL Controls 95 (0.11) 757 (0.89) 3.08 0.08
UCL Schizophrenia 119 (0.14) 733 (0.86)
Aberdeen Controls 151 (0.13) 969 (0.87) 0.031 0.86
Aberdeen Schizophrenia 216 (0.13) 1414 (0.87)
Combined Controls 246 (0.12) 1726 (0.88) 1.01 0.314
Combined Schizophrenia 335 (0.13) 2147 (0.87)
Mantel Haenszel meta analysis calculated odds ratio 1.09 (Cl 0.88-1.35)
rs6427680* 160756842 4861 C T
UCL Controls 436 (0.5) 436 (0.5) 3.30 0.07
UCL Schizophrenia 385 (0.46) 459 (0.54)
Aberdeen Controls 554 (0.48) 600 (0.52) 1.76 0.18
Aberdeen Schizophrenia 730 (0.45) 876 (0.55)
Combined Controls 990 (0.49) 1036 (0.51) 5.01 0.025
Combined Schizophrenia 1115 (0.46) 1335 (0.54)
Mantel Haenszel meta analysis calculated odds ratio 1.14 (Cl 0.99-1.32)
rs6694863 160771556 14714 A C
UCL Controls 72 (0.08) 868 (0.92) 5.37 0.02
UCL Schizophrenia 46 (0.05) 868 (0.95)
Aberdeen Controls 74 (0.06) 1074 (0.94) 1.26 0.26
Aberdeen Schizophrenia 91 (0.05) 1583 (0.95)
Combined Controls 146 (0.07) 1942 (0.93) 5.86 0.015
Combined Schizophrenia 137 (0.05) 2451 (0.95)
Mantel Haenszel meta analysis calculated odds ratio 1.34 (Cl 1.0-1.8)
rsl 0753578 160788440 16884 A G
UCL Controls 157 (0.18) 729 (0.82) 5.7 0.017
UCL Schizophrenia 201 (0.22) 703 (0.78)
Aberdeen Controls 272 (0.23) 886 (0.77) 5.23 0.022
Aberdeen Schizophrenia 332 (0.20) 1336 (0.80)
Combined Controls 429 (0.21) 1615 (0.79) 0.049 0.83
Combined Schizophrenia 533 (0.21) 2039 (0.79)
Mantel Haenszel meta analysis calculated odds ratio 0.98 (Cl 0.82-1.16)
rs6704428 160795129 6689 G A
UCL Controls 51 (0.06) 853 (0.94) 2.89 0.089
UCL Schizophrenia 69 (0.08) 835 (0.92)
Aberdeen Controls 93 (0.08) 1051 (0.92) 2.56 0.11
Aberdeen Schizophrenia 109 (0.07) 1557 (0.93)
Combined Controls 144 (0.07) 1904 (0.93) 0.019 0.89
Combined Schizophrenia 178 (0.07) 2392 (0.93)
Mantel Haenszel meta analysis calculated odds ratio 0.98 (Cl 0.74-1.28)
a two tailed significance p from 2x2 chi squared 1 df
* Original results in section 6.0 Table 6:2 (Puri et al. 2007).
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Table 7:3 Haplotypic association with schizophrenia with UHMK1 markers in UCL and Aberdeen samples.
Haplotype Composition Alleles
Haplotype
name
Cases
UCL
Controls
Global
empirical
significance Cases
Aberdeen
Global
empirical 
Controls - rsignificance Cases
Combined
Global 
empirical 
Controls s jgnincance
rs 10494370-rs 7513662- 
rs423227-rs 6427680- 
rs6694863-rs 10753578- 
rs 6704428
A-A-T-T-C-G-A
A-A-T-C-C-G-A
A-A-C-T-C-A-A
UHMK1A 
UHMK1B 
UHMK1C
26.9%
12.2%
12.8%
30.2%
11.7%
10.9%
0.0033
30.2%
13.8%
12.4%
24.8%
11.4%
12.8%
0.0004
29.1%
13.2%
12.7%
27.1%
11.7%
11.9%
0.00005
A-A-T-T UHMK1D 30.1% 33.0% 32.7% 29.1% 31.9% 30.8%
rs 10494370-rs 7513662- 
rs423227-rs 6427680
A-A-T-C
A-A-C-T
UHMK1E
UHMK1F
12.3%
16.2%
12.3%
13.0%
0.0086
13.7%
13.1%
11.6%
13.2%
0.0135
13.2%
13.4%
12.0%
12.2%
0.011
G-A-T-T UHMK1G 10.2% 6.5% 8.3% 9.6% 8.9% 8.2%
rs 7513662-rs 10753578 A-G
A-A
UHMK1H
UHMK1I
45.1%
22.3%
45.4%
17.5%
0.024
48.3%
19.9%
40.9%
22.6%
0.0002 47.1 % 
20.9%
42.6% 
, 20.6%
0.0004
rs423227-rs 6427680- 
rs 6704428
C-T-A UHMK1J 14.1% 10.6% 0.067
rs 10494370-rs 7513662- 
rs 6694863-rs 10753578
A-A-C-A UHMK1K 16.2% 13.0% 0.004
rs 7513662-rs 6427680 A-T
A-C
UHMK1M
UHMK1N
54.3%
13.6%
51.3%
12.0%
0.0006
rs 7513662-rs 6427680- 
rs 6694863
A-T-C
A-C-C
UHMK10
UHMK1P
54.3%
13.6%
51.1%
11.8%
0.00005
Figure 7:1 Linkage disequilibrium between all markers genotyped at CAPON, SH2D1B, UHMK1, HSD17B7 and RGS4 on chromosome 
lq23 J , genotyped in the UCL dataset, produced by Locus View.
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8.0 FUNCTIONAL SCREENING FOR AETIOLOGICAL 
CHANGES INCREASING SUSCEPTIBILITY TO 
SCHIZOPHRENIA
8.1 R E-SEQ U EN C IN G  OF UHM K1 -  IN  SEARCH  OF 
M UTATIO N S
UHMK1 had been associated to schizophrenia on chromosome lq23.3 which is 
situated between CAPON and RGS4. The association of UHMK1 had been 
replicated in the Scottish population using a larger independent case control sample 
from the University of Aberdeen. The replication confirmed markers within 
UHMK1 were associated with schizophrenia, and UHMK1 as putative susceptibility 
gene in the cause of schizophrenia (see section 7.0).
The next step to validate UHMK1 as a schizophrenia susceptibility gene, is to find 
DNA changes that would cause UHMK1 to have an abnormal structure or abnormal 
expression. To discover such aetiological base pair changes within UHMK1 
resequencing of affected cases and in controls needs to be carried out. It was noticed 
that schizophrenic cases had a higher frequency of haplotype 1 (GATT) and 
haplotype 2 (AACT), than in controls.
Thirty two schizophrenic patients with the most significantly associated at risk 
haplotypes 1 & 2 (rsl0494370, rs7513662, rs423227, rs6427680) were sequenced 
(section 2.8.4), and when mutations (DNA variants) were found, they were screened 
in thirty two control individuals selected at random, to ascertain if the variant was 
more frequent in the schizophrenic cases compared to the controls.
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8.1.1 RE-SEQUENCING OF THE UHMK1 GENE
8.1.1.1 MUTATION MECHANISMS
Before re-sequencing the UHMK1 gene was commenced, it was necessary to 
consider where any aetiological base-pair change was most likely to be located. 
Botstein & Risch (2003), have reviewed the past successes of linkage studies to 
delineate the different types of mutation which result in human disease and their 
relative frequencies:-
Table 8:1 the types and frequencies of different mutations leading to human disease (Botstein et 
al. 2003).
Change Number % of total
deletion 6,085 21.8
Insertion/duplication 1,911 6.8
Complex rearrangement 512 1.8
repeat variations 38 0.1
Missense/nonsense 16,441 58.9
Splicing 2,727 9.8
Regulatory 213 0.8
Total 27,027 100
The data indicate that most Mendelian clinical phenotypes are associated with 
alterations in normal coding sequence proteins: so far, very few (0.8%) are 
associated with regulatory changes. Linkage studies have proved very successful in 
the identification of both complex disease genes, as well as rare disease-associated 
mutations. They have clear inheritance patterns.
Clearly, it is important to consider where the mutations causing schizophrenia or the 
other complex disorders are likely to be found?
Botstein & Risch (2003) favour the coding regions on the basis that the moderate to 
low risk polymorphisms found so far mainly appear in the coding regions of genes. 
Outside of the coding regions the mechanisms by which diseases arise are complex 
and varied. Most genes encoding for proteins are organised into multiple exons, 
which must be spliced to produce the mRNA that is translated into protein. A 5’ 
promoter element, contiguous with the transcription start site, is required to
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assemble the protein complex necessary for RNA synthesis (Levine et al. 2003). For 
many genes, the region immediately upstream of the minimal promoter contains 
sufficient transcription factor binding sites to direct correct expression of the gene -  
called regulatory promoters. Many genes also require multiple cfs-acting distant 
genomic elements for correct expression to occur. These “enhancers” can be located 
upstream, within introns, or downstream of the transcription unit (which is made up 
of the transcribed exons and introns from the promoter to the polyadenylation site 
(Kleinjan et al. 2001)). The genomic regions harbouring regulatory elements can 
stretch as much as 1Mb in either direction from the transcription unit (Pfeifer et al. 
1999) and (Kimura-Yoshida et al. 2004). Some or all of these elements may reside 
within the introns of neighbouring genes, often with function unrelated to the 
regulated gene ((Kleinjan et al. 2001; Lettice et al. 2002)). From a regulatory 
viewpoint, genes can be grouped into three classes:-
Housekeeping genes required for the functioning of most or all cells; these are 
generally ubiquitously expressed and have promoters that are active in all cells 
without needing enhancers.
Tissue-specific genes, which play a specific role in the particular function of the 
differentiated cell-type; these genes are regulated through one or a few specific 
enhancers.
Developmental regulator genes, which function in specific tissues at defined time- 
points in development -  sometimes at critically defined levels -  and have to be 
strictly inactive in all other tissues and time points. These genes require multiple 
enhancer elements that all need to be fitted into the cis region surrounding the gene. 
Thus far most genes, in which disturbance of long-range control have been observed, 
are key developmental regulators (Kleinjan et al. 2005).
The effects of regulatory elements reaching a long distance are clearly illustrated by 
callipyge mutation in sheep. The callipyge (CLPG) phenotype is characterised by 
hindquarter muscle overgrowth that only affects heterozygotes with paternal 
inheritancy of the CLPG mutation. By use of DNA from the mutants and from the 
mosaic founder individual, the CLPG mutation was identified as a single-base
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substitution in a region of strong sequence conservation 33 Kb upstream of one of 
the genes involved (Freking et al. 2002).
Clearly, finding such mutations and the effects of such mutations is difficult. A 
striking example of a small deletion or mutation in a cis element is provided by the 
case of preaxial polydactyl (PPD) and sonic hedgehog in which a single nucleotide 
substitution located 1Mb from the causative gene produces a severe genetic defect 
(Lettice et al. 2003). With regard to UHMK1 the decision was made to focus 
attention upon the exons and their surrounding splice sites and the 5' region.
8.1.2 METHOD OF SEQUENCING UHMK1
8.1.2.1 SAMPLE SELECTION FOR SEQUENCING
Samples were selected for sequencing following analysis of the results of the 
haplotypic association (see section 6.3). It can be seen that certain haplotypes 
generated from this analysis had a marked increase in frequency in cases compared 
to controls, and these were selected for use in identifying samples likely to contain 
aetiological base pair changes, in this case haplotype 1 and haplotype 2 were most 
significant. Samples from the schizophrenic cases were chosen if they contained one 
or both of the haplotypes in either the heterozygous or homozygous state. This 
resulted in the selection of 44 samples. Forty of these were selected for PCR 
amplification and 32 of the amplified PCR products were bi-directionally sequenced 
to screen for aetiological base pair changes.
Sequencing of the exons included approximately 100 bases of the intronic region to 
take into account any abnormal intron/exon splice site variations. Primers were 
designed (Section 2.8.4) to amplify between 100 to 600 bases, and large regions 
were covered by sequencing overlapping regions. Primers which failed to amplify 
were redesigned with different annealing positions (list of primer sequences used is 
seen in appendix 1 section 13.2). It was found that the CpG island was very difficult 
to amplify, this was eventually overcome by reducing the size of the amplimer.
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Sequencing commenced using the Sanger-Coulson Chain termination method as 
described in the Methods Section 2.8.4.1.
Figure 8:1 Schematic diagram of UHMK1 and the regions sequenced.
UHMK 1
Exonl Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8
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CpG Island
Sequenced regions covered the Exons, the Exon-Intron 
boundaries and the 5’ and 3’ UTR’s.
Figure 8:2 Diagram from UCSC genome browser database showing the simple repeats covering 
the promoter region indicated by the thick black lines (March 2006 assembly).
RefSeq Genes
CpG Islands.' 
IfcpMMwfeJ 
Simple Repeats
1607350:3 | 160740000 I 60745000 I T60750000 | -60755:30 I i6o?e:aoo I
: s c  Known Genes Based on UniProt, RefSeq and Gen Bank mRNA
IUHMK1 |rtMM t  > > *4 >[»>
4 i+
160765000
RefSeq S T +
CpG Islands (Islands < 300 Bases are U0« Green) 
eating £*emen» l-»y ReteatVasKefRece atria El ents to oeatMaakat
IB I III I I  B I B 1  IB BI  U B I I I B i H I I I B I
Smnp e Tandem Repeats by TRF
I I
8.1.3 RESULTS OF RE-SEQUENCING UHMK1 EXONS, 5’UTR AND 
3’UTR
Certain promoter regions could not be amplified (even with alterations to PCR 
cycling conditions, maser mix alterations and primer re-design) due to the region 
consisting of repeats such as LTRs (long terminal repeats), LINES (long interspersed 
nuclear elements) and SINES (short interspersed nuclear elements). This resulted in 
no amplification or amplification of many different regions due to the lack of 
binding specificity (see Figure 8:2). However, over 1Kb of the promoter region and
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all of the exons were successfully sequenced and screened for mutations (see Figure 
8 :1).
None of the exons were found to contain DNA variants in the 32 schizophrenics that 
were sequenced. However, a number of DNA Variants were found in the promoter 
region which will be discussed next.
Table 8:2 Table of DNA variants, position and location.
DNA Variant Location
Position UCSC 
march 2004 
assembly
Distance from 
previous 
mutation (bp)
Figure
4 Base INDEL Promoter P6 160731824 0 8.3
1 Base INDEL ( ±  /G) Promoter Exla3 160734180 2356 8.4
Rare SNP (A/C) CpG Exla3 160734272 92 8.5
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Figure 8:3 sequence of a four base insertion in schizophrenia in amplimer P6 in the promoter 
region of UHMK1.
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As seen in Figure 8:3 a four base insertion has shifted the bases up by four positions 
after the AACC repeat. This insertion deletion was later found to be approximately 
equal in cases and controls (position 160731824).
154
Figure 8:4 sequencing of an insertion/deletion in the promoter region near exon 1 of UHMK1 in 
controls.
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Figure 8:4 shows a single base insertion after the poly G tract, moving all subsequent bases up one 
position. This insertion deletion was later found to be in approximately equal frequencies in cases and 
controls ( ±  /G position 160734180).
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Figure 8:5 shows an SNP change from an adenine to a cytosine in 3 individuals this can be seen 
parallel to the adenine calls and shows that all individuals are heterozygous for the SNP (A/C position 
160734272).
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Figure 8:5 Sequence of a single nucleotide polymorphism SNP of A to C in schizophrenia caes.
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As seen in Table 8:2 DNA variants were found in the promoter and CpG island 
located close to exon 1. The variants consisted of a 4 base pair insertion deletion in 
the promoter region (Figure 8:3), and 2.4Kb down stream a single base pair insertion 
deletion (± /G  IN/DEL) Figure 8:4. In addition there was a low frequency adenine to 
cytosine change in the CpG island only 92 bases away from the single base IN/DEL 
(Figure 8:5).
Of interest was the fact that the rare SNP (A/C position: 160734272, Figure 8:5) was 
found in only 3 of the chosen 32 schizophrenic patients and in none of the 32 
randomly chosen controls. However when the controls were screened a high 
frequency single base IN/DEL (± G  160734180, Figure 8:4) was seen only 92 bases 
from the SNP location that was not present in the Schizophrenic samples. The 4 base 
IN/DEL further up the promoter (location 160731824, Figure 8:3) was observed in 
only half of the schizophrenics and in most of the controls as well.
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Re-sequencing of the exons and the promoter region of the UHMK1 gene, led to the 
discovery of three non-database variants. Because of its location in the 5' region of 
the UHMK1 gene and because of time constraints upon this investigator, both the 
effects of the non-dbSNP and INDELS on binding of transcription factors (carried 
out by a bioinformatic prediction program TESS (Section 8.1.4)) and the genotyping 
of allele frequencies in the whole case control sample were undertaken 
simultaneously.
With these intriguing results, to find if these DNA variants were more prevalent in 
schizophrenic population than the control population the variants had to be typed in 
the full case control population. The single base INDEL from Exla3 (Figure 8:4) 
and the 4 base INDEL found in P6 (Figure 8:3) was genotyped on LiCOR DNA 
sequencers using a 40cm polyacrylamide sequencing gels to increase the resolution 
and hence enable better separation of the product sizes. The individuals were 
genotyped using SAGA-GT. The rare SNP found in Exla3 (Figure 8:5) in the CpG 
island was genotyped using EPOCH probes in a qPCR machine (method described 
in section 2.8.3.2). The results are shown below.
Table 8:3 The results of typing detected DNA variants in the entire case control UCL sample.
Variants chi2 P-Value
4 Base INDEL P6
(Figure 8.3)
Deletion Insertion 
Controls 346 428 
Cases 363 453
0.008 0.930
1 Base INDEL Exla3
(Figure 8.4)
±/G
Deletion Insertion 
Controls 577 233 
Cases 618 214
1.920 0.166
SNP Exla3
(Figure 8.5) 
A/C
A C 
Controls 928 8 
Cases 925 13
1.193 0.275
Table 8:3 shows that none of the observed DNA variants were significantly 
associated with schizophrenia in the entire sample. Although the results look 
disappointing, there is a possibility that the SNP in the CpG island (Exla3 A/C
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Figure 8:5) could be present in a particular sub-type of schizophrenia, or become 
positive if the sample size is increased. This could be possible due to the complexity 
of the disease, which is why it was easily picked up in the most significantly 
associated individuals chosen with the significant haplotypes. There is a possibility 
that the sample does not have the power to detect a low frequency SNP.
Once the DNA variants were found, the variants in the promoter region were 
screened bioinformatically with a program called transcription element search 
system (TESS) before the variants were fully genotyped in the whole sample. TESS 
compares variant with the wild type sequence, to see in any transcription factor 
binding sites were significantly disrupted.
8.1.4 TRANSCRIPTION ELEMENT SEARCH SYSTEM (TESS)
The novel DNA variants identified by re-sequencing the promoter region of the 
UHMK1 gene were examined by TESS in an attempt to identify altered transcription 
factor binding.
Twenty five base pairs either side of the non database SNPs were selected and 
analysed in the transcription factor binding site search engine, TESS (transcription 
element search system), (http://www.cbil.upenn.edu/cgi- 
bin/tess/tess?RQ=WELCOME).
Both the normal and variant sequences were submitted to TESS and the analysis 
recorded. The numerical values shown in the output from TESS predict in a 
logarithmic scale the strength of the binding for various transcription binding 
factors.
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T a b le  8 :4  W ild  ty p e  seq u en ce  a n d  v a r ia n t  seq u en ce  th a t  w e re  a n a ly s e d  b y  T E S S  to  d e te rm in e  i f  
th e  b in d in g  e ffic ien cy  o f  tr a n s c r ip tio n  fa c to rs  w e re  s ig n if ic a n tly  a lte re d .
Mutation type Sequence
4 Base INDEL W T
P6 (Figure 8:3) G AGT G AG ACTTT GTCT C AAAC AAAC AAACC AACC AAC CAACCT AT CTT GT
G AGTG AG ACTTTGTCTCAAAC AAACca a a AAACCAACC AACC AACCT ATCTTGT INS
1 Base INDEL 
Ex1a3 (Figure
W T
8:4) T CT CTT CTAGCCCCGCCCCTT CT G AGCCCCCCCT CTT CGGCCT GTAT GATA
T CT CTT CTAG CCCCGCCCCTTCT G AGcCCCCCCCT CTTCGGCCTGTAT GATA INS
SNP Ex1a3 W T
(Figure 8:5) CACGGCTT CCGGT GT C ATGGCT GCTt GAAGT CCCG GG AGTCGGT G AGGCGG  
CACGGCTT CCGGT GT C ATGGCT GCTg G AAGTCCCGGG AGT CGGT G AGGCGG
WT = Wild type sequence 
INS = insertion
The results showed that neither the rare SNP in Exla3 (Figure 8:5) nor the 1 base 
IN/DEL in Exla3 (Figure 8:4), significantly altered the predicted binding 
efficiencies of any transcription factors. However, the wild type sequence which 
contains the 4 base IN/DEL P6 (Figure 8:3), demonstrates significant binding 
capabilities to transcription factors Freac-6 and Stel 1 both with a LOD value of 
17.00. When the 4-base insertion is added to the sequence as seen in Table 8:4, the 
two transcription factors disappear. Freac-6 (Forkhead-related transcription factor 6) 
is involved in the regulation of embryonic development in humans, and Stel 1 is a 
Serine/threonine protein kinase required for cell-type-specific transcription and 
signal transduction involved in pheromone response and pseudohyphal/invasive 
growth pathways in yeast, it has no known function in humans.
After genotyping in the entire UCL case control sample, none of the variants found 
by sequencing were associated with schizophrenia. However because some of the 
variants may have low penetrance it is still just possible that they have aetiological 
significance. Only a much larger sample could show this. It might be worth while to 
test the effects of the mutated sequences on transcription factor binding using an 
Electrophoretic Mobility Shift Assay (EMSA), which is a technique described by 
Fried et al (1981). This is a method where a sequence of interest is compared to its
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wild type, if a sequence binds to a protein from a nuclear extract such as a 
transcription factor it would migrate more slowly through a gel compared to a DNA 
fragment where no linking has occurred. This would be the first sign in finding out if 
a mutated nucleotide sequence prevents protein-nucleotide interaction compared to 
the wild type. However based on the low significance of these results and time 
constraints, this was not carried out.
There are many other complexities that affect gene expression that could to be 
explored. For example the methylation state of the promoter region (particularly the 
CpG island) would be interesting to look at because all of the sequence variants were 
found in the promoter region. A larger region of the 5’ and 3’ UTR should be 
sequenced because distant mutations can effect gene expression as previously 
discussed. The introns should also be fully sequenced because they are known to be 
important in gene regulation, for example mutations in introns can cause incorrect 
splicing resulting in “exon skipping” or premature termination of the protein.
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9.0U2AF HOMOLOGY MOTIF (UHM) KINASE 1
(UHMK1), GENE, FUNCTION AND INTERACTIONS
9.1 UHMK1 BASIC CHARACTERISTICS
The U2AF Homology Motif (UHM) Kinase 1 gene is located on chromosome 
lq23.3, genomic position 160734279-160760468 and is transcribed on the positive 
strand. The gene consists of 8 exons and has a CpG island in the 5’ end that overlaps 
exon 1.
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Figure 9:1 The location and features of UHMK1
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The transcript contains 2901 bases (UCSC March 2006 assembly) and has an ATG 
start codon within the sequence ccaacaccgATGg that has weak homology to the 
Kozak sequence (Maucuer et al. 1997). The transcript is translated into the UHMK1 
protein which contains 419 amino acids with a molecular weight of 46.4 
KiloDaltons.
9.2 BRIEF GENE FUNCTION
UHMK1 is a serine/threonine-protein kinase, which phosphorylates 
CDKNlB/p27Icipl when serum is present, thus controlling CDKN1B subcellular 
location and cell cycle progression in G1 phase. The gene may be involved in 
trafficking and/or processing of RNA as it contains an RNA recognition motif (by 
similarity) (provided by UCSC March 2006 assembly). UHMK1 does not fit into
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any known kinase subfamily because it has a catalytic core that does not share 
homology with any known kinase. It is also the only know kinase that contains an 
RNA recognition motif. Therefore UHMK1 belongs to a new subfamily of kinases.
UHMK1 is ubiquitously expressed, but expression is much more abundant in the 
nervous system during development and in the brain during adulthood. The protein 
has the ability to phosphorylate in vitro classical substrates such as myelin basic 
protein and synapsin 1 (Maucuer et al. 1997). UHMK1 is expressed in neurons 
during development and also in mature neurons (Maucuer et al. 1995; Maucuer et al. 
1997; Maucuer et al. 2000; Boehm et al. 2002; Bieche et al. 2003).
9.3 D ETER M IN IN G  THE FU NC TIO NAL R O LE OF UHMK1
UHMK1 is a complex multifunctional protein that interacts with a wide rage of 
substrates, however the action and true role of this protein still remains unknown. 
The literature provides evidence that UHMK1 interacts closely with a number of 
proteins, which were established by yeast two hybrid screening techniques. These 
interactions may provide further clues to the function of UHMK1 in the cells and 
how it may be involved in the aetiology of schizophrenia. These proteins are:-
• Stathmin
• Splicing Factor 1 (SF1)
• p27Kipl
• Peptidyl-glycine a-amidating monooxygenase (PAM).
Each protein will be discussed below along side an interpretation of the complex 
function of the UHMK1 gene product.
9.3.1 EXPRESSION OF UHMK1
In a study which quantified normalised UHMK1 mRNA levels by real time RT-PCR 
in a panel of tissues from adult and developing rat, and a collection of human 
tissues. It was found that UHMK1 expression is greater in nervous tissues in both rat
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and human, and expression outside the nervous system seem to be evenly distributed 
with a ratio of 10 between the kidney and pancreas (Bieche et al. 2003) Figure 9:2. 
This shows that UHMK1 may have a particular function in the nervous system 
during development of the human nervous system and in the maintenance of the 
adult brain.
Figure 9:2 (Figure taken from (Bieche et al. 2003)), showing the expression of UHMK1 across 
human tissue samples.
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Figure 9:2 shows UHMK1 mRNA is ubiquitously expressed in human tissues. The 
higher levels are detected in the brain and spinal cord. UHMK1 mRNA was 
quantified using real-time RT-PCR in a series of RNA samples from human tissues. 
Results were normalised to RPLPO signal and then to the lowest signal measured 
(pancreas).
In situ hybridisation experiments in developing rat embryos showed that UHMK1 
mRNA was strongly expressed in the developing nervous system, Figure 9:3. The 
role for UHMK1 expression in the developing nervous system was further supported
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by the finding that UHMK1 expression in human also increases during nervous 
tissue ontogenesis (Bieche et al. 2003).
Figure 9:3 Expression of UHMK1 mRNA in the rat embryo.
Figure 9:3 Shows UHMK1 mRNA expression in rat embryo. In situ hybridisation 
was preformed on embryos at 14 days of gestation using a digoxygenin labeled 
riboprobe. UHMK1 mRNA was mainly detected in the central nervous system and 
dorsal root ganglia. No labeling was observed when hybridising with the sense probe 
as control. (Figure taken from (Maucuer et al. 1997)
Research by Maucuer et al (1997) has also shown that during nervous system 
maturation, the levels of UHMK1 mRNA decreased, and then increased again in the 
adult brain (Maucuer et al. 1997).
In-situ hybridisation of rat brain tissue were carried out to observe the distribution of 
UHMK1 expression by Bieche et al (2003). The results showed differential 
expression in the cortical layers, as well as variable expression in regions of the 
hippocampus. Particularly strong expression was observed in the substantia nigra 
compacta, and nuclei of the brain stem, MA3 (medullar accessory occulomotor
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nucleus) and red nucleus, motor trigeminal nucleus (Mo5), mesencephalic trigeminal 
nucleus (Me5), pontine reticular nucleus caudal (PnC), trapezoid body (Tz),
Superior olive (SO), Vestibular nucleus, gigantocellular reticular nucleus (Gi) and 
facial nucleus (Bieche et al. 2003)(results not shown).
In addition, by observation of in situ hybridisation (ISH) of the sagittal section of the 
mouse brain (Paul Allen Brain Atlas) shown in Figure 9:4. High expression of 
UHMK1 in the hippocampal formation was shown. Also ISH showed that UHMK1 
is expressed at lower levels through out the brain, and confirms expression patterns 
described by Maucuer et al (1997) and Bieche et al (2003).
Figure 9:4 In situ hybridisation with UHMK1 carried out in the mouse brain and highlighted 
by software, section extracted from the Allen Brain Atlas website.
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Extensive analysis firmly establishes a ubiquitous but preferentially neural 
expression of UHMK1 gene in the rat and human. It has been shown to be highly 
expressed in the mature brain. Both the gene and its protein are highly conserved in 
the mouse, rat and human (Bieche et al. 2003).
Although UHMK1 is highly expressed in the brain its precise role is still unknown. 
The functional domains of the protein and the recently discovered interacting
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proteins, provide only hints to its function, as described next, previous experiments 
with Stathmin which interacts with UHMK1 have been carried out.
9.3.2 UHMK1 WITH STATHMIN
UHMK1 has also been designated with the gene names KIS and KIST. KIST stands 
for “Kinase interacting with Stathmin.” This interaction had originally been found 
by yeast two hybrid screening system using stathmin as bait (Maucuer et al. 1995). 
Stathmin is a small ubiquitously expressed cytoplasmic phosphoprotein that is 
enriched in neurons. It is hypothesised to play a role in the relay and integration of 
diverse intracellular signalling pathways and networks. Stathmin is phosphorylated 
in response to many signals such as hormone growth and neuronal differentiation 
factors, neurotransmitters or upon activation of T lymphocytes. It has also been 
proposed as a key regulator of microtubule dynamics in particular during the cell 
cycle and hence involved in cell proliferation and differentiation (Maucuer et al. 
1997; Maucuer et al. 2000; Boehm et al. 2002).
UHMK1 phosphorylates stathmin on serine residues in different positions from 
those sites already known to be phosphorylated by other proteins in vivo (Maucuer 
et al. 1997). This may indicate another regulatory role of stathmin in a cell type or a 
situation that has not currently been explored. It is now known that UHMK1 has 
preferential expression in the developing nervous system and in the mature brain, 
and this expression is correlated with stathmin expression and related neuronal 
proteins which interact with UHMK1 (Maucuer et al. 1997). Studies have shown 
that stathmin is important in neuronal migration and also interacts through 
phosphorylation with brain derived neurotrophic factor (BDNF), with the possibility 
that it may be important in the development of cortical neurons (Cardinaux et al. 
1997; Giampietro et al. 2005).
The stathmin gene locus has been subjected to “knock out” transgenic experiments 
in the mouse. It was found that mice homozygous for the stathmin gene deletion
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lacked instinctive fear and had other behavioural abnormalities. The stathmin 
knockout also had poor memory for past aversive experiences such as those in fear 
conditioning tests (Shumyatsky et al. 2005). The gene is highly enriched in the 
lateral nucleus of the amygdala. Because of the interaction of UHMK1 protein with 
stathmin protein, UHMK1 might also be expected to produce similar behavioural 
abnormalities. Some of these abnormalities might be symptoms of schizophrenia.
A separate investigation by Liedtke et al (2002) showed that aging stathmin deficient 
mice developed an axonopathy of the central and peripheral nervous systems. The 
pathological hallmark of the early axonal lesions was a highly irregular axoplasm 
predominantly affecting large, heavily myelinated axons in the motor tracts. As the 
lesions progressed, degeneration of axons, dysmyelination, and an unusual glial 
reaction were observed. These findings further support the essential role that 
stathmin plays in the maintenance of axonal integrity (Liedtke et al. 2002).
A study comparing anterior cingulate cortex gray matter proteomes between patients 
with schizophrenia and controls found that stathmin was increased significantly by 
1.8 fold in the schizophrenia cohort (Clark et al. 2006). This is possibly relevant 
because UHMK1 is directly associated with stathmin and we know that the stathmin 
knock out mouse exhibits behavioural abnormalities that are compatible with 
schizophrenia.
9.3.3 UHMK1 AND RNA METABOLISM
As stated earlier UHMK1 (U2AF homology motif kinase 1) is a serine/threonine- 
protein kinase with an RNP-type RNA recognition motif with an intriguing 
homology to the C-terminal motif of the splicing factor U2AF. U2AF is known to 
specifically bind to polypyrimidine (T,C) tracts associated with 3’ splice sites 
(Maucuer et al. 1997).
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UHMK1 is thought to be involved in RNA processing. Over-expression of UHMK1 
in HEK293 fibroblastic cells demonstrated that the protein is present in the 
cytoplasm and enriched in the nucleus. This may reflect the shuttling of the kinase in 
relation to its function in regulating RNA associated factors. Thus UHMK1 may be 
implicated in the trafficking and/or splicing of RNAs and phosphorylating RNA 
associated proteins, and may ultimately have a role in the control of gene expression, 
given its RNA recognition motif and phosphorylation potential (Maucuer et al. 1997; 
Maucuer et al. 2000). UHMK1 also been shown to have a narrow substrate 
specificity because it preferentially phosphorylates serine or threonine residues 
flanked by a carboxy-terminal proline.
9.3.3.1 UHMK1 INTERACTION WITH SPLICING FACTOR 1
The yeast two hybridisation system has shown that splicing factor 1 (SF1), interacts 
with UHMK1. UHMK1 phosphorylates the two serine residues adjacent to proline 
residues at positions 80 and 82. The phosphorylated SF1 protein increases its affinity 
to the U2AF65 motif of UHMK1 and forms a complex to the pre-mRNA (Manceau 
et al. 2006). SF1 binds to the branch point pre-mRNA consensus sequence (BPS) 
near the 3’ splice site and facilitates binding of the U2AF65 motif to the adjacent 
polypyrimidine tract forming the initial spliceosome. SF1 is displaced from the 
spliceosome by the ATP-dependent entry of the U2 small nuclear ribonucleoprotein 
particle (snRNP), whose SF3b 155/SAP 155 protein subunit interacts with U2AF65 
and whose RNA component (U2 snRNA) anneals with the BPS. This first ATP- 
dependent step of 3’ splice site recognition represents a critical step in the regulation 
of pre-mRNA splicing (Manceau et al. 2006). Protein kinase (PKG) is a potential 
regulator of this step, by inhibiting the initial SF1-U2AF65 interaction by 
phosphorylation of SF1 serine(20) in the U2AF65 interacting domain.
9.3.4 UHMK1 and
UHMK1 was found to regulate the cell cycle by responding to mitogens and 
negatively regulating cdk inhibitor p27kipl, phosphorylating it on serine 10 and 
promoting its nuclear export into the cytoplasm. This resulted in the promotion of
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cell cycle progression from growth arrest (quiescence Go through to Gi) (Boehm et 
al. 2002).
Relatively low levels of UHMK1 mRNA were detected in the rat embryo, but an 
increase was observed in the brain around birth and postnatal development.
Similarly Bieche et al (2003) has found a higher mRNA level in adult human brain 
as compared to foetus. Thus its been proposed that UHMK1 may inhibit p27Kipl 
activity in most tissues and during development but it plays additional functions and 
phosphorylates different substrates in the mature adult nervous system (Bieche et al. 
2003). This potentially links UHMK1 in neural differentiation and function on one 
side and the control of cell cycle on the other.
9.3.5 THE ROLE OF INTERACTION BETWEEN UHMK1, P27KII’, 
AND STATHMIN
New research has identified the conection between the two proteins that closely 
interact with UHMK1, stathmin and cytoplasmic p27Klpl. Iancu-Rubin et al (2005) 
has implicated them in relation to cell migration and proliferation.
Cytoplasmic p27Kipl was shown to play a role in the regulation of cell migration 
(Denicourt et al. 2004). It has been shown in two studies that stathmin is necessary 
for the migration of neurons in vivo and in vitro. Jin et al (2004) demonstrated that 
inhibition of stathmin mRNA caused inhibited migration of newly formed neurons 
of the olfactory system in adult rat brain. In addition Giampietro et al (2005) showed 
that migration of immortalised neurons is decreased when stathmin expression is 
down regulated and is increased when stathmin is over expressed.
Baldassarre et al (2005) showed that p27Kipl inhibits cell migration and p27Kipl 
interferes with the ability of stathmin to sequester tubulin, leading to increased 
microtubule polymerisation. Over expression of stathmin has the effect of increasing 
cell migration, and hence when p27Kipl has phosphorylated stathmin it leads to a
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reduction of cell migration. Although p27Kipl and stathmin were originally 
discovered as important regulators of the eukaryotic cell cycle, both are now thought 
to be involved in the process of cell migration. A dual role for these proteins in cell 
migration and proliferation should not be surprising as microtubules are known to be 
important in both processes (Iancu-Rubin et al. 2005).
9.3.6 UHMK1 INTERACTION WITH PAM
UHMK1 has also been found to interact with the cytoplasmic domain of the 
peptidyl-glycine a-amidating mono-oxygenase (PAM) suggesting an additional 
function for the protein (Alam et al. 1996; Maucuer et al. 1997; Maucuer et al.
2000). PAM also known as P-CIP2 (PAM COOH-terminal interactor protein) and a 
second interacting protein P-CIP10 which is similar to Huntingtin-associated 
protein-interacting protein (Caldwell et al. 1999), was found to directly interact with 
PAM by means of the yeast two hybrid system in a rat hippocampal cDNA library, 
all three proteins are highly expressed in the brain in neurons (Alam et al. 1996).
PAM has two enzymatically active domains with catalytic activities - 
peptidylglycine alpha-hydroxylating monooxygenase (PHM) and peptidyl-alpha- 
hydroxyglycine alpha-amidating lyase (PAL). These catalytic domains work 
sequentially to catalyze neuroendocrine peptides to active alpha-amidated products.
PAM is also involved in the regulated secretory pathway in neurons and endocrine 
cells in which biologically active peptides are stored in large dense core vesicles 
(LDCVs) and undergo regulated release (Alam et al. 1996). PAM is thought to be 
involved in activating peptides and routing them to LDCVs. PAM itself can be 
tethered to the vesicles and does so almost exclusively in the nervous system (Alam 
et al. 1996) PAM is also likely to be involved in vesicle routing and trafficking. 
UHMK1 and PAM are both found to be expressed in neurons (Caldwell et al. 1999), 
and UHMK1 was found to bind to the C-terminal domain of integral membrane 
PAM. UHMK1 is thought to be an important part in the routing and distribution of
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the PAM protein by the process of phosphorylation of serine (949) residues. The 
expression of PAM may signal UHMK1 to become more diffuse in the cytoplasm.
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Figure 9:5 Diagram showing protein interactions with UHMK1 deduced from a number of sources.
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9.4 D ESC R IPTIO N  OF PA TH W A Y S O CCU RRING  IN Figure 
9:5
A. Mitogens are released which stimulate UHMK1 to autophosphorylate and 
become active.
B p27K,P] inhibits cell cycle progression GO to G l, UHMK1 phosphorylates the 
serine 10 (S10) amino acid of P27Kipl in the nucleus which causes it to be 
exported into the cytoplasm, decreasing the concentration of P27Kipl in the 
nucleus and allowing cell cycle progression
C. UHMK1 interacts with Splicing Factor 1 (SF1). UHMK1 Phosphorylates the 
serine (80) proline -  serine (82) proline (SPSP) motif of SF1. This increases 
the binding affinity of SF1 for the U2AF65 motif of UHMK1, and enhances 
formation of the ternary SF1-U2AF65-RNA complex.
D. This complex (SF1-U2AF65-RNA complex ) is thought to contribute to pre- 
mRNA splicing (at the 3 ’ intronic end) and export form the nucleus (Gama- 
Carvalho et al. 2001; Manceau et al. 2006).
E. Protein Kinase (PKG) regulates UHMK1 and SF1 interaction by 
phosphorylating serine 20 of the SF1 U2AF65 interacting domain preventing 
attachment on to pre-mRNA and formation of the splicosome.
F. Export of P27K,pl out of the nucleus permits cell cycle progression.
G. Export of UHMK1 from the nucleus possibly with mRNA and/or P27K,pl out 
of the nucleus into the cytoplasm.
H. Stathmin is phosphorylated by UHMK1 and inactivates stathmin. This in 
turn leads to microtubule stability, as stathmin disrupts microtubule 
dynamics.
I. Stathmin is phosphorylated by P27Kipl which inhibits stathmin, as a result 
stabilises microtubule formation, which decreases cell migration.
J. P27Kipl is degraded by a number of pathways, one being the ubiquitin 
proteosome pathway.
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K. Dependent on the Stathmin phosphorylation state (whether phosphorylated or 
not, in addition to the location of phosphorylation) Stathmin will effect 
tubulin stability and in turn microtubule formation.
L. Inactivation of stathmin will lead to Cell proliferation.
M. Inactivation of stathmin will lead to reduced cell migration.
N. PAM interacts with UHMK1 by yeast 2 hybrid system, PAM is
phosphorylated by UHMK1 at serine 949, it is suggested that this is required 
to localise PAM to large dense core vesicles which aid in activating bioactive 
peptides in neurons. PAM is seen to be involved in the regulated secretory 
pathway in neurons and endocrine cells.
Because it is known that the stathmin mouse knockout exhibits behavioural 
abnormalities, it is of interest to know if pharmacological interventions might effect 
UHMK1 gene expression.
This was investigated with the antipsychotic drug clozapine in an independent 
microarray study comparing the effect of clozapine and haloperidol antipsychotic 
therapy in mice Rizig et al (2009). It was found that UHMK1 was significantly 
down regulated by clozapine but not haloperidol. This does not prove involvement 
of UHMK1 in schizophrenia but does hint at a possible reason why clozapine is a 
more effective drug than haloperidol.
With the known effect of UHMK1 on neuronal growth and differentiation and its 
high level of expression in the hippocampus, it is posible to envisage the effect of an 
abnormally expressed UHMK1 would have on an individual. Currently there are no 
animal models for altered UHMK1 expression, and whether neuronal loss would be 
a result of such an abnormality. However, studies have shown the effect and possible 
causes of neuronal loss around the hippocampal formation, and the importance of 
growing neurons in this area. One such study showed that neural stem cells, located 
in the subventricular zone (svz) and the subgranular zone (SGZ) of the dentate gyrus
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(DG), produce new neuronal and glial cells in the hippocampus of adult mammals 
(neural stem cell proliferation; NSP). Some of these neuronal cells differentiate into 
neurons that intergate functionally and structurally into existing neural networks a 
process known as adult neurogenesis. Thereby maintaining neuronal plasticity and is 
probably involved in memory formation or stress responses. The hippocampus is 
thought to be involved in the etiopathology of depression and adult neurogenesis has 
been suggested to be involved in the pathophysiology and treatment of mood 
disorders with both tricyclic and serotonin reuptake inhibitor antidepressants (Reif et 
al. 2006).
Findings by Reif et al (2006) suggest that reduced neural stem cell proliferation is 
present in the hippocampus of schizophrenia patients and may contribute to the 
pathogenesis of schizophrenia, due to a reduction in the amount of newly formed 
cells (Reif et al. 2006). These findings fit with the known functions of UHMK1 such 
as being involved in cell cycle progression, neuronal migration and outgrowth in 
addition to its high expression in the hippocampal formation.
9.5 CO NC LUSIO N
With the evidence shown, it can be seen that the actions of UHMK1 protein are 
complex and multifunctional. Functions of UHMK1 involve activation of the cell 
cycle, pre-mRNA processing involving intronic splicing and export into the nucleus. 
As discussed earlier UHMK1 is also involved in interacting with PAM, which is 
involved in the neuronal secretory pathway of bioactive peptides. UHMK1 also 
interacts with stathmin which is involved in microtubule destabilisation and neuronal 
integrity. It seems that UHMK1 is part of a delicate and complex network of 
neuronal control, regulating neuronal growth and possibly neuronal signalling. 
UHMK1 gene is highly expressed in the hippocampus, which is known to be part of 
the brain where neurons still divide and regenerate. UHMK1 is an attractive 
candidate gene for schizophrenia susceptibility as shown through the genetic linkage 
and association studies as well as from neurobiological pespective.
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10.0 THESIS DISCUSSION
In this thesis I have tested for association of previously implicated genes RGS4 and 
CAPON to schizophrenia (section 4.0 & 5.0). We found no allelic association with 
schizophrenia with either of these genes using the UCL case control sample. As a 
result further fine mapping had been carried in the chromosomal region between the 
two genes as described in section 6.0
Section 6.0 and 7.0 had shown significant allelic and haplotypic association had 
been detected implicating the U2AF homology motif kinase 1 (UHMK1) as a 
schizophrenia susceptibility gene.
Sequencing of UHMK1 exons, 3’ and 5’ UTR, had produced three mutations in the 
promoter region. Genotyping of these genetic variants in the case control samples 
showed no evidence of association with schizophrenia (section 8.1.3). Sequencing of 
the greater promoter region and the introns are suggested, which may hold further 
interesting and potential aetiological mutations.
It was also seen in this thesis that UHMK1 is highly expressed in the nervous system 
and brain, and has a role in its development, the interactions of UHMK1 with other 
proteins such as stathmin and PAM added further weight to the possibility of 
UHMKls role in behavioural characteristics and neuronal development and 
signalling as discussed in section 9.0.
UHMK1 is known to be highly expressed in regions of the brain implicated in 
schizophrenia, it has been found to be significantly down regulated in mice treated 
with antipsychotic drug clozapine (Rizig et al (2009)). Further confirmation of the 
involvement of this gene in schizophrenia is needed followed by further efforts to 
detect genetic variation in or next to the gene (which may even effect neighbouring 
genes).
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10.1 FUTURE WORK
10.1.1 FURTHER REPLICATIONS
Further fine mapping around the gene should be carried out to exclude neighbouring 
genes more convincingly and to show that the association was not attributed to 
linkage to a close neighbouring gene. This, as a result would give further support to 
UHMK1 as the candidate susceptibility gene. Clearly, for the UHMK1 gene to 
become a credible contender as an important component in the susceptibility of 
schizophrenia the association findings need to be repeated in several more 
populations. However, before any replications are attempted, attention should be 
paid to the methodology. Replication of association studies have become a universal 
cause for concern, in the field of genetics as a whole. Several journals have proposed 
guidelines or state in their editorial “Policies and Practices” that genetic association 
studies related to complex disorders are unlikely to be accepted (Saito et al. 2006).
A recent meta-analysis concluded that popultaion heterogeneity was in evidene for 
association studies (Ioannidis et al. 2001).
False-negative results may come from studying genes of modest effect that may only 
have odds ratios of between 1.1-1.5, explaining 1-8% of the overall disease risk in a 
population. Locus heterogeneity may further weaken the genetic signal. In reality 
locus heterogeneity has been proven for all common complex disease.
False-positive results may also be due to population stratification; this can result 
from hidden allele frequency differences detected due to ethnic and ancestral 
differences between cases and controls. This is observed when cases and controls are 
drawn from two or more racial groups where the disease prevalence varies by race 
along with the genetic variant frequency.
However, despite the above, over 50% of allelic associations in case control samples 
are replicated and confirmed Lohmueller (2003).
Therefore, any future investigations of UHMK1 and schizophrenia must involve 
attempts at replicating the positive associations reported here. Such replications 
should aim to use the same markers of the initial study and sufficient numbers of 
cases and controls so as to obtain sufficient power.
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10.1.2 RE-SEQUENCING
In the re-sequencing of the UHMK1 gene or any gene thought to be involved in the 
susceptibility to schizophrenia it is of utmost importance either to discover any 
aetiological base-pair changes or to confirm that no such abnormalities are present. 
The bi-directional method of re-sequencing is employed in this thesis is not without 
faults. It would be appropriate to suggest that any areas which have been re­
sequenced be repeated with an alternative method e.g. capillary sequencing. In 
addition a larger region of the 5’ and 3’ UTR should be sequenced to detect long 
range control regions or enhancer elements which could affect the expression 
efficiency of the gene. These locus control regions could be further than 14 kilobases 
away and situated within another gene (Ho et al. 2006). Indeed UHMK1 could be 
containing a long distance control region that could effect another gene, hence 
complete sequencing of the entire genomic extent of the gene is important.
Furthermore, as stated above, although UHMK1 is a highly plausible candidate for 
the susceptibility to schizophrenia, it may simply be that there is an alternative gene 
or control region within the region of UHMK1 responsible for the association.
It is not therefore unreasonable to suggest that any future work may involve the re­
sequencing of introns of the UHMK1 gene. Indeed several diseases have been found 
to have a mutation within the introns as noted above. Myotonic dystrophy (type 2) 
has been found to be caused by a CCTG expansion (mean-5000 repeats) located in 
intron 1 of the zinc finger protein 9 (ZNF9) gene (Liquori et al. 2001). Also closely 
linked or even causative abnormalities can be found in the introns, such as the three 
SNP haplotype in intron 1 of OCA2 (Oculocutaneous Albinism, type 2) which is 
now thought to influence eye colour variation (Duffy et al. 2007).
10.1.3 GENOTYPING
In any future work, the non-dbSNPs discovered during re-sequencing of the introns 
and UTRs should be genotyped in the whole case-control sample. In addition, more
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data-base SNPs including those found by re-sequencing and further SNPs chosen 
from the HapMap should be genotyped across the region so that the importance of 
UHMK1 as a susceptibility gene in schizophrenia can be investigated further and 
also, further fine mapping around the gene to help exclude neighbouring genes that 
may be the true susceptibility gene linked to the positive UHMK1 markers. It should 
also be pointed out that HapMap does not contain all the known SNPs covering all 
regions, and that typing of tagged SNPs within UHMK1 has been carried out to the 
best of our knowledge. The gene should be fully sequenced in order to find 
additional SNPs.
This study has failed to replicate association with previously implicated genes 
CAPON (NOS1AP) and RGS4, although this reduces evidence for association to 
schizophrenia with these genes we can not exclude it. NOS1AP is a large gene that 
according to the data in HapMap would require over 18 tagged SNPs to thoroughly 
evaluate the association with schizophrenia. Therefore both of the implicated genes 
could be more vigorously genotyped with tagged SNPs to increase confidance to 
exclude the genes as candidates to schizophrenia susceptibility. In addition the 
neighbouring genes to UHMK1 (UAP1 and DDR2) should also be typed with 
tagged SNPs to prove that they are not implicated in schizophrenia susceptibility and 
UHMK1 is not picking up LD with these genes.
10.1.4 GENOME SCANS
Whole genome scan association studies using large numbers of SNPs have been 
carried out looking at several other diseases including myocardial infarction, 
osteoarthritis (Abel et al. 2006) and breast cancer. Recently, Mah et al (2006) carried 
out a genome-wide scan using over 25,000 SNPs located within approximately 
14,000 genes. They repeated the scan within several populations. They found a 
marker on lq32 within a novel candidate gene for schizophrenia (PLXNA2).
Work in the future will include high density genome wide association studies aiming 
to reinforce current findings and/or identify further candidate genes. The
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identification of genes by markers associated with specific loci may not be the final 
route by which complex disorders are completely understood. The loci may simply 
be regions for interaction or control. It is the understanding of these interactions and 
control mechanisms that will possibly be the focus of the attention of scientists over 
the next decade.
10.1.5 EXPRESSION VECTORS AND KNOCK-OUT/KNOCK-DOWN 
MOUSE MODELS
Once association with UHMK1 is beyond doubt and aetiological base pair changes 
have been identified then expression vectors and “knock down” experiments can be 
conducted. Transgenic knock out experiments are also highly desirable and would be 
of further interest to investigate what the effect it would have on UHMK1 
expression and the organisms brain pathology and also behaviour.
10.1.6 METHYLATION STATUS AT CpG
DNA methylation involves the addition of a methyl group to the number 5 carbon of 
the cytosine pyrimidine ring. Methylation of the CpG island suppresses gene 
expression of the upstream gene. This activity is important for developmental roles 
and specific tissue expression. We have found a rare non-database SNP in the CpG 
island as described in section 8.1.3, and also two other mutations further upstream. It 
would be interesting to investigate how these mutations could affect the methylation 
status in the promoter region, especially in the case where we have the rare SNP.
Measuring DNA methylation can be carried out by sodium bisulfite treatment, which 
creates sequence differences by converting unmethylated cytosines to uracils, but 
leaving methylated cytosine unchanged. The differences can then be detected 
quantitatively by several techniques, such as sequencing of subclones or PCR 
products, restriction-digestion or pyrosequencing (Clark et al. 1994; Xiong et al. 
1997; Colella et al. 2003).
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10.1.7 MRI SCANS OF UHMK1 ASSOCIATED CASES.
Magnetic Resonance Imaging (MRI) is a powerful scanning devise which is able to 
build up detailed pictures of internal tissue organs, using safer form of radio waves, 
unlike the ionising waves of x-rays.
Upon further implication and conformation that UHMK1 is a schizophrenia 
susceptibility gene. One may want to investigate how the abnormally expressed gene 
would affect the brain morphology of schizophrenic patients which have the 
abnormal UHMK1 gene. This can be carried out by scanning the patients using an 
MRI machine; it would be interesting to see which areas of the brain (if any) are 
affected, compared to other schizophrenics and to normal controls. The results could 
be compared to what we have already discovered by MRI scanning of schizophrenic 
patients to see if they overlap, and potentially be implicated as a main cause factor to 
abnormal brain morphology.
10.1.8 INVESTIGATING EXPRESSION IN SCHIZOPHRENIC 
PATIENTS.
An important implication of a gene causing schizophrenia is whether it is 
abnormally expressed in schizophrenic patients compared to controls. That can be 
carried out by using quantitative RT-PCR, unfortunately obtaining suitable brain 
tissue not easy. One would need to use human brain tissue to extract mRNA, and 
this could only be obtained from external organisations. As a result it would not be 
possible to screen before hand which patients will be the most likely to have an 
abnormal UHMK1 gene. However, it would be of great interest if mRNA can be 
extract from the hippocampal formation where UHMK1 was found to be highly 
expressed, from a number of patients and compare it to the same number of matched 
controls. In addition the tissue samples could be used to extract the UHMK1 protein 
and investigate if there are different isoforms present in higher concentrations in the
181
schizophrenics or the controls when compared to one another. Caution is needed in 
evaluating post motem mRNA levels because drug effects can influence UHMK1 
mRNA levels as has been shown with clozapine.
10.1.9 BETTER UNDERSTANDING OF PROTEIN-PROTEIN 
INTERACTIONS
In order to fully understand UHMK1 ’s role in the pathology of schizophrenia and to 
look to find potential therapeutic targets to control the disease, one needs to fully 
understand the protein interactions associated with UHMK1. For future work, it 
would be worth investigating the protein interactions further. Biochemical 
techniques such as the yeast two hybrid screening should be employed to help build 
up the proein network picture. Coprecipitation and 2D gel studies also looking at 
glycosylation and phosphorylation changes may also aid in the study of the protein 
function and control.
10.1.10 GENE-GENE INTERACTIONS
It is important to consider gene-gene interactions, as well as recessive and dominant 
gene effects. The associated gene may not be directly responsible for schizophrenia 
susceptibility but its product may interact with other abnormal genes effecting their 
expression which may have an even greater effect on the pathology of 
schizophrenia. Specific gene interactions may occur in specific sub-types of 
schizophrenia. The gene interactions will not only help to confirm known candidate 
genes, but help to implicate other genes in schizophrenia susceptibility.
10.1.11 GENE SUSCEPTIBILITY AND SUB-TYPES OF 
SCHIZOPHRENIA
Sequencing and screening of the gene was carried out as previously stated (section 
2.8.4 & 8.1) by using the individuals with the most significantly associated 
haplotypes. Screening of these individuals lead to the detection of the rare SNP in
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the CpG island and also the two INDELs. Further genotyping of these changes in the 
entire population showed them not to be associated with schizophrenia. However, 
they could nevertheless be responsible for very rare subtypes of schizophrenia. 
Further work should be done to investigate whether these mutations are in fact a rare 
cause of schizophrenia. In the future even larger sample size would be justified by 
increasing the power to detect polymorphisms with high frequency SNPs as well to 
screen for additional rare susceptibility mutations.
10.2 CO NC LUSIO N
UHMK1 is attractive as a schizophrenia susceptibility gene because it contains both 
a kinase and a RNA recognition motif which is widely expressed in the brain. The 
gene has been implicated in the British UCL case control sample and also replicated 
in a larger independent Scottish Aberdeen case control sample. UHMK1 is an 
attractive gene highly expressed in the developing nervous system and in the mature 
brain. UHMK1 expression is greatest in the hippocampal formation which links it to 
behaviour and memory. The protein is involved in cell cycle progression, neuronal 
out growth and possibly neuronal signalling. Further association studies in 
independent populations are still required, to fully confirm UHMK1 as a 
susceptibility gene for schizophrenia.
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13.0 APPENDIX
13.1 RAW RESULTS OF LD BETWEEN ALL 55 MARKERS USED.
Figure 13:1 LD plot of all 55 markers used in the UCL sample. Above is Cram er’s V. Below are P-values.
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13.2 P R IM E R  SEQ U ENCES OF UHM K1 SEQUENCING
Table 13:1 Primer sequences used to sequence UHMK1 as described in section 8.1.2
Primer Name Location Sequence
KIS_P9_L_ml3r 5' UTR GGATAACAATTTCACACAGGcaacaaagcaggggtgatg
KIS_P9_R_ml3F 5' UTR CACGACGTTGTAAAACGACgggggaaatttgcatctgta
KIS_P8_L_ml3r 5' UTR GGATAACAATTTCACACAGGtctcatttaatatcttcagggttgg
KIS P8_R_ml3F 5' UTR C ACG ACGTT GT AAAACG ACtacaggcatccaccaccac
KIS_P7_L_m 13F 5' UTR CACGACGTTGTAAAACGACtgggtgaaattccatctcaaa
KIS_P7_R_ml3r 5’ UTR GG AT AACAATTT C AC AC AGGcaccatgcccggttaaat
KIS_P6_L_m 13F 5' UTR CACGACGTTGTAAAACGACtggggttaaacaaaacccatc
KI S_P6_R_m 13 r 5' UTR GG AT AACAATTT C ACAC AGGagcctaagctgttgctctgc
P5L_r_M13R 5’ UTR GG AT AACAATTT CAC AC AGGggacctcacgcaagaaag aa
P 5 R r M 1 3 F 5' UTR CACGACGTT GT AAAACGACttcaaaccagagcaactcca
P4aL_r_M13F 5' UTR CACGACGTTGTAAAACGACcatggtggcaaattcctgta
P4aR_r_M13R 5' UTR GGATAACAATTTCACACAGGggaaagtttgaggagaggttga
P4bL_r_M13F 5’ UTR CACGACGTT GT AAAACG ACctggaaatgcagcccagt
P4bR r_M13R 5' UTR GGATAACAAI I I CACACAGGggcatgatctcggcatct
P3L_r_M13R 5' UTR GGATAACAATTTCACACAGGgcaagagagaagacaggtcaga
P3R_r_M13F 5' UTR CACGACGTTGTAAAACGACtttctgggccaaatcaatgt
K I S P 2 L m l 3 R 5' UTR GGATAACAATTTCACACAGGtgagccaactatgagtgacca
KI S_P2_R_m 13 F 5' UTR CACGACGTTGTAAAACGAC cccatgattctggaagccta
ExlaO_L_M13R CpG GGATAACAATTTCACACAGGgctgtggcaggtacagagc
ExlaO_R_M13F CpG CACGACGTTGTAAAACGACactgtgacctgggcaagaag
KIS_EXla3_Lml3R CpG GGAT AACAATTT CACACAGGaaggaccagttttggcttca
K I S E X 1 a3_Rm 13 F CpG CACGACGTT GT AAAACGACgttaagggcacggacacg
K I S E X 1 a2_Rm 13F CpG CACGACGTTGTAAAACGACcagcgaacccgatacacc
K I S E X  1 a2_Lm 13R CpG GGAT AACAATTT CACACAGGtgtcatggctgcttgaagtc
KIS_EXlal_Lm l3R Exon 1 G GAT AACAATTT C AC AC AG Gcgtgcccttaacccacac
KIS_EXlal_Rm l3F Exon 1 CACGACGTT GT AAAACG ACctttgcggaaaccatactcg
U H M K E X 2 L M  13R Exon 2 GGATAACAATTTCACACAGGcagtggaagcttgctcatca
UHMK EX2 R M 13 F Exon 2 CACGACGTTGTAAAACG ACcggtggcactgaaattcttt
U H M K E X 3 L M 13 R Exon 3 GGATAACAATTTCACACAGGtgcccagttaatgaaccaaa
U H M K E X 3 R M 13 F Exon 3 CACGACGTTGTAAAACGACtgaaagtaaggaccccaaagc
KI ST_EX4r_L_M 13 R Exon 4 GGAT AACAATTT CACACAGGtgttttctgttgcattttactctca
KIST_EX4r_R_M 13 R Exon 4 CACGACGTT GT AAAACG ACgcaaaagagcattcctttgaa
K I S E X 5 M 13R Exon 5 GGAT AACAATTT CAC AC AGGcaacaatcatcccaccgata
KI S E X5  _M 13F Exon 5 CACGACGTTGTAAAACGACagtgggaagcatgaccagat
KI S_EX6_M 13 R Exon 6 GGAT AACAATTT CACACAGGgcttcatgatgatccaagca
KIS EX6 M13F Exon 6 CACGACGTTGTAAAACGACtgaggcttgaacccagga
UHMK EX7 L M13R Exon 7 GGATAACAATTTCACACAGGttcaaggagagtagaaggtggaa
U H M K E X 7 R  M 13F Exon 7 CACGACGTT GT AAAACGACtgcaaaactcataatccttagca
U H M K E X 8 A L M 13F Exon 8 CACGACGTTGTAAAACGACttggcatcacctggaagttt
UHMK EX8A R M13R Exon 8 GGAT AACAATTT C ACAC AGGccaaatgtatgcaacgcagt
U H M K E X 8 B L M 13F Exon 8 CACGACGTTGTAAAACGACgcaggactacccccttacca
Continued.
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UHMK
UHMK
UHMK
UHMK
UHMK
UHMK
UHMK
EX8B
EX8C
EX8C
EX8D
EX8D
EX8E
EX8E
R M 1 3 R
L M 1 3 R
R M 1 3 F
L M 1 3 F
R M 1 3 R
L M 1 3 R
R M13F
Exon 8 
Exon 8 
Exon 8 
Exon 8 3'UTR 
Exon 8 3'UTR 
Exon 8 3'UTR 
Exon 8 3'UTR
GGATAACAATTTCACACAGGgtgcaagatcaagcatcagc 
GGATAACAATTTCACACAGGataagctggcactggatgct 
CACGACGTT GT AAAACG ACggcacaacttagtctttgttcca 
CACGACGTT GT AAAACG ACgagaggcccagaacaaact
GG ATAAC AATTTCACAC AGGtgggatgctgctcctctagt 
GGAT AACAATTT CACACAGGtatccctgctccctttttcc
CACGACGTT GT AAAACG ACaaaggagagtcctgaatttgaca 
M13F/R tails are indicated in uppercase of the primers.
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